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Arene Ruthenium(II) Thiosemicarbazone Complexes
as Anticancer Agents
Abstract
This thesis presents the synthesis and characterisation of thiosemicarbazones
(TSCs) and their arene ruthenium complexes for the use as anticancer
agents. Based on substituted benzaldehyde derivatives, 12 different TSCs
were used as N,S-chelating ligands in 24 different ruthenium half-sandwich
complexes. The variations in their general structure [(p-cymene)Ru(R-
TSC)Z]+[A−] include the use of both chloride and iodide as monodentate
Z ligand. Iodine substituents in the TSC (R = I) were used to introduce a
possible tracer moiety.
Structure and reactivity elucidations by NMR, ESI-MS and X-ray ab-
sorption spectroscopy in Chapters 2 and 3 include the 15N-NMR chemical
shift determination for the 12 TSCs by 1H15N-HMBC NMR in solution.
The TSC imino (N1) and the hydrazinic (N2) nitrogen atoms exhibit sig-
nificant 15N-NMR chemical coordination shifts of -60 ppm and +122 ppm,
respectively. The latter indicates deprotonation of the NH in solution.
X-ray crystal structures of two complexes are presented, for [(p-cymene)
Ru(PTSCNMe2)][PF6] [10] and for the dinuclear complex [(p-cymene)Ru
(DTSCIPh)]2[PF6]2 [30]. The crystallographic data were used as models
for theoretical fitting of Ru K-edge EXAFS data. The EXAFS fits to data
obtained for the presented complexes strongly match the first coordination
sphere found in the crystal structure of complex [10]. Solution-state XAS on
freeze-quenched aliquots of a solution of [(p-cymene)Ru(DTSCNMe2)Cl]Cl
confirm its conversion into [30].
[(p-cymene)Ru(PTSCNMe2)I]PF6 [12] and [(p-cymene)Ru(ITSCNMe2)I]PF6
[29] with an iodine substituent are investigated in Chapter 4. Both have
antiproliferative activity (IC50 = 2 µM) against human ovarian cancer cells
(A2780) , causing cell-cycle arrest in G1-phase and induction of apoptotic
pathways. The strategic positional variations of iodine labels within this
series combined with the simultaneous detection of 101Ru and 127I by ICP-
MS showed that the monodentate ligand Z does not enter the cancer cells.
In contrast to this, the aromatic iodine substituent in the TSC ligand of [(p-
cymene)Ru(R-TSC)I]+ enhances cellular accumulation of both ruthenium
and TSC-bound iodine, but not the cytotoxicity of the complex.
vi
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Chapter 1
Introduction
Cancer is one of the most frequent causes of death in the developed world
today. In the field of bio-organometallic chemistry, the research of organo-
metallic co-ordination compounds with anticancer properties contributes to
the search for new cancer chemotherapeutics. Within this field of research,
arene ruthenium anticancer complexes are an area that has grown and es-
tablished itself in recent years. The work presented in this thesis contributes
to this field with the synthesis of new ruthenium(II) arene complexes and
the investigation of their cytotoxicity towards cancer cells.
Thiosemicarbazones (TSCs) are a class of organic molecules that has
shown vast therapeutic potential in the past. Furthermore, their use as che-
lating ligands for ruthenium-based anticancer research has recently gained
substantial interest in the field. For these reasons, the presented work com-
bines TSCs with the ruthenium-arene fragment, with the aim to derive
novel TSC ruthenium half-sandwich complexes that have added potential
to become new anticancer compounds.
1
1.1 Motivation for the Research
In its recent report on trends in cancer incidencei and mortalityii world-
wide, the World Health Organisation (WHO) highlights how fast the cancer
burden grows: In 2012, 14.1 million people died of cancer, but the latest
estimates suggest that the mortality is likely to rise to 19.3 million by 2025,
an increase of 5 million cancer deaths per year.1
Figure 1.1: The two charts visualise the gender-specific abundance of common
cancer types: breast/prostate, colorectal and lung cancer were the most frequent
in Western Europe in 2012. [Data reproduced from: GLOBOCAN 2012: Estim-
ated Cancer Incidence, Mortality and Prevalence Worldwide (published by the
WHO in February 2014)2, 3]
iCancer Incidence is the number of new cases arising in a given period in a specified
population. This information is collected routinely by cancer registries.
iiCancer Mortality is the number of deaths occurring in a given period in a specified
population. It can be expressed as an absolute number of deaths per year or as a rate
per 100,000 persons per year.
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1.1.1 Cancer Incidence and Mortality 2012
Two pie charts in Figure 1.1 illustrate the most frequent types of cancers
diagnosed in male and female patients in Western Europeiii in 2012. The
graphic shows that the most abundant cancers in the Western European
population are the gender specific ones. Prostate cancer alone made up
29.1% of cancer diagnoses in men, while breast (32.6%), uteral (4.8%), and
ovarian cancer (2.9%) accounted for almost half (42.6%) of all incidences
in female patients. Breast cancer also remains the most lethal form of the
disease in women. Noticeably, lung cancer appears to be twice as frequent
in men than in women, while both genders are equally affected by colorectal
cancer (ca 12%).
The report by the WHO emphasises the need for urgent implementation
of efficient prevention strategies in order to counteract climbing cancer in-
cidence rates. However, it is also apparent from the presented statistics that
improved ways of treatment and novel chemotherapeutics are paramount in
coping with the increasing number of cancer cases.
1.1.2 The Need for Novel Cancer Treatments
There are several options of treatment available when a tumour is detec-
ted. The most effective of those treatments is the surgical removal of a
solid tumour mass, followed by radiation therapy to reduce the risk of a
recurrence due to cancerous cells which might have remained in the tissue.
Where surgery is not possible, radiation therapy alone, chemotherapy, or a
combination of the two is the next most favourable option.
iiiDetails about the exact region this data represent can be found in the online resource
www.globocan.iarc.fr
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Drug Resistance Limits the Scope of Current Chemotherapeutics
Patients in clinical chemotherapy have been treated with Cisplatin, cis-
[PtCl2(NH3)2], for more than 30 years, and two close variants, Carboplatin
and Oxaliplatin (Figure 1.2), have also been approved for the treatment of
cancers. A drawback, however, is that side-effects such as nausea, neuro-,
nephro-, and myelotoxicity impair the success of platinum-based chemo-
therapeutics.4
Figure 1.2: Platinum drugs in clinical use: Cisplatin cis-[(NH3)2PtCl2)], Car-
boplatin (Paraplatin R©), and Oxaliplatin (Eloxatin R©)
In addition to the severe side-effects, the scope of platinum drugs is more
and more limited by cellular drug resistance.5 This phenomenon, when a
chemotherapeutic agent looses its effect and over the course of the treatment
becomes inactive, occurs on the cellular level.6 Chemotherapeutics aim to
stop tumour growth by inhibiting cell proliferation, and also to reduce the
number of cancer cells, i.e. decrease tumour mass.7 However, cancer cells
can develop mechanisms by which they detect and subsequently excrete the
drug molecules.6 When this process happens faster than the original drug-
action, the net result is complete activity loss, or, in other words, the cells
have become resistant. This ‘acquired drug resistance’ has rendered some
cancer types untreatable with todays most commonly used chemotherapeut-
ics, which is one of the reasons for many cancer related fatalities.8
As a result of drug resistance, the highest demand for new anticancer
4
drugs resides with the types of cancers that show both high numbers of
incidence and drug resistance. Ovarian cancer is the most frequent type
diagnosed in women in Western Europe, and it is most commonly treated
with Cisplatin, cis-[PtCl2(NH3)2],
9 but most strains are already resistant
against this platinum based drug.9, 10 Therefore, advanced ovarian cancer
is one for which new treatments are urgently required.
The following sections introduce and explore the use of ruthenium com-
plexes in anticancer drug research and give an overview over recent research
with ruthenium arene complexes, which provides the background of the
work presented in thesis.
1.2 Metal-based Anticancer Agents
Researchers in metal-based medicinal chemistry aim to develop new cancer
treatments that can overcome the resistance and side-effects connected with
cisplatin.11, 12 A vast number of transition metals other than platinum are
under investigation in the development of new coordination compounds with
better bioavailability, selectivity and fewer side-effects.11–17
Coordination complexes offer versatile reactivities, and because of this
they can be subject to modification during their uptake and transport inside
the human body. Hence they are almost always pro-dugs. Therefore, the
ligands must be chosen carefully, as they may possess different functions.
Not only can they influence the reactivity of the metal or be involved in
redox reactions, but also greatly affect the absorption and delivery of the
complex, and sometimes even the specificity of target recognition.
5
Organometallic Iron Complexes against Breast Cancer
An example of an organometallic compound that achieves the difficult task
of target recognition is the Tamoxifen analogue Ferrocifen. The similarit-
ies between the structures of Ferrocifen and Hydroxytamoxifen, the active
metabolite of Tamoxifen, are illustrated in Figure 1.3.
The growth of several types of breast and prostate cancer cells is de-
pendent on the natural hormones estradiol and testosterone, respectively.
These cancer cells over-express hormone receptors, and treatment usually
relies on drugs that modulate the receptors in order to lower overall hormone
levels. An example is the selective endocrine receptor-modulator (SERM)
Tamoxifen, which is widely used for anti-oestrogen treatment of hormone
dependent breast cancer.18
Figure 1.3: Molecular structures of the Tamoxifen metabolite Hydroxitamoxifen
and its iron-containing analogue Ferrocifen.
Iron-incorporating derivatives of Tamoxifen exhibit improved anticancer
activity.19 Ferrocifen (Figure 1.3), in which one phenyl ring is replaced with
a ferrocenyl unit, is used as a vector to recognise the oestrogen receptor,
and to carry the redox active fragment into cancer cells. Ferrocifen is an
example for the scope that lies in metal-based anticancer compounds.
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1.2.1 Inorganic Ru(III) Anticancer Complexes
Two ruthenium(III) complexes are currently undergoing clinical trials. Fig-
ure 1.4 shows the structures of the imidazolyl-complex NAMI-A and of its
indazolyl congener KP1019. Both molecules are monoanionic octahedral
Ru(III) complexes with two axial heterocyclic N-donor ligands and four
equatorial chlorido ligands.
Figure 1.4: Structures of NAMI-A and KP1019, two Ru(III) complexes under-
going clinical trials as anticancer agents.
NAMI-A, invented by Sava and co-workers, is an antimetastatic agent.20
Its activity is likely related to integrin dependent inhibition of cancer cell
motility and invasiveness.20, 21
KP1019 has a very similar general structure, but its activity profile is
different from NAMI-A. The indazolyl-ruthenium complex is cytotoxic to-
wards solid cancer and has been evaluated in a phase–I clinical trial in 2004;
but the study had to be stopped early due to the insolubility of the com-
pound.22, 23 Compared to KP1019, its sodium salt NKP1339 (Figure 1.4) is
more water soluble, and therefore more suitable for clinical development.24
NKP1339 is currently being developed by NikkiPharm as a ‘first-in-class’
ruthenium-based anti-tumour drug,25 and the first clinical trial has been
7
completed.26
These examples show that ruthenium complexes are promising antican-
cer drug candidates that might potentially overcome cellular drug-resistance
mechanisms, although further studies are required.
1.2.2 Arene Ruthenium and Osmium Anticancer Com-
plexes
Half-sandwich anticancer complexes are of the general structure depicted
in Figure 1.5. The corresponding formula that describes this ’piano-stool’
geometry is [(η6-arene)Ru(XY)Z]+, where XY is a bidentate chelating ligand
and Z− is a monodentate halido ligand.
Figure 1.5: General structure of arene ruthenium/osmium half-sandwich com-
plexes: The ‘piano-stool’ geometry around the metal centre is given by the facially
co-ordinated arene, and the three legs opposite which are the donor atoms X, Y,
and Z. Chelating ligands connect X and Y to form a mostly five membered ring
including the metal.
Different ligand sets can give rise to relatively labile or rather inert
complexes, depending on the nature of M, X-Y, Z, and the arene ligand,
and the possible variations of each of these four building blocks are countless.
It is therefore even more important to systematically investigate the way
in which particular structural groups affect the anticancer activity of the
resulting complexes.
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Progress within the field has been reviewed frequently in recent years.27–32
The next sections will briefly summarise the current state of structure-
activity relations for ruthenium and osmium arene anticancer complexes.
Structure - Activity Relations
Figure 1.6 depicts three important examples of arene anticancer complexes.
It highlights the fact that these three compounds have very different ligand
sets, while all belong to the same class of molecules. The ruthenium arene
PTA complex RAPTA-C (PTA = 1,3,5-triaza-7-phosphaadamantane, C =
p-cymene) has three monodentate ligands instead of an XY chelating ligand
+ monodentate Z ligand. The complex is selective for acidic tumour tissue
by virtue of the PTA ligand. The biphenyl complex RM175 is an early
example from the Sadler lab,33 with an ethylenediamine chelating ligand
and Z = Cl. Development of the early structure has yielded iodido-Os(II)
complexes such as FY26, with azopyridine chelators and Z = I.34
Figure 1.6: Examples of half-sandwich anticancer complexes: RAPTA-C,35 RM
17533 and Os(II) complex FY2634
The research of the last decade has revealed a number of promisingly
active structures, and systematic studies have led to first structure-activity
relations for osmium anticancer complexes.30, 36 Figure 1.7 highlights a set
of four structures, two containing Ru and two with Os. Two of the structures
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contain a chlorido ligand ([Ru-Cl] & [Os-Cl]) and two contain I ([Ru-I] &
[Os-I]).
Figure 1.7: Only one atom is different between [Ru-Cl] & [Ru-I] (top),
between [Os-Cl] & [Os-I] (bottom), between [Ru-Cl] & [Os-Cl] (left), and
between [Ru-I] & [Os-I] (right).
Between the four complexes in Figure 1.7, either the metal centre changes
from Ru to Os, while the ligands remain the same, or the monodentate lig-
and Z changes from Cl to I while keeping the metal centre constant. Recent
research showed that such one-atom changes within the structure of two
otherwise identical complexes can have a significant effect on the biological
properties of piano-stool anticancer complexes.
For example, the nature of the monodentate ligand Z influences the
way in which ruthenium half-sandwich complexes [Ru-Cl] and [Ru-I] of
Figure 1.7 are internalised by human ovarian cancer cells (A2780), and
change the antiproliferative activity of the compounds as a result.37
These findings are not as surprising when one takes into account that a
change in biological activity of a metal complex can also be caused by ligand
substitution reactions such as hydrolysis of the Z-ligand. Those reactions
10
may occur, for example, in the bloodstream or inside a cancer cell, which
makes it implicit that it is important to elucidate speciation(-changes) of
anticancer metal complexes. The next section outlines the structural prop-
erties that can control the exchange of the monodentate Z–ligand in aqueous
solutions.
Structural Switches: Activation by Hydrolysis
Activation of a metal-based drug by hydrolysis of the M-Z bond can play an
important role in their mode of action, as is precedent for cisplatin. Most
arene anticancer complexes also undergo hydrolysis of the monodentate lig-
and Z (Figure 1.8), and for some this is an activation mechanism of their
anticancer activity.29
Figure 1.8: Scheme shows the steps involved in the hydrolysis of ruthenium
half-sandwich complex [(arene)Ru(en)Cl]+ (where en = ethylenediamine).
The rate with which the Z-ligand is replaced by water depends on the
nature of the metal centre, the Z-ligand, and on the chelating ligand (XY).
While dissociation of the M-Z bond appears to be the rate-determining
step, density functional theory (DFT) calculations suggest that aquation
occurs in a concerted ligand exchange mechanism which is associative in
character.38 As such, sterically demanding XY ligands can affect the rate
of aquation by hindering access to the metal, and this consequently slows
down the formation of a possible transition state.
In general, ruthenium arene complexes that hydrolyse readily are more
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likely to exhibit cancer cell cytotoxicity, whereas those which do not undergo
aquation exhibit little or no activity. The concentration gradient between
blood and cytoplasm can be used as a switch for anticancer activity after a
complex has entered the cell.39 High concentrations of chloride ions suppress
the hydrolysis of [(η6-arene)Ru(en)Cl]+ in the bloodstream (103 mM Cl),39
but chloride concentrations are much lower in the cytoplasm (23 mM) and
in the nucleus (4 mM).40 At these concentrations, it is more likely that a
ruthenium complex hydrolyses.
Osmium(II) arene complexes can also be activated by hydrolysis of the
OsZ bond. However, two parameters differ markedly between osmium com-
plexes and their ruthenium parent compounds. Firstly, aquation reactions
can be up to 100x slower for Os,29 and secondly, the resulting aqua adducts
are ca. 1.5 pKa units more acidic than [Ru]-OH2 species.
Fine-tuning with the Chelating Ligand
The cytotoxic effects of piano-stool complexes towards cancer cells can be
tuned by appropriate choice of the other building blocks.38
For both Ru and Os complexes, changing the donor atoms in the che-
lating ligand from N to O increases the hydrolysis rates and decreases the
acidity of the aqua adducts.27, 41 Hydrolysis rates increase with a change in
chelating ligand donors in the order N,N to N,O to O,O.
N,O-chelated Os(II) arene complexes exhibit intermediate behaviour
compared to N,N- and O,O-chelates.42, 43 Within the N,O-series, the re-
activity is highly dependent on the balance of the σ-donor vs. pi-acceptor
power of the ligand. For example, complexes with N,O-chelating amino
acids hydrolyse rapidly, whereas complexes with pi-acceptor pyridine as N-
donor and carboxylate as O-donor hydrolyse much more slowly.
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Figure 1.9: Effect of substituents on the rate of hydrolysis and cytotoxicity of
Os(II) picolinato complexes.
The rates of hydrolysis of Os picolinato complexes [(η6-biphenyl)Os(R-
pico)Cl] that differ only in their pico-substituent (R-pico, Figure 1.9) de-
crease with a decrease in electron donating ability of the substituent OH ≤
Me ≤ Br ≤ COO−. In this series, a para–carboxylate proves to be the most
deactivating substituent – it slows the hydrolysis down the most. This
complex was also the least active against human ovarian cancer cells.
Hydrogen-bonding Interactions
A change in XY from ethylenediamine (en) to acetylacetone (acac) can not
only significantly increase the pKa of the aqua-complex,44 but can also influ-
ence recognition patterns in biological targets. For example, the selectivity
towards the nucleobase Guanine (G) over Adenine (A) changes with the
choice of the donor atoms X and Y.44 Primary and secondary amine N,N-
ligands such as en can act as H–bond donors and enhance the selectivity for
G-binding by H–bond formation to C6O of the nucleobase. O,O-ligands,
in contrast, are H-bond acceptors and can H-bond with the C(6)NH2 of
adenine.39 Therefore, H-bonding properties can be used to direct a metal
complex towards specific target molecules. Selective recognition might be
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particularly crucial for the activity of drugs that target DNA.
In summary, the systematic structural investigations of the last years
conclusively point out that the activity of osmium(II) and ruthenium(II)
anticancer complexes can be modulated by chelate-ligand variations. One
aim of this thesis is therefore the design of new XY-chelating ligands and
the investigation of their ruthenium(II) half-sandwich complexes under bio-
logically relevant conditions.
Advancing the Selection of Chelating Ligands
Because ruthenium arene complexes of both N,N– and N,O–chelating lig-
ands have been studied extensively in the past, this thesis focusses on thi-
osemicarbazones as a new class of N,S-chelators. These are structurally
related to picolinamide ligands that were investigated previously by Van
Rijt and McGowan.45 The structures and properties of thiosemicarbazones
will be introduced in the next sections which constitute the second part of
this chapter. The aim of this choice for the chelating ligand is to contribute
to the search for new active anticancer compounds on the one hand, and
to the pool of information that relates their structure to anticancer activity
on the other.
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1.3 Thiosemicarbazones
Thiosemicarbazones (TSCs) were chosen for this research project due to
their biological and structural properties. The general structure of these
small organic molecules is shown in Figure 1.10.
Figure 1.10: General molecular structure of thiosemicarbazones.
One of the reasons why TSCs are interesting for drug development is
their ratio of hydrogen-bond donors and acceptors in the structure compared
to a generally low molecular weight. These properties fit well into Lipinski´ s
‘Rule of 5’ iv– the rule of thumb by which medicinal chemists have estimated
‘drug-likeness’ of organic molecules since 1997.46, 47
But TSCs have been investigated in medicinal chemistry for several dec-
ades longer than Lipinski’s ‘Rule’ has been used. The earliest reference to
a TSC with antiviral activity was published in the British Medical Journal
in 1964.48 The one-page report briefly describes the success of N-methyl-
isatin-β-thiosemicarbazone (Marborane, Figure 1.11) in the prevention of
smallpox infections. More reports on Methisazone followed this early study
and supported the antiviral activity of the TSC that was subsequently mar-
keted under the tradename Marborane R©.49, 50
The first detailed assessment of the anticancer activity of thiosemicar-
ivIn his first publication of these estimations, Lipinski suggests that an organic mo-
lecule is easier absorbed, or better permeating, in a physiological environment when it
containes ≤ 5 H-bond donors, ≤ 10 H-bond acceptors, a molecular weight below 500 Da,
and a log P value ≤ 5.46
When Lipinski reviewed these guidelines in 2004,47 they had been cited more than 1000
times - in less than 10 years. Today, his approximations of the relationship between
the structural properties of a molecule and its physiological availability are still popular
amongst medicinal chemists
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bazones was discussed in 1966.51 Studies by French et al. showed that
a nitrogen heterocycle in alpha position to the imine bond improved the
results for many TSC compounds.
(a) (b)
Figure 1.11: Structures of the smallpox drug Marborane R© (Methiazone) and
the P-gp-inhibitor NSC73306.
Thiosemicarbazones are still under investigation for their biological prop-
erties today,52 and the α -N-heterocycle appears to have been a consistent
structural feature. For example, NSC73306 (Figure 1.12) showed that the
incorporation of an isatin site in the molecule is essential for the thiosemicar-
bazone to be active against cell-lines that over-express P-glycoprotein.53 By
targeting this (drug-)eﬄux pathway, NSC73306 might overcome multi-drug
resistance.53, 54
(a) (b)
Figure 1.12: Structures of the iron-chelators Triapine R© and Dp44mT.
The iron-chelators 3-aminobenzaldehydethiosemicarbazone and di-pyridylketone-
4,4-dimethylthiosemicarbazone ((Triapine R© and Dp44mT, Figure 1.12) both
have N-heterocyclic moieties that are discussed to be closely linked to their
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activity as anticancer agents. Triapine is currently under clinical develop-
ment for the treatment of cervical cancer,55 and for iron-chelators of the
di-2-pyridylketone thiosemicarbazone (DpT) class, progress is steady.56–58
DpTs show excellent antiproliferative activity against neuroepithelioma cells
(SK-N-MC) with IC50 values in the low nano molar (nM) range and have
the ability to overcome cellular resistance to other cancer therapeutics.59
In summary, these examples show that TSCs are promising new drug
candidates, and the hypothesis that their potential for anticancer activity
may be transferable into new ruthenium based therapeutics is not without
reason. The following sections will give an overview of the general coordina-
tion chemistry of TSCs towards transition metal ions, and describe possible
relations to their biological activity.
1.3.1 Properties of Thiosemicarbazone Metal-Complexes
Many of the biological activities of TSCs seem to involve interactions with
metal ions inside the body. In fact, one of the first anticancer metal com-
plexes that included a TSC was a thiosemicarbazone-copper complex.60
During the last ten years, most of the related literature has described re-
search of TSCs as chelators for biologically important transition metals such
as iron(II/III)58, 59 or copper(I/II),.61–63 Tri- and tetradentate TSCs form
particularly stable complexes with copper64 or gallium ions, and those find
their application in radioimaging.65
As this thesis is focussed on the investigation of TSC ruthenium half-
sandwich complexes, the following sections will give an overview of the
general coordination chemistry of TSCs towards transition metal ions, and
the relation to biological activity.
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Tautomerisation of TSCs in Solution
TSC molecules in solution exist in one or more tautomeric forms. Fig-
ure 1.13 depicts the two tautomers; the thione form with a C=S double
bonded sulfur on the left, and the thiolate form with a N=C double and
C-SH single bond. Depending on the nature of the solvent and the pH, the
equilibrium between these forms can shift to either side. In the thiolate
form, the TSC can be deprotonated at the sulfur atom, which leads to the
negatively charged thiolato structure that is shown in Figure 1.13 on the
right. The different tautomeric forms need to be taken into account when
metal coordination of a TSC is discussed.
Figure 1.13: Tatomerism in TSCs.
Figure 1.14 summarises possible structures of thiosemicarbazone co-
ordination modes towards metal ions. The central metal ion is shown in
pink, and the structures that arise from the different binding modes are ar-
ranged in two rows, one for the thione form (top), and one for the thiolate
(bottom). From left to right, the denticity of the TSC towards the metal
increases, from monodentate to bi- and tridentate.
When the TSC sulfur atom is deprotonated, the coordination to a metal
ion leads to reduction of one positive charge at the metal centre. Coordin-
ation in the neutral thione form, however, yields a complex that bears the
original charge of the metal ion.
Most thiosemicarbazones that are discussed in the literature concerned
with biologically active TSC metal complexes contain a pyridine moiety in
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Figure 1.14: TSC - metal binding modes.
their structure. As the structure in the bottom right corner of Figure 1.14
suggests, the pyridine nitrogen can also act as a donor atom towards metal
ions, and thus most TSCs of current interest appear to be tridentate ligands.
For example, pyridyl-N,N-dimethylthiosemicarbazones, with a structure
similar to Dp44mT (Figure 1.12), form octahedral bis-ligand complexes with
GaIII , FeIII and RuIII in which the N,N,S-ligands are deprotonated.66, 67
This is understandable, as the coordination of two tridentate TSCs, bound
in the deprotonated thiolate form, is both sterically and entropically more
favoured than the coordination of three bidentate ligands.68 The steric
component in this explanation is important, because the strict planarity
of α N-heterocyclic TSCs aids deprotonation and tridentate meridional co-
ordination to metals with d6 electron configuration. Those metals, such as
Fe3+ in its low-spin form, prefer octahedral coordination, and the tridentate
planar TSC ligands offer good overlap between their donor atoms and three
meridional d-orbitals of the metal.
Metal Coordination Can Enhance Biological activity
Coordination to metal ions can enhance the biological activity of TSCs
compared to their unbound state. For example, benzoylpyridine thiosemi-
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carbazones show activity against leukaemia cells (HL60) with IC50 values
in the micromolar (µM) range, but become significantly more active (from
µM to nM) when bound to Sb3+.69
The antimicrobial activity of N-alkyl-substituted TSCs (alkyl = H, Me,
Et)was found to increase when they are incorporated into organometallic
tin compounds.70 Furthermore, the activity of these TSCs against brain
tumour cells increased not only with longer alkyl chains, but their Ga3+
complexes showed much higher activity than the free ligands. Overall, the
Ga-methyl analogue proved to be best.71
Interestingly, the main increase in activity upon coordination to the
metal is attributed to a conformation change of the ligand from E to Z
with regard to the (S=)CN(-N) bond. It can therefore be concluded that
coordination to a metal ion is a means to activate thiosemicarbazone cyto-
toxicity.
Thiosemicarbazone Complexes with Precious Metals
Many recent studies focus on complexes of thiosemicarbazones with precious
metals. Moving systematically from group nine to group ten metals, this
section summarises the main findings with respect to structural as well
as biological data. In the platinum group, most examples are of Pd(II)
and Pt(II) along with some Ni(II) complexes. The group ten examples are
mostly of Cu(I/II) amongst a few Au(I) and Au(III) complexes.
The TSC ligands bind differently in square planar d8-complexes of Pd(II)
and Ni(II).72, 73 In the former, the TSC is coordinated to Pd(II) in the
thiolate form, while it binds in the neutral thione form to Ni(II). The nickel
complexes are more active than the palladium derivatives against A549
cancer cells.
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The ligand substituents seem to tune this activity further. In partic-
ular, derivatisation of O,N,S-ligands by systematically substituting one of
the thioamide NH2 protons showed a dependency of the biological activ-
ity on the electron donating ability of the substituent (Et > Me > H >
Ph).74, 75 Furthermore, H and Ph substituted compounds showed inter-
calative binding towards ct-DNA, while Me and Et derivatives exhibited
weaker interactions due to the increased steric bulk. This result shows that
the amide substituents, the charge of the TSC and the metal itself all have
an effect on structure and activity of the complex.
The strong effect of the d8-configuration in Pd(II) and Pt(II) complexes
forcing their square-planar coordination environment is demonstrated by ex-
amples reported by Quiroga et al. who found examples of bidentate TSCs,
i.e. without a pyridine moiety, that acted as planar tridentate (C,N,S)-
ligands via a cyclometallated phenyl ring. The tetranuclear complexes ex-
hibit cytotoxic activity comparable to cisplatin and are also active in cell
lines with resistance to the clinical Pt drug.76, 77
Moving to group ten of the d-block elements, the structures of TSC com-
plexes depend on the charge of the metal centre. In Cu(I) complexes the
d10 configuration forces octahedral geometries, while Au(I) prefers linear
S-coordination. Au(III), in contrast, pushes towards square-planar coordin-
ation due to its d8-configuration, comparable to Pt(II) and Pd(II).
Similarly, Au(I)-TSC complexes are formed by linear monodentate S-
coordination. Examples presented by Beraldo et al. exhibit anticancer
activity and inhibit thioredoxin reductase better than the free ligands.78 Or-
ganometallic square-planar Au(III) complexes are formed both with bident-
ate and tridentate TSCs,79 and the low affinity of the Au3+ cation for oxygen
ligands (according to the HSAB concept) could explain bidentate coordina-
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tion of a potentially tridentate ligand, as found for a salicylaldehyde-derived
thiosemicarbazone.
The main conclusion that results from this overview is that the structures
of organometallic TSC complexes with precious metals are highly governed
by the d-electron configuration of the metal. In particular, most complexes
of the d8 metal ions Pd2+, Pt2+ and Au3+ appear to be of the expected
square planar geometry.
For the work presented herein, this finding implies that the coordination
of a TSC to the ruthenium arene fragment might be affected more by the
electronic structure of the metal than steric factors introduced by the p-
cymene ligand. Most certainly, α-N-heterocyclic TSCs that lend themselves
easily to planar meridional coordination should be avoided in the search for
a chelating ligand for a piano-stool complex. The facially bound arene only
leaves room for another facial ligand, or for mono- / bidentate coordination.
1.3.2 Organometallic Ruthenium Thiosemicarbazone
Complexes
The facile availability of thiosemicarbazones can lead to a great structural
diversity of this class of chelators. Because small variations to their sub-
stituents can influence the biological properties of the TSC as well as their
metal complexes, they appear to be ideal ligands for anticancer metal com-
plexes. Although TSCs have been widely studied as ligands for metals such
as palladium, platinum, copper and gold, not many examples can be found
for organometallic ruthenium or osmium complexes.
Only few arene-ruthenium complexes of thiosemicarbazone ligands have
been reported. In those, it has been found that the TSC either binds as
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N,S-chelator towards a Ru2+ centre, or coordinates in a monodentate, S-
bound fashion.80, 81 Examples of both anticancer and antimicrobial activ-
ity of Ru TSC complexes exist,82–84 and those early reports encourage the
work presented in this thesis as they indicate that the combination of
thiosemicarbazones with the ruthenium-arene fragment could potentially
yield novel active complexes. One example shows how target selectivity for
acidic tumour tissue might be introduced by coordination of a TSC to a
ruthenium(III) centre.85
It can be concluded that TSC metal complexes offer a broad variety
of structural switches, not only because the ligands are easily available,
but also because they have potential anticancer activity of their own. Co-
ordination to metals further increases this potential, and also allows for the
properties of the resulting compounds to be tuned more precisely. In sum-
mary, it is worth to investigate all properties of both thiosemicarbazones
and their various metal complexes in order to understand how these can
be utilised for particular biological applications. For this reason, combining
thiosemicarbazones with the ruthenium-arene fragment to TSC ruthenium
half-sandwich complexes bears the potential for new anticancer chemothera-
peutics.
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1.4 Synchrotron Radiation for X-ray Spec-
troscopy
Synchrotron radiation (SR) contains a broad spectrum of high-energy X-
rays, and the brilliance and focus that dedicated synchrotron light sources
can achieve is much greater than what is attainable with laboratory X-
ray sources. The high flux and brightness allow good quality XAS data
to be obtained on a much shorter timescale than with bench-top X-ray
spectrometers. Beamlines of third-generation synchrotrons that host XAS
experiments, such as B18 at the Diamond Light Source, use high-precision
optical equipment to provide a tuneable monochromatic X-ray beam of
excellent focus and energy resolution. Hence, X-ray absorption spectroscopy
benefits greatly from the use of synchrotron light.
As an introduction to the synchrotron XAS experiments that are presen-
ted in Chapter 3 of this thesis, the following sections will briefly describe
the basic theory of XAS and the production of synchrotron radiation.
1.4.1 Synchrotron Radiation
Synchrotron radiation (SR) was discovered as a by-product that occurred
in particle accelerators. Purpose-built 3rd-generation synchrotrons such as
Diamond Light Source generate synchrotron light of a broad energy spec-
trum that ranges from infrared (IR), visible (vis), and ultraviolet (UV) light
up to the energy of X-rays.
When charged particles (e.g. electrons) travel at almost the speed of
light, their energy increases as a function of their velocity. Upon entering
a magnetic field which forces the travelling high-energy electrons to alter
their flight path, this change in direction slows the electrons down, they
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loose kinetic energy. This energy is emitted in the form of photons, and
these constitute synchrotron radiation. The phenomenon is well described
(quite literally) by the German word “Bremsstrahlung”.
Photons are non-charged particles, and as such they are unaffected by
the magnetic field that bends the electron path. As a result, the photon
beam propagates along the original trajectory of the parent electrons at the
point their path was bent.
1.4.2 The Production of Synchrotron Light
A synchrotron light source (Figure 1.15) accelerates a beam of electrons
by directing it around a ring of bending magnets, known as the storage
ring. Figure 1.15 summarises the constituents of a typical synchrotron,
navigating through the path of the beam by starting from the electron gun
(a) and ending in the experimental hutch of a beamline (e), where it can
be used for X-ray spectroscopy.
The path of the beam starts at the heart of the synchrotron, at the
electron gun (a) which emits thermionic high-energy electrons. Those are
linearly accelerated (b) directly into the booster synchrotron (c). Here,
acceleration to near speed of light increases the beam energy to 3.0 GeV.
The main synchrotron (d), i.e. the storage ring, receives regular injections
of electrons to maintain the beam energy as well as a stable current and
flux. Each bending magnet represents a corner of the ring at which insertion
devices such as wigglers or undulators produce additional “Bremsstrahlung”
that exits the storage ring into a beamline (e). The optics set-up inside each
beamline uses collimating and focussing mirrors to immediately refocus (and
filter) the synchrotron radiation for its respective experimental use.
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Figure 1.15: Operating scheme of a Synchrotron Light Source: (a) electron
gun produces high-energy electrons, (b) the linear accelerator and (c) booster
synchrotron accelerate electrons to approx. speed of light, (d) the storage
ring maintains the electron beam. Insertion devices produce synchrotron radi-
ation that exits the storage ring, (e) beamlines re-focuss and filter the SR for
experimental use.
v.
1.4.3 X-ray Absorption Spectroscopy
The Beer − Lambert law (Equation 1.1) describes the attenuation of light
that has the energy E and intensity I0 by a sample of the length d. Equa-
tion 1.1 states that the intensity of transmitted light It depends on the
molar absorption coefficient μ(E) of the material as well as the sample thick-
ness.86, 87
It = I0 · e−µ(E)· d (1.1)
X-ray absorption spectroscopy measures the element specific absorption
coefficient of a material whose core-electrons are excited by light in the
energy range of X-rays (2-35 keV). Figure 1.16 depicts a Ru K-edge XAS
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Figure 1.16: A Ru K-edge X-ray absorption spectrum, showing the edge posi-
tion E0 and the two main spectral regions of interest: X-ray absorption near-edge
structure (XANES) around ± 30 eV of E0 and the extended X-ray absorp-
tion fine-structure (EXAFS), consisting of the higher-energy oscillations beyond
E0 + 50 eV. Inset shows expansion of XANES region.
spectrum.
During the experiment, the energy of the incident X-ray beam sweeps
from lower to higher values within the range of a few hundred eV around the
ionisation energy of a core-electron level of the respective element. When
the incident monochromatic X-ray beam has sufficient energy to eject a core
electron from the K-shell, this electron is being excited to a higher orbital.
At this energy, an abrupt increase in the absorption coefficient µ(E) is
visible in the spectrum. This dominant feature is known as absorption edge
or rising edge. The inflection point of the absorption edge is used to determ-
ine the edge energy E0.
88, 89 Spectral features within E0 ± 50 eV are referred
to as near-edge structure, and are analysed in X-ray absorption near-edge
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spectroscopy (XANES).90 This region can contain useful information about
the electronic structure of metal-ligand interactions.91 In particular, ligand
K-edge XANES is an increasingly popular tool, for example in the study of
proteins that contain spectroscopically silent metals,92 but can also be used
for the study of ligand binding in organometallic anticancer complexes.93
The extended X-ray absorption fine-structure (EXAFS) comprise of the
high-energy oscillations in the XAS spectrum beyond E0 + 50 eV. These are
visible modulations to an otherwise linearly decaying absorptivity, and are
caused by electron-scattering within the coordination sphere of the central
absorber whose core-electron has been ejected. The EXAFS oscillations
therefore hold specific information about the atomic structure of a material
that can be extracted by careful theoretical modelling of the experimental
data.
Chapter 3 presents XAS studies of novel arene ruthenium TSC com-
plexes. It describes the procedure and results of EXAFS fitting of their first
coordination sphere, which elucidates Ru-TSC coordination in both solid
state and solution.
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1.5 Aims
The hypothesis that combining the properties of TSCs with the ruthenium
arene motif can lead to new anticancer piano-stool complexes give rise to
the following aims for this thesis.
• Synthesise and characterise thiosemicarbazones and incorporate iod-
ine as a substituent in some of the TSCs to introduce a possible re-
porter label.
• Synthesise and characterise novel p-cymene Ru(II) complexes with
these TSCs as chelating XY ligands and both chloride and iodide as
the respective monodentate Z ligand.
• To elucidate the structures of the TSC ligands in solution and the
nature of their coordination to Ru(II) using 1H and 15N NMR spec-
troscopy.
• Characterise the complexes in the solid state by X-ray crystallography
and by X-ray absorption spectroscopy. Use EXAFS to determine the
first co-ordination sphere of complexes that do not crystallise, and
extend this to solution studies.
• Determine the antiproliferative activities of selected new complexes
in human ovarian cancer cells (A2780) and investigate their mode of
action.
• Investigate the use of ICP-MS for the detection of iodine and ruthenium
and study the accumulation of both elements from the complexes in
A2780 cells to determine whether Ru(II) and its ligands, both the
TSC and iodide as Z ligand are accumulated inside cancer cells.
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Chapter 2
Synthesis, Structure and NMR
Spectroscopy of
Thiosemicarbazone Arene
Ruthenium Complexes
Thiosemicarbazones have been investigated as therapeutic agents for over
50 years. The structures of current interest contain a nitrogen heterocycle
in alpha position to the imine bond, which is the result of historic antic-
ancer studies which concluded that α-N-heterocyclic TSC showed stronger
activities.1, 2 NSC73306 is one current example with potential to overcome
multi-drug resistance.3, 4 Moreover, coordination to metal ions often en-
hances the biological activity of cytotoxic or antibacterial TSCs.5
Because of the promising anticancer activity of some TSCs, this work
sets out to shed light on the activity of thiosemicarbazone ruthenium arene
complexes against human ovarian cancer cells.
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2.1 Introduction
Ruthenium arene complexes are promising candidates in the research for
novel anticancer treatments. One of their intrinsic properties is their struc-
tural versatility, which can yield labile structures or rather inert ones, de-
pending on the ligand set. Labile structures have the potential to be fine-
tuned in a way that allows the controlled release of ligands inside cells. For
this purpose, it is important to develop a method of tracking the ligands
inside cells or other biological matrices.
This chapter presents the synthesis and characterisation of twelve thi-
osemicarbazones, including six structures that incorporate iodine substitu-
ents in order to use their complexes in iodine tracing experiments. Sub-
sequently, the synthesis and characterisation of p-cymene ruthenium com-
plexes of the general formula [(η6-arene)Ru(XY)Z]+A− will be presented,
which includes the chlorido (Z = Cl−) and iodido (Z = I−) analogue for each
TSC ligand. Single crystal structures for two examples will be discussed.
In-depth characterisation by NMR-spectroscopic methods is an objective
to elucidate as many potential reporter atoms within the structure of a
ruthenium arene TSC complex as possible. Therefore, 1H15N-HMBC-NMR
studies will be used to characterise the 15N-NMR chemical shifts for the
TSCs and their corresponding complexes.
38
2.2 Experimental Section
2.2.1 Materials
Chemicals for the synthesis and characterisation of thiosemicarbazone lig-
ands and arene ruthenium TSC complexes are listed in Table 2.1 below. The
table lists the quality and sources of the purchased materials. Chemicals
were used as received, without further purification.
Table 2.1: Materials which were used to carry out the work presented in this
chapter, listing their source and the quality/purity as stated by the vendor.
Material (Quality) Source
Chemicals:
Benzaldehyde Fischer Scientific
3-Iodobenzaldehyde Apollo Scientific
4-N,N-Dimethylaminobenzaldehyde Sigma Aldrich
Thiosemicarbazide (99 %) Sigma Aldrich
4-Methyl-3-thiosemicarbazide (97 %) Sigma Aldrich
4-Dimethyl-3-thiosemicarbazide (98 %) Sigma Aldrich
4-Iodophenylisothiocyanate (97 %) Sigma Aldrich
RuCl3·na) H2O (min. 42-44 % Ru) Precious Metals Online,
PMO Pty Ltd.
Deuterated solvents:
Chloroform-d (CDCl3, ≥ 99 % D) Cambridge Isotopes
Laboratories, Inc.
DMSO-d6 (CD3SOCD3)
Methanol-d4 (CD3OD)
a) For stoichiometric calculations, an average Ru content of 43% was as-
sumed, equal to n = 1.5.
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2.2.2 Thiosemicarbazone Synthesis
Thiosemicarbazone ligands were synthesised using adapted literature pro-
cedures.6, 7 The basic reaction is the condensation of an aldehyde compon-
ent with a free NH2 moeity of a thiosemicarbazide (Figure 2.1).
Figure 2.1: Reaction scheme of Schiff-base formation between aldehydes (1-3)
and thiosemicarbazides (a-c) in methanol to form thiosemicarbazones 1-3a-c.
The following section contains the experimental details and also sum-
marises the spectroscopic data which were obtained for each ligand. To aid
clarity, the TSCs are systematically referred to by their aldehyde compon-
ent, combined with the respective substitution of the parent thiosemicar-
bazide and the suffix ‘thiosemicarbazone’.
Benzaldehydethiosemicarbazones
1a 1b 1c 1d
Figure 2.2: TSC ligands of benzaldehyde.
(1a) Benzaldeydethiosemicarbazone
Thiosemicarbazide (0.91 g, 10 mmol) was dissolved in ethanol (10 mL) by
stirring at ambient temperature for 10 min. A solution of benzaldehyde
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(1.1 mL, 1.06 g, 10 mmol) in ethanol (15 mL) was added and the reaction
mixture was heated to reflux and stirred for 16 h while refluxing. Cool-
ing to room temperature yielded a white precipitate which was isolated by
filtration and dried in air (551 mg, 30%). 1H NMR (400 MHz, dmso-
d6) 7.50-7.32 (m, 3H), 7.86-7.70 (m, 2H), 7.99 (s, 1H, NH), 8.05 (s, 1H,
NH), 8.20 (s, 1H, N=CH), 11.43 (s, 1H, N-NH) 13C NMR (100 MHz,
dmso-d6) 127.2 (CH), 128.5 (CH), 129.7 (CH), 134.1 (CH), 142.1 (C=N),
177.9 (C=S), ESI-MS (MeOH) m/z (rel. int.) 360 (100) [2M+H]+ , 202
(30) [M+Na]+, CHN (calc. for C8H9N3S, FW = 179.25) 53.50 (53.61) %C,
5.07 (5.06) %H, 23.45 (23.44) %N, 17.94 (17.89) %S.
(1b) Benzaldeyde-4-methyl-3-thiosemicarbazone
Procedure as for 1a, except solvent change to methanol for solubility reas-
ons. Benzaldehyde was added without prior dilution. Reaction of 4-methyl-
3-thiosemicarbazide (213 mg, 2 mmol) with benzaldehyde (200 µL, 2 mmol)
in methanol. Yield: 339 mg (88%) white powder. 1H NMR (400 MHz,
dmso-d6) 3.02 (3H, d, J=4.6 Hz), 7.40 (2H, m), 7.80 (3H, m), 8.04 (1H, s,
N=CH), 8.50 (1H, q, J=4.3 Hz, NHMe), 11.47 (1H, s, NH-N) 13C NMR
(100 MHz, dmso-d6) 30.9 (NCH3), 127.2 (2 CH), 128.6 (2 CH), 129.7 (CH),
134.3 (Cq), 141.7 (C=N), 177.8 (C=S) ESI-MS (H2O) m/z (rel. int.) 194
(10) [M+H]+, 409 (10) [2M+Na]+, 425 (100) [2(M-H)+Na+H2O]
+ UV/Vis
(H2O) 307 nm (5199 L·mol−1·cm−1) CHN (calc. for C9H11N3S, FW =
193.27) 55.41 (55.93) %C, 5.74 (5.74) %H, 22.08 (21.74) %N.
(1c) Benzaldeyde-4-dimethyl-3-thiosemicarbazone8
Procedure as for 1b. Reaction of 4-dimethyl-3-thiosemicarbazide (238 mg,
2 mmol) with benzaldehyde (200 µL, 2 mmol) in methanol. Yield: 213 mg,
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(51%) white crystalline powder. 1H NMR (400 MHz, dmso-d6) 3.33 (s,
6H), 7.41 (m, 3H), 7.64 (m, 2H), 8.19 (s, 1H, N=CH), 10.94 (s, 1H, NH)
13C NMR (100 MHz, dmso-d6) 42.2 (NCH3), 126.7 (2 CH), 128.9 (2
CH), 129.6 (CH), 134.6 (Cq), 143.8 (C=N), 180.5 (C=S) ESI-MS (H2O)
m/z (rel. int.) 208 (5) [M+H]+, 230 (100) [M+Na]+. UV/Vis (H2O)
302 nm (9811 L·mol−1·cm−1) CHN (calc. for C10H13N3S, FW = 207.30)
57.62 (57.94) %C, 6.21 (6.32) %H, 20.13 (20.27) %N.
(1d) Benzaldehyde-4-(4-iodophenyl)-3-thiosemicarbazone
4-Iodo-phenylisothiocyanate (4.0 mmol, 1.04 g) was dissolved in methanol
(25 mL). With stirring, hydrazine monohydrate (4 mmol, 200 µL) and ben-
zaldehyde (4 mmol, 400 µL) were added. The mixture was heated to reflux
and a white solid precipitated subsequently. The mixture was stirred under
reflux for 2 hours. After cooling to room temperature, the white solid was
isolated by filtration and dried in air (1.09 g, 71%). 1H NMR (400 MHz,
dmso-d6) 7.42 (d, 2H, J=2.5 Hz), 7.45 (d, 2H, J=8.6 Hz), 7.71 (d, 2H,
J=8.6 Hz), 7.83-7.98 (m, 2H), 8.17 (s, 1H), 10.11 (s, 1H, NH), 11.91 (s, 1H,
N-NH) dmso-d6 (100 MHz, dmso-d6) 89.9 (Cq), 127.7 (2CHarom), 127.9 (2CHarom),
128.6 (2CHarom), 130.1 (CHarom), 133.9 (Cq), 136.7 (2CHarom), 139.0 (Cq),
143.2 (C=N), 175.8 (C=S) ESI-MS (MeOH) m/z (rel. int.) 404 (100)
[M+Na]+ CHN (calc. for C14H12N3ISNa, FW = 404.23) 41.50 (41.60) %C,
2.98 (2.99) %H, 10.72 (10.40) %N.
42
N,N-Dimethylaminobenzaldehydethiosemicarbazones
2a 2b 2c 2d
Figure 2.3: TSC ligands prepared from N,N-dimethylaminobenzaldehyde (2).
(2a) N,N-Dimethylaminobenzaldehydethiosemicarbazone9, 10
Procedure as for 1b. Thiosemicarbazide (467 mg, 5 mmol) was reacted with
4-N,N-dimethlaminobenzaldehyde (748 mg, 5 mmol) in methanol. Yield:
740 mg, 67%. 1H NMR (400 MHz, dmso-d6) 2.94 (s, 6H, NMe2), 6.69 (d,
2H, J = 9.3 Hz CHarom), 7.58 (d, 2H, J = 8.7 Hz, CHarom), 7.77 (s,
1H, NH2), 7.93 (s, 1H, N=CH), 8.01 (s, 1H, NH2), 11.19 (s, 1H, NH)
13C NMR (100 MHz, dmso-d6) 39.9 (NCH3), 111.7 (CHarom), 121.5 (Cq),
128.7 (CHarom), 141.4 (Cq), 143.4 (C=N), 177.1 (C=S) ESI-MS (MeOH)
m/z (rel. int.) 507 (90) [(2M+Na)+OH−]+, 245 (95) [M+Na]+, 223 (100)
[M+H]+ CHN (calc. for C10H14N4S, FW = 222.31) 53.93 (54.03) %C,
6.27 (6.35) %H, 25.23 (25.20) %N, 14.41 (14.42) %S.
(2b) N,N-Dimethylaminobenzaldehyde-4-methyl-3-thiosemicarbazone11
Procedure as for 1b. 4-Methyl-3-thiosemicarbazide (210 mg, 2 mmol) was
reacted with 4-(N,N-dimethylaminobenzaldehyde (298 mg, 2 mmol) in meth-
anol. Yield: 100 mg, 21 %. Suitable single-crystals of DTSCNMe 2b for
structure determination by X-ray diffraction grew by slow evaporation of
solvent from a saturated solution of the ligand in dmso-d6.
1H NMR
(400 MHz, dmso-d6) 2.96 (s, 6H, NMe2), 3.00 (d, 3H, J=4.6 Hz, NHCH3),
6.71 (d, 2H, J=9.3 Hz), 7.58 (d, 2H, J=8.7 Hz), 7.92 (s, 1H, N=CH),
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8.28 (q, 1H, J=4.4 Hz, NHMe), 11.19 (s, 1H, NH-N) 13C NMR (100 MHz,
dmso-d6) 30.7 (NHCH3), 39.8 (NMe2), 111.7 (2 CH), 121.5 (Cq), 128.5 (2
CH), 142.8 (C=N), 151.3 (CqN), 177.1 (C=S) ESI-MS (H2O) m/z (rel
int.) 235 (70) [M-H]+, 259 (100) [M+Na]+ CHN (calc. for C11H16N4S, FW
= 236.64) 55.58 (55.90) %C, 6.77 (6.82) %H, 23.29 (23.71) %N.
(2c) N,N-Dimethylaminobenzaldehyde-4-dimethyl-
3-thiosemicarbazone
Procedure as for 1b. 4-Dimethyl-3-thiosemicarbazide (240 mg, 2 mmol) re-
acted with 4-N,N-dimethylaminobenzaldehyde (298 mg, 2 mmol) in meth-
anol. Yield: 73 mg, 14%. 1H NMR (dmso-d6) 2.95 (s, 6H, NMe2),
3.26 (s, 6H, NMe2), 6.74 (d, 2H, J=8.8 Hz), 7.45 (d, 2H, J=8.9 Hz),
8.03 (s, 1H, NCH), 10.65 (s, 1H, NNH) 13C NMR (dmso-d6) 39.8 (NCH3),
42.1 (NCH3), 111.9 (2CHarom), 122.0 (Cq), 128.0 (2CHarom), 144.9 (C=N),
151.3 (Cq), 170.5 (C=S) ESI-MS (H2O) m/z (rel. int.) 249 (20) [M-H]
+,
273 (100) [M+Na]+ UV/Vis (H2O) 352 nm (20693 L·mol−1·cm−1) CHN
(calc. for C12H18N4S·H2O, FW = 268.38) 53.75 (53.70) %C, 7.47 (7.51) %H,
20.36 (20.88) %N.
(2d) N,N-Dimethylaminobenzaldehyde-4-(4-iodophenyl)-
3-thiosemicarbazone
Procedure as for 1d. 4-Iodophenyl-isothiocyanate (840 mg, 3.1 mmol) re-
acted with 4-N,N-dimethylaminobenzaldehyde (465 mg, 3.1 mmol) and hy-
drazine monohydrate (200 µL, 4 mmol). Yield: 1.13 g, 76%. 1H NMR
(300 MHz, dmso-d6) 2.97 (s, 6H, NMe2), 6.72 (d, 2H, J=9.2 Hz), 7.47 (d,
2H, J=13.9 Hz), 7.47 (d, 2H, J=4.7 Hz), 7.47 (d, 2H, J=8.7 Hz), 7.70 (d,
2H, J=1.5 Hz), 8.04 (s, 1H, N=CH), 9.94 (s, 1H, NH), 11.67 (s, 1H, NH)
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1H NMR (400 MHz, CDCl3) 3.05 (s, 6H, NMe2), 6.88 (d, 2H, J=7.2 Hz),
7.46 (d, 2H, J=8.6 Hz), 7.58 (d, 2H, J=8.9 Hz), 7.68 (d, 2H, J=8.4 Hz),
7.77 (s, 1H, N=CH), 9.13 (s, 1H, NH), 9.47 (s, 1H, NH) 13C NMR
(75 MHz, dmso-d6) 174.8 (C=S), 151.6 (Cq), 144.3 (C=N), 139.1 (Cq),
136.9 (2CHarom), 129.3 (2CHarom), 127.6 (2CHarom), 121.0 (Cq), 111.6 (2CHarom),
89.6 (Cq), 30.4 (NCH3) ESI-MS (MeOH/H2O) m/z (rel. int.) 447 (100)
[M+Na]+ CHN (calc. for C16H17IN4S, FW = 424.30) 45.22 (45.29)%C,
3.95 (4.04)%H, 13.13 (13.20)%N.
3-Iodobenzaldehydethiosemicarbazones
3a 3b 3c 3d
Figure 2.4: TSC ligands of 3-iodobenzaldehyde (3).
(3a) 3-Iodobenzaldehydethiosemicarbazone
Procedure as for 1b. 3-Iodobenzaldehyde (5 mmol, 1.17 g) was reacted
with thiosemicarbazide (5 mmol, 459 mg) in methanol. Yield: 1.15 g,
77%. 1H NMR (400 MHz, dmso-d6) 7.18 (t, 1H, J=7.8 Hz), 7.71 (t,
2H, J=7.0 Hz), 7.96 (s, 1H), 8.16 (s, 1H), 8.23 (s, 1H), 8.29 (s, 1H),
1.47 (s, 1H, NH) 13C NMR (100 MHz, dmso-d6) 178.2 (C=S), 140.6 (C=N),
138.2 (CH), 136.5 (Cq), 138.8 (CH), 130.8, 127.3, 95.5 (Cq) ESI-MS (MeOH)
m/z (rel. int.) 328 (100) [M+Na]+ CHN (calc. for C8H8IN3S, FW
= 305.14) 31.44 (31.49) %C, 2.57 (2.64) %H, 13.77 (13.77) %N, 10.40
(10.51) %S.
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(3b) 3-Iodobenzaldehyde-4-methyl-3-thiosemicarbazone
Procedure as for 1b. Reaction of 4-methyl-3-thiosemicarbazide (210 mg,
2 mmol) with 3-iodobenzaldehyde (467 mg, 2 mmol). Yield: 573 mg, 90%.
1H NMR (dmso-d6) 3.02 (d, 3H, J=4.5 Hz), 7.20 (t, 1H, J=7.8 Hz),
7.72 (dt, 2H, J=12.40, 7.7 Hz), 7.96 (s, 1H, N=CH), 8.26 (d, 1H, J=3.0 Hz),
8.60 (q, 1H, J=4.5 Hz, NHMe), 11.53 (s, 1H, NH-N) 13C NMR (dmso-d6)
30.9 (NCH3), 95.4 (Cq), 127.2 (CH), 130.7 (CH), 134.6 (CH), 136.6 (Cq),
138.1 (CH), 140.1 (C=N), 177.8 (C=S) CHN (calc. for C9H10IN3S, FW =
319.17): 33.85 (33.87) %C, 3.07 (3.16) %H, 13.33 (13.17) %N.
(3c) 3-Iodobenzaldehyde-4-dimethyl-3-thiosemicarbazone
Procedure as for 1b. 4-Dimethyl-3-thiosemicarbazide (240 mg, 2 mmol) was
reacted with 3-iodobenzaldehyde (464 mg, 2 mmol) in methanol. Yield:
532 mg, 80%. 1H NMR (dmso-d6) 3.28 (s, 6H, NMe2), 7.22 (t, 1H,
J=7.8 Hz), 7.64 (dt, 1H, J=7.8, 1.1 Hz), 7.74 (dt, 1H, J=7.88, 1.4 Hz),
8.00 (t, 1H, J=1.6 Hz), 8.12 (s, 1H, N=CH), 11.01 (s, 1H, NH). 13C NMR
(dmso-d6) 42.1 (CH3), 95.3 (Cq), 126.4 (CH), 131.0 (CH), 134.6 (CH),
137.0 (Cq), 138.0 (CH), 142.2 (C=N), 180.5 (C=S) ESI-MS-pos (H2O)
m/z (rel. int.) 356 (100) [M+Na]+ ESI-MS-neg (H2O) m/z (rel. int.) 332
(100) [M-H]− CHN (calc. for C10H12N3ISNa (356.19)) 34.08 (33.72) %C,
3.55 (3.40) %H, 12.08 (11.80) %N.
(3d) 3-Iodobenzaldehyde-4-(4-iodophenyl)-3-thiosemi-carbazone
Procedure as for 1d. Reaction of 4-iodophenylisothiocyanate (840 mg,
3.1 mmol), 3-iodobenzaldehyde (718 mg, 3.1 mmol), and hydrazine mono-
hydrate (200 µL, 4 mmol) in methanol. Yield: 1.41 g, 89 %. 1H NMR
(300 MHz, dmso-d6 7.22 (1H), 7.39 (2H), 7.71 (2H), 7.82 (1H) 8.08 (1H),
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8.35 (1H), 10.20 (1H, NH), 11.95 (1H, NH) 13C NMR (75 MHz, dmso-d6)
176.2 (C=S), 141.7 (N=CH), 139.0 (Cq), 138.6 (CH), 136.9 (2CH arom.),
136.3 (Cq), 135.1 (CH), 130.7 (CH), 128.5 (CH), 127.6 (CH), 95.4 (Cq), 90.3
(Cq) ESI-MS m/z (rel. int.) 530 (100) [M+Na]
+, 508 (20) [M+H]+ CHN
(calc. for C14H11I2N3S) 32.92 (33.16) %C, 2.13 (2.19) %H, 8.56 (8.29)% N.
2.2.3 Synthesis of Ruthenium Complexes
Arene Ruthenium Starting Materials
Ethanol used during the preparation of p-cymene-ruthenium starting ma-
terials was freshly distilled over Mg prior to the synthesis.
For the preparation of ruthenium TSC complexes, [(p-cymene)RuCl2]2
([4]) and [(p-cymene)RuI2]2 ([5]) were used as precursors, which were syn-
thesised according to literature procedures.12, 13 The reaction of α-phellandrene
(Figure 2.5) with ruthenium(III) chloride (RuCl3·1.5 H2O) yields the ruthenium
chlorido dimer [4].
Reacting [4] with excess KI (Figure 2.6) substitutes all four chlorido
ligands in the molecular structure with iodide, resulting in the iodido dimer
[5]. The purity of the two precursor compounds was assessed by comparison
of their individual 1H NMR spectra with reported values.
[4] [(p-cymene)RuCl2]2 A 1L three-necked round-bottom flask was equipped
with a reflux condenser and evacuated four times prior to addition of RuCl3·1.5
H2O (5.27 g, 22.5 mmol Ru). Freshly distilled ethanol was added (350 mL)
to give a dark brown solution. With stirring, α-phellandrene (34 mL, 29 g,
209 mmol, 9.5 mol. eq.) were added to the mixture which was stirred un-
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Figure 2.5: Synthesis of [(p-cymene)RuCl2]2
der reflux for 36 h. A black solid was separated from the hot, dark red
solution by suction filtration while hot, washed with hot ethanol (15 mL)
and the filtrate was left to cool overnight. Bright red crystals precipitated
from the solution. These were isolated by filtration and dried in air (3.1 g,
50 %).1H NMR (300 MHz, CDCl3) 1.25 (d, J=6.8 Hz, 6H), 2.13 (s, 3H),
2.9 (m, 1H), 5.31 (d, J=5.8 Hz, 2H), 5.44 (d, J=5.8 Hz, 2H).
Figure 2.6: Synthesis of [(p-cymene)RuI2]2
[5] [(p-cymene)RuI2]2 ([4], 1.22 g, 2 mmol) was suspended in water
(250 mL) and heated to reflux. The red solution was stirred for one hour
and then filtered while hot. To the filtrate, a solution of potassium iodide
(4.0 g, 24 mmol) in water (15 mL) was added drop wise. The colour of
the reaction mixture changed immediately from orange to purple as a solid
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precipitated with further addition of KI. After cooling to room temperature,
the dark purple suspension was filtered, the purple solid was washed with
cold water (30 mL) and subsequently dried with suction and in vacuum
(1.8 g, 100 %). 1H NMR (400 MHz, CDCl3) 1.23 (d, J=6.9 Hz, 6H),
3.00 (m, J=7.4 Hz, 1H), 5.41 (d, J=5.4 Hz, 2H), 5.51 (d, J=5.9 Hz, 2H).
Arene Ruthenium TSC Complexes
This section summarises the experimental details for the synthesis of arene
Ru(II) complexes, using the TSCs prepared above as chelating ligands. The
complexes were synthesised by an adapted literature method.14–16 Figure 2.7
presents the reaction scheme. Briefly, the precursors [(p-cymene)RuCl2]2 or
Figure 2.7: Reaction scheme showing the synthesis of arene RuII TSC com-
plexes.
[(p-cymene)RuI2]2 were reacted with 2 mol equivalents of a thiosemicar-
bazone in dichloromethane at room temperature. After a reaction period of
30 min - 18 h (detailed for individual complexes below), the mixtures were
added to a ten-fold excess volume of diethyl ether, in which the products
precipitated as yellow to red solids. This procedure yields complexes of the
general formula [(p-cymene)Ru(TSC)X]X (Figure 2.7).
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[7] [(p-cymene)Ru(1a)I]I [(p-cymene)RuCl2]2 (194 mg, 0.20 mmol) and
benzaldehydethiosemicarbazone (1a, 82 mg, 0.46 mmol) were mixed in di-
chloromethane (10 mL). The dark red mixture was stirred at room tem-
perature for 16 h. The solution was reduced in volume to 4 mL and sub-
sequently poured into diethylether (40 mL). A red solid precipitated which
was separated by filtration. The red filtrate was evaporated to dryness,
the residue taken up in dichloromethane (2 mL) and immediately poured
into diethylether (50 mL). The orange precipitate was isolated by filtra-
tion and the combined solids were dried under vacuum (127 mg, 48%).
ESI-MS (MeOH) m/z (rel. int.) = 414 (100) [M-I-HI]+ CHN (calc. for
C18H23N3SRuI2, FW = 668.34) 33.28 (32.35) %C, 3.59 (3.47) %H, 7.06
(6.29) %N.
[10] [(p-cymene)Ru(1c)Cl]PF6 [(p-cymene)RuCl2]2 (82 mg, 0.14 mmol)
and benzaldehyde-4-dimethyl-3-thiosemicarbazone (1c, 57 mg, 0.28 mmol)
were mixed in dichloromethane (8 mL) and the resulting red solution stirred
for 14 h. A solution of NH4PF6 (218 mg, 1.35 mmol) in methanol (10 mL)
was added and the red solution was stirred for 2 h and then kept at 278 K for
several days. Orange block shaped crystals, suitable for X-ray diffraction,
were isolated by filtration, washed with methanol and dried in air (70 mg,
40 %). 1H NMR (400 MHz, CDCl3) 1.13 (3H, d, J=6.6 Hz), 1.17 (3H, d,
J=6.9 Hz), 2.06 (3H, s), 2.71 (1H, m, J=6.9 Hz), 4.76 (1H, d, J=5.7 Hz),
4.80 (1H, d, J=6.0 Hz), 5.03 (1H, d, J=5.7 Hz), 5.34 (1H, d, J=6.0 Hz), 7.58
(3H, m), 8.30 (2H, d, J=5.9 Hz), 9.13 (1H, s, N=CH), 10.89 (1H, s, NH).
13C NMR (100 MHz, CDCl3) 18.6 (CH3), 21.5 (CH3), 23.3 (CH3), 30.7
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(CH), 43.0 (NMe2), 82.8 (CH), 83.3 (CH), 88.5 (CH), 88.7 (CH), 129.2 (CH),
131.0 (CH) 165.9 (N=CH) ESI-MS (MeOH) m/z (rel. int.) 442 (100) [M-
PF6-HCl]
+ CHN (calc. for C20H27N3SRuClPF6): 38.44 (38.56) %C, 4.36
(4.37) %H, 6.69 (6.74) %N.
[11] [(p-cymene)Ru(1c)I]I [(p-cymene)RuI2]2 (55 mg, 0.06 mmol) and
benzaldehyde-4-dimethyl-3-thiosemicarbazone (1c, 23.5 mg, 0.11 mmol) were
mixed in dichloromethane (2.5 mL). The red solution was stirred for 10 min
before it was poured into diethylether (25 mL) to precipitate a red solid.
The resulting suspension was stirred for 30 min before filtering and isol-
ating the red solid and drying under vacuum (66 mg, 83 %). 1H NMR
(400 MHz, CDCl3) 1.14 (3H, d, J=6.9 Hz), 1.19 (3H, d, J=7.3 Hz), 1.54
(H2O), 2.29 (3H, s), 2.88 (1H, m), 4.65 (1H, d, J=6.5 Hz), 4.70 (1H, d,
J=6.9 Hz), 4.99 (1H, d, J=5.6 Hz), 5.34 (1H, d, J=5.6 Hz), 7.57 (3H, m),
8.33 (2H, m), 9.83 (1H, s), 12.22 (1H, s, NH). 13C NMR (100 MHz, CDCl3)
20.5 (CH3), 21.5 (CH3), 31.2 (NMe2), 82.9 (CH), 83.5 (CH), 87.6 (CH), 88.9
(CH), 103.6 (Cq), 106.7 (Cq), 128.6 (CH), 130.6 (CH), 131.6 (CH), 133.1
(CH), 167.0 (C=N), 175.6 (C=S). ESI-MS (MeOH) m/z (rel. int.) 442.50
(100) [M-I-HI]+, CHN (calc. for C20H27N3SRuI2): 34.39 (34.49) %C, 3.84
(3.91) %H, 5.91 (6.03) %N.
[12] [(p-cymene)Ru(1c)I]PF6 [(p-cymene)RuI2]2 (70 mg, 0.075 mmol)
and benzaldehyde-4-dimethyl-3-thiosemicarbazone (1c) (31 mg, 0.15 mmol)
were mixed in dichloromethane (8 mL) and the resulting clear red solution
was stirred for 60 min before a solution of NH4PF6 (130 mg, 0.67 mmol)
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in methanol (5 mL) was added. The red solution was kept at 278 K for
5 days. Dark red crystals were isolated by filtration, washed with meth-
anol and diethylether and dried with suction (81 mg, 76 %). 1H NMR
(400 MHz, CDCl3) 1.12 (3H, d, J=7.0 Hz), 1.18 (3H, d, J=7.0 Hz), 2.30
(3H, s), 2.85 (1H, m), 4.66 (1H, d, J=6.0 Hz), 4.70 (1H, d, J=6.0 Hz), 4.96
(1H, d, J=6.6 Hz), 5.30 (1H, d, J=6.2 Hz), 7.62 (3H, m), 8.28 (2H, m),
8.86 (1H, s), 9.90 (1H, s) 13C NMR (100 MHz, CDCl3) 19.1 (CH3), 19.7
(CH3), 22.0 (CH3), 41.1 (NMe2), 82.0 (CH), 83.4 (CH), 87.6 (CH), 90.0
(CH), 128.7 (2 CH), 129.8 (2CH), 131.1 (CH), 163.5 (HC=N), 175.8 (C=S)
ESI-MS (MeOH) m/z (rel. int.) 442.50 (100) [M-PF6-HI]
+, CHN found
(calc. for C20H27N3SRuIPF6CH3OH) 33.69 (33.79) %C, 4.18 (4.19) %H,
5.60 (5.63) %N.
[13] [(p-cymene)Ru(1d)Cl]Cl [(p-cymene)RuCl2]2 (53 mg, 0.09 mmol)
and benzaldehyde-4-(4-iodophenyl)-3-thiosemicarbazone (1d, 63 mg, 0.17
mmol) were placed in a Schlenk tube and dissolved in dichloromethane (10
mL). The red mixture was stirred at room temperature for 18 hours. A
yellow solid precipitated which was isolated from a red solution by suction
filtration and dried in air (75 mg, 63 %). 1H NMR (400 MHz, methanol-
d4) 1.10 (3H, d, J=6.9 Hz), 1.16 (3H, d, J=6.5 Hz), 2.06 (3H, s), 2.61 (1H,
m, J=6.9 Hz), 4.80 (1H, d, J=5.8 Hz), 5.00 (1H, d, J=6.3 Hz), 5.05 (1H,
d, J=6.8 Hz), 5.63 (1H, d, J=6.0 Hz), 7.29 (2H, d, J=8.3 Hz), 7.67 (3H,
d, J=5.0 Hz), 7.73 (2H, d, J=8.9 Hz), 8.25 (2H, q, J=3.0 Hz), 9.00 (1H,
s) 13C NMR (100 MHz, MeOD) ESI-MS (MeOH) m/z (rel. Int.) = 615.9
(100) [M-Cl-HCl]+ IR (solid) 697, 766 (C=S), 1004, 1103, 1480, 1544, 1576
(C=N), 2959 CHN (calc. for C24H26N3SIRuCl2CH2Cl2 (772.37)): 38.96
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(38.88) %C, 3.47 (3.65) %H, 5.80 (5.44) %N.
[14] [(p-cymene)Ru(1d)I]I [(p-cymene)RuI2]2 (192 mg, 0.19 mmol) and
benzaldehyde-4-(4-iodophenyl)-3-thiosemicarbazone (3d, 167 mg, 2.3 eq,
0.44 mmol) were mixed in dichloromethane (10 mL). The deep violet-red
mixture was stirred at room temperature over night. Leftover solid particles
were separated by filtration and the dark red filtrate poured into diethyl-
ether (50 mL). A red precipitate was isolated with suction filtration and
dried under vacuum (143 mg, 42%). 1H NMR (CDCl3) 1.10 (3H, d,
J=6.9 Hz), 1.17 (3H, d, J=6.9 Hz), 1.29 (1H, d, J=7.3 Hz), 2.35 (3H, s),
2.78 (1H, m, J=6.9 Hz), 4.57 (1H, d, J=5.9 Hz), 4.73 (1H, d, J=5.9 Hz),
4.86 (1H, d, J=5.6 Hz), 5.31 (1H, d, J=5.9 Hz), 7.36 (2H, d, J=8.4 Hz),
7.62 (3H, d, J=2.8 Hz), 7.71 (2H, d, J=8.7 Hz), 8.15 (2H, d, J=3.1 Hz),
8.17 (1H, d, J=2.1 Hz), 9.05 (1H, s), 10.36 (1H, s), 13.86 (1H, s) 13C-NMR
(100 MHz, CDCl3) 175.2 (C=S), 161.2 (C=N), 138.5, 138.2, 136.1 (Cq),
132.8 (Cq), 130.5 (CH), 129.0 (CH), 128.1 (CH), 127.6 (CH), 125.8 (CH),
107.5 (Cq), 104.2 (Cq), 89.4 (CH), 86.9 (CH), 84.2 (CH), 83.0 (CH), 82.4
(CH), 31.4 (CH3), 23.5 (CH3), 21.3 (CH3), 20.7 (CH3) ESI-MS (MeOH)
m/z (rel. int.) = 616 (100) [M-H-HCl]+ CHN (calc. for C24H26N3SRuI3,
(870.34) 33.83 (33.12) %C, 2.93 (3.01) %H, 4.75 (4.83) %N.
[15] [(p-cymene)Ru(2a)Cl]Cl [(p-cymene)RuCl2]2 (62 mg, 0.1 mmol)
and N,N-dimethylamino-benzaldehydethiosemicarbazone (2a, 50 mg, 0.22
mmol) were mixed with dichloromethane (5 mL). The red mixture was
stirred at room temperature for 20 hours, filtered through a syringe filter
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and evaporated to dryness (123 mg, 58%). 1H NMR (400 MHz, CDCl3)
1.12 (d, J=6.9 Hz, 3H, cym-iPr), 1.19 (d, 3J=6.9 Hz, 3H, cym-iPr), 2.14 (s,
3H cym-iPr), 2.67 (sept, 1H, cym-iPr), 3.12 (s, 6H, NMe), 5.03 (d, J=6.1 Hz,
1H, cym-CH), 5.08 (d, J=6.1 Hz, 1H, cym-CH), 5.14 (d, J=6.1 Hz, 1H, cym-
CH), 5.53 (d, J=6.1 Hz, 1H, cym-CH), 6.77 (d, J=9.1 Hz, 2H, arom. CH),
8.18 (d, J=9.1 Hz, 2H, arom. CH), 8.76 (s, 1H, N=CH) 13C NMR (100
MHz, CDCl3): 31.1 (cym-iPrCH), 40.4 (NCH3), 82.6 (cym-CH), 83.7 (cym
CH), 88.0 (cym CH), 88.8 (cym CH), 111.6 (Ph CH), 133.9 (Ph CH), 162.6
(N=CH) ESI-MS (MeOH) m/z = 457 [M-Cl-HCl]+ UV-vis (MeOH/H2O
= 10/90 v/v) λmax = 362 nm CHN (calc. for C20H28N4SRuCl2, FW =
528.51) 45.11 (45.45) %C, 5.37 (5.34) %H, 11.53 (10.60) %N.
[19] [(p-cymene)Ru(2c)Cl]PF6 [(p-cymene)RuCl2]2 (21 mg, 0.04 mmol)
and N,N-dimethylaminobenzaldehyde-4-dimethyl-3-thiosemicarbazone (2c,
17 mg, 0.08 mmol) were mixed in dichloromethane (4 mL) and the clear,
red solution was stirred at room temperature for 1 h before NH4PF6 (55 mg
in 5 mL methanol) was added. The red solution was stored at 278 K for
two days. Red crystals were isolated by filtration and dried in air (26 mg,
0.04 mmol, 57 %). 1H NMR (600 MHz, dmso-d6) 0.91 (3H, d, J=7.1
Hz), 0.97 (3H, d, J=7.0 Hz), 2.39 (3H, s) 3.07 (6H, s), 5.95 (1H, d, J=6.7
Hz), 6.12 (1H, d, J=6.2 Hz), 6.25 (1H, d, J=6.4 Hz), 6.32 (1H, d, J=6.4
Hz), 6.71 (2H, d, J=9.3 Hz), 8.04 (2H, d, J=9.1 Hz), 8.17 (1H, s). ESI-
MS (MeOH) m/z (rel. int.) = 485 [M-PF6-HCl]
+ (100) CHN (calc. for
C22H32N4SRuClPF6, FW = 666.07) 40.07 (39.67) %C, 4.69 (4.84) %H, 8.68
(8.41) %N.
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[20] [(p-cymene)Ru(2c)I]I [(p-cymene)RuI2]2 (15.0 mg, 0.015 mmol) and
N,N-dimethylaminobenzaldehyde-4-dimethyl-3-thiosemicarbazone (2c, 7.9
mg, 2.1 eq, 0.032 mmol) were placed in a small glass vial. The solids were
mixed in chloroform-d (0.6 mL, final concentration ca. 50 mM). The red
solution was transferred into a 5mm NMR tube and a proton spectrum was
recorded approx. 2 hours after mixing the reactants. 1H NMR (400 MHz,
CDCl3) 1.14 (3H, d, J=6.9 Hz), 1.21 (3H, d, J=7.1 Hz) 2.26 (3H, s), 2.94
(1H, m7, J=7.1 Hz), 3.09 (6H, s), 3.46 (6H, s, br), 4.96 (1H, d, J=6.2 Hz),
5.17 (2H, s), 5.61 (1H, d, J=6.0 Hz), 6.73 (2H, d, J=9.0 Hz), 8.37 (2H, d,
J=8.6 Hz), 9.61 (1H, s), 11.45 (1H, s, br) 13C NMR (100 MHz, CDCl3)
19.9 (CH3, p-cym-Me), 21.2 (CH3, p-cym-iPr), 23.9 (CH3, p-cym-iPr), 31.1
(CH, p-cym-iPr), 40.0 (Ph-NMe2), 43.9 (SCNMe2), 83.8 (p-cym-CH), 85.3
(p-cym-CH), 87.6 (p-cym-CH), 88.3 (p-cym-CH), 102.7 (Cq, p-cym-Me),
105.2 (Cq, p-cym-iPr), 110.5 (Ph-CH), 117.1 (Cq, Ph-CN), 134.0 (Ph-CH),
152.6 (Cq, Ph-NMe2), 167.0 (N=CH) ESI-MS (MeOH) m/z (rel. int.) =
485 (100) [M-I-HI]+.
[21] [(p-cymene)Ru(2d)Cl]Cl [(p-cymene)RuCl2]2 (64 mg, 0.1 mmol)
and N,N-dimethylaminobenzaldehyde-4-(4-iodophenyl)-3-thiosemicarbazone
(2d, 91 mg, 0.21 mmol) were placed in a Schlenk-tube and mixed with 10 mL
dichloromethane. The clear red solution was stirred at room temperature for
19 hours. The solution was reduced to 2 mL and subsequently poured into
diethylether (40 mL). A red solid precipitated which was stirred in the sus-
pension for 15 min before suction filtration. It was washed with diethylether
and dried with suction to yield a red powder (131 mg, 86 %). 1H NMR
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(400 MHz, CDCl3) 1.12 (3H, d, J=6.9 Hz), 1.17 (3H, d, J=7.0 Hz), 2.12
(3H, s), 2.67 (1H, m7, J=6.8 Hz), 3.11 (6H, s), 4.99 (1H, d, J=5.7 Hz), 5.11
(2H, dd, J=13.96, 5.7 Hz), 5.49 (1H, d, J=5.9 Hz), 6.77 (2H, d, J=9.0 Hz),
7.35 (2H, d, J=8.8 Hz), 7.67 (2H, d, J=8.7 Hz), 8.19 (2H, d, J=9.0 Hz)
ESI-MS (MeOH) m/z (rel. int.) = 659 (100) [M-Cl-HCl]+ CHN (calc. for
C26H31N4SIRuCl2 FW = 730.50): 42.59 (42.75) %C, 4.23 (4.28) %H, 7.61
(7.67) %N.
[22] [(p-cymene)Ru(2d)I]I [(p-cymene)RuI2]2 (185 mg) and N,N-dimethyl-
aminobenzaldehyde-4-(4-iodophenyl)-3-thiosemicarbazone (2d, 160 mg) were
mixed in 10 mL anhydrous dichloromethane and stirred at room temper-
ature for 3 hours. The volume was reduced to 3 ml and the solution was
poured into 50 mL diethylether. A solid precipitated which was filtered and
dried under vacuum. 1H NMR (CDCl3) 1.12 (3H, d, J=7.0 Hz), 1.19 (3H,
d, J=7.0 Hz), 2.34 (3H, s), 2.82 (1H, m, J=7.0 Hz), 3.12 (6H, s), 4.93 (1H,
d, J=6.1 Hz), 5.05 (1H, d, J=6.0 Hz), 5.16 (1H, d, J=5.8 Hz), 5.53 (1H,
d, J=5.8 Hz), 6.78 (2H, d, J=9.2 Hz), 7.37 (2H, d, J=8.6 Hz), 7.68 (2H, d,
J=8.8 Hz), 8.20 (2H, d, J=9.2 Hz), 8.73 (1H, s), 10.30 (1H, s), 13.44 (1H,
s). ESI-MS (MeOH) m/z (rel. int.) = 659 (100) [M-I-HI]+, CHN (calc.
for C26H31N4SRuI3, FW = 913.41): 33.85 (34.19) %C, 3.33 (3.42) %H, 6.00
(6.13)%N.
[23] [(p-cymene)Ru(3a)Cl]Cl [(p-cymene)RuCl2]2 (54 mg, 0.09 mmol)
and 3-iodobenzaldehyde-3-thiosemicarbazone (3a, 50 mg, 0.16 mmol) were
stirred in dichloromethane (10 mL) for 16 h. After 4 h a yellow precipitate
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had formed. It was filtered off with suction and washed with small amounts
of petroleum ether and dried in air. (69 mg, 71 %) 1H-NMR (400 MHz,
methanol-d4) 1.17 (6H, dd, J=7.2, 24.5 Hz), 2.13 (3.0H, s), 2.65 (1H, m7,
J=6.8 Hz), 4.95 (1H, d, J=6.6 Hz), 5.05 (1H, d, J=5.8 Hz), 5.10 (1H, d,
J=6.6 Hz), 5.69 (1H, d, J=5.8 Hz), 7.44 (1H, t, J=7.8 Hz), 8.05 (2H, dd,
J=1.6, 7.8 Hz), 8.79 (1H, s), 8.90 (1H, s) ESI-MS (MeOH) m/z (rel. int.)
= 540 (100) [M-Cl-HCl]+ CHN (calc. for C18H22N3SIRuCl2, FW = 611.34)
34.87 (35.36) %C, 3.53 (3.63) %H, 6.48 (6.87) %N.
[24] [(p-cymene)Ru(3a)I]I [(p-cymene)RuI2]2 (203 mg, 0.21 mmol) and
3-iodobenzaldehyde-3-thiosemicarbazone (3a, 115 mg, 2.5 eq, 0.52 mmol)
were mixed in dichloromethane (10 mL). The violet-red mixture was stirred
at room temperature for 16 h. The resulting dark solution was reduced in
volume to 3 mL and subsequently poured into diethylether (75 mL). A red-
orange precipitate was separated by filtration and dried under vacuum (130
mg, 41 %). ESI-MS (MeOH) (rel. int.) m/z = 668 (5) [M-I]+, 540 (100)
[M-I-HI]+ CHN (calc. for C18H22N3SRuI3 FW = 794.24) 27.09 (27.22) %C,
2.78 (2.79) %H, 5.13 (5.29) %N.
[27] [(p-cymene)Ru(3c)Cl]Cl [(p-cymene)RuCl2]2 (50 mg, 0.08 mmol)
and 3-iodobenzaldehyde-4-dimethyl-3-thiosemicarbazone (3c) (51 mg, 0.15
mmol) were mixed in dichloromethane (5 mL) and the resulting clear red
solution stirred for 2 h before it was poured into excess diethylether to
precipitate a yellow solid. The suspension was stirred for 30 min before the
solid was isolated by filtration and dried in air (55 mg, 60%). 1H NMR
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(400 MHz, CDCl3) 1.14 (3H, d, J=7.2 Hz), 1.21 (3H, d, J=7.2 Hz), 2.35
(3H, s), 2.89 (1H, m), 3.47 (6H, s, br), 4.77 (1H, d, J=6.0 Hz), 4.84 (1H,
d, J=5.9 Hz), 5.02 (1H, d, J=5.9 Hz), 5.45 (1H, d, J=6.0 Hz), 7.34 (1H,
t, J=7.8 Hz), 7.90 (1H, d, J=8.0 Hz), 8.15 (1H, d, J=8.0 Hz), 9.00 (1H,
s), 9.66 (1H, s), 12.02 (1H, s). 13C NMR (100 MHz, CDCl3) 20.8 (CH3),
21.7 (CH3), 23.8 (CH3), 31.3 (CH), 44.2 (NMe2), 83.3 (CH), 83.4 (CH), 88.1
(CH), 88.7 (CH), 93.8 (Cq), 111.2 (Cq), 130.1 (CH), 130.3 (CH), 134.8 (Cq),
138.5 (CH), 140.6 (2 CH), 165.1 (N=CH).ESI-MS (MeOH) m/z (rel. int.)
568 (100) [M-Cl-HCl]+, CHN (calc. for C20H25N3SIRuCl2) (37.63) %C,
(3.95) %H, (6.58) %N.
[28] [(p-cymene)Ru(3c)I]I [(p-cymene)RuI2]2 (36.4 mg, 0.037 mmol) and
3-iodobenzaldehyde-4-dimethyl-3-thiosemicarbazone (3c) (25 mg, 0.08 mmol)
were mixed in dichloromethane (5 mL) to give a clear, dark red solution
which was left to stand for 24 hours. Red crystals formed which were isol-
ated by filtration and dried in air (32 mg, 52 %). 1H NMR (400 MHz,
CDCl3) 1.16 (3H, d, J=6.8 Hz), 1.21 (3H, d, J=7.0 Hz), 1.55 (3H, s, H2O),
2.33 (3H, s), 2.91 (1H, m), 3.52 (6H, s), 4.76 (1H, d, J=6.0 Hz), 4.85 (1H,
d, J=5.8 Hz), 5.03 (1H, d, J=6.0 Hz), 5.28 (2H, s, CH2Cl2), 5.47 (1H, d,
J=6.8 Hz), 7.31 (1H, t, J=7.9 Hz), 7.90 (1H, d, J=8.1 Hz), 8.14 (1H, d,
J=8.1 Hz), 9.02 (1H, s), 9.77 (1H, s), 12.22 (1H, s). 13C NMR (100 MHz,
CDCl3) 20.6 (CH3), 21.6 (CH3), 23.7 (CH3), 27.7 (CH), 46.7 (NMe2), 82.8
(CH), 87.9 (CH), 88.0 (CH), 129.8 (CH), 130.1 (CH), 138.0 (CH), 140.5
(CH), 164.8 (N=CH), 174.4 (C=S). ESI-MS (MeOH) m/z (rel. int.) 568
(100) [M-I-HI]+. CHN (calc. for C20H25N3SRuI3) 27.90 (29.25) %C, 3.05
(3.07) %N, 4.62 (5.12) %H.
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[29] [(p-cymene)Ru(3c)I]PF6 [(p-cymene)RuI2]2 (41.6 mg, 0.043 mmol)
and 3-iodobenzaldehyde-4-dimethyl-3-thiosemicarbazone (3c) (28 mg, 0.084
mmol) were mixed in dichloromethane (5 mL) and diluted with a solution
of NH4PF6 (71 mg, 0.43 mmol) in methanol (5 mL) to give a clear red
solution. This was kept at 278 K for 4 days to precipitate a red crystalline
solid which isolated by filtration, washed with diethylether and dried in air
(33.5 mg, 53 %). 1H NMR (400 MHz, CDCl3) 1.15 (3H, d, J=6.4 Hz), 1.21
(3H, d, J=7.2 Hz), 2.34 (3H, s), 2.88 (1H, m), 3.53 (6H, s, br), 4.76 (1H,
d, J=6.1 Hz), 4.85 (1H, d, J=5.8 Hz), 5.02 (1H, d, J=5.8 Hz), 5.46 (1H,
d, J=6.1 Hz), 7.31 (1H, t, J=7.9 Hz), 7.90 (1H, d, J=7.8 Hz), 8.14 (1H, d,
J=7.8 Hz), 9.03 (1H, s), 9.71 (1H, s), 12.00 (1H, s, NH). 13C NMR (100
MHz, CDCl3) 20.8 (CH3), 21.7 (CH3), 23.8 (CH3), 31.3 (CH), 44.2 (NMe2),
83.3 (CH), 83.4 (CH), 88.1 (CH), 88.7 (CH), 93.8 (Cq), 111.2 (Cq), 130.1
(CH), 130.3 (CH), 134.8 (Cq), 138.5 (CH), 140.6 (2 CH), 165.1 (N=CH).
ESI-MS (MeOH) m/z (rel. int.) 568 (100) [M-I-HI]+, CHN found (calc.
for C20H25N3SRuI2PF6) 29.18 (28.62) %C, 3.11 (3.00) %H, 5.07 (5.01) %N.
Synthesis for in-situ 1H NMR Reaction Monitoring
The ruthenium TSC complexes listed below were synthesised only on an
NMR scale (approx. 20 mg). While NMR and ESI-MS data were collected
on the sample solutions, the reaction products were not isolated as solids.
The following procedure describes the preparation of complexes [6], 8,
[9], 16 - 18, [20], [25], and [26].
NMR scale synthesis: Dinuclear ruthenium precursors [(p-cymene)RuCl2]2
(10 mg, 16 µmol) or [(p-cymene)RuI2]2 (15 mg, 15 µmol) were weighed into
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small glass vials, followed by addition of 2 mol eq. of thiosemicarbazone
ligand. Mixing the starting materials in deuterated chloroform resulted in
red solutions of the corresponding complexes which were immediately trans-
ferred into NMR tubes. Filtration over celite assured that the samples were
free from any remaining undissolved solid. 1H NMR spectra were recorded
within 30 min after mixing the reactants. Approx. 20 µL of the reaction
mixture were diluted with methanol (1 mL) to prepare a sample for ESI-MS
measurements of the reaction mixtures.
The NMR and MS data are summarised and described in Section 2.3,
where Table 2.13 (Section 2.3.7, page 90) presents the corresponding 1H
NMR data and Table 2.5 (Section 2.3.3, page 69) contains the corresponding
ESI-MS results for the complexes specified here.
2.2.4 Elemental Analysis
Elemental analysis (CHN) was carried out on a CE440 CHN/O/S Elemental
Analyser by Warwick Analytical Services of Exeter Analytical (UK) Ltd.,
University of Warwick Science Park, Coventry, CV4 7EZ.
2.2.5 Mass Spectrometry
Electrospray mass-spectra were collected on a Bruker Esquire 2000 Ion
Trap spectrometer in positive acquisition mode. Sample introduction was
achieved by flow injection, using an Agilent 1100 LC system and meth-
anol/TFA as the carrier solvent.
High-resolution accurate mass data for confirmation of molecular formulae
were acquired by Dr. Lijiang Song or Phil Aston on a Bruker MaXis Ultra-
60
High Resolution Quadrupole Time-Of-Flight Mass Spectrometer (UHR-Q-
TOF-MS) in the Mass Spectrometry Facility at the University of Warwick.
Samples of ruthenium complexes were prepared at 1 mg/mL in methanol for
further dilution by the MS operators as appropriate. Data were acquired
in the mass range of 50 - 2500 m/z in positive ion mode, using an ESI
source with a capillary voltage of 3000 V and a nebulizer pressure of 0.4 bar
(gas flow 4.0 L/min). Bruker Compass DataAnalysis 4.0 was used for the
calculation of molecular formulae from the experimental m/z results.
2.2.6 X-ray Crystallography
Crystallographic data and refinement were provided by Dr. G. Clarkson in
the Department of Chemistry. Data were collected using an Oxford Dif-
fraction Gemini four-circle system with Ruby CCD area detector which was
cooled to 100 ± 2 K or 150 ± 2 K by an Oxford Cryosystem Cryostream
Cobra. With the SHELXS17 software suite, successful structure refinement
confirmed the respective space groups as indicated by the refined data, pla-
cing additional light atoms by Fourier methods with refinement of calculated
hydrogen atom positions by a riding model; NHs were located in a difference
map. The H-atoms were given isotropic displacement parameters equal to
1.2 times the equivalent isotropic displacement parameter of the atom to
which they are attached (1.5 times for methyl and NH protons).
2.2.7 Nuclear Magnetic Resonance Spectroscopy
Samples were dissolved in deuterated solvents and the solutions were filtered
into 5 mm Wildmann “economy” NMR tubes. Basic one-dimensional (1D)
1H and 13C NMR experiments for purity control were carried out on Bruker
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drx spectrometers with either 400 MHz or 300 MHz proton resonance fre-
quency. Two dimensional (2D) correlation experiments such as 1H,1H-
COSY, 1H,13C-HSQC and 1H,13C-HMBC, were performed on the same in-
struments to obtain additional data for structure confirmation.
1H NMR Studies with [(p-cymene)Ru(2a)Cl]Cl [15]
Complex [15] was dissolved in dmso-d6 and diluted into D2O to achieve
a final concentration of approx. 1 mM with a maximum dmso content of
5% (v/v). Two samples were prepared, one was inserted into the magnet
immediately and the 1H NMR spectrum was recorded, while the other one
was equilibrated at room temperature for 48 h. Spectra were also recorded
after 12 h.
Observation of Dimerisation by 1H NMR
Complex [21] (3.7 mg) was dissolved in CDCl3 (50 µL) and diluted into
a solution of NH4PF6 (5 mg in 500 µL). The resulting clear red solution
was transferred into a Wildman precision 5 mm NMR tube, and a 1H NMR
spectrum was recorded 30 min after sample preparation. The sample was
kept at 293 K for 14 h before a second 1H NMR spectrum was recorded.
Red crystals were found at the bottom of the tube. These were isolated by
filtration and analysed by single crystal X-ray diffraction (see Section 2.3.4,
page 76).
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2.2.8 1H15N-Heteronuclear Multiple-bond Coherence
Spectroscopy
Samples of thiosemicarbazones for 1H15N HMBC NMR experiments were
dissolved in dmso-d6 at a concentration of 100 mM and subsequently filtered
into 5 mm Wildman 507 precision NMR tubes.
A Bruker Avance III 600 MHz spectrometer was used for the 1H15N-
HMBC NMR experiments. This was equipped with one of the two following
probes: an auto-tunable multinuclear (31P−109Ag) Broad Band Observe
(BBO) probe, or a Triple Resonance Inverse (TXI) probe (1H, 13C (inner
coil), 15N (outer coil)). Both probes also use gradient coils.
Experiment Parameters:
The NMR probe was tuned automatically (using the Bruker automatic
tunig and matching device (ATM)) closest to the 1H resonance frequency of
600.13 MHz and the corresponding 15N frequency of 60.83 MHz. Automated
shimming in three dimensions was achieved by the topshim programme.
Table 2.2 lists parameters which were used in the Bruker pulse pro-
gramme hmbcgpndqf (Avance version, 07/04/04) for the 1H,15N-HMBC ex-
periment. The parameters and abbreviations are consistent with Bruker
naming conventions.
Spectral widths (SW) were optimised to 10 ppm for 1H and 400 ppm for
15N to achieve a measurement time of 60 min. Individual offsets were set
according to the shift range of the 1D 1H NMR spectrum (O1P) which was
recorded beforehand for each compound. 16 scans in f2 (TD = 1024) were
acquired per transient in f2 (TD = 256), with zero-filling to 2048 (1H) and
1024 (15N) points during data processing. As a result, the processed spectra
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Table 2.2: Selected parameters for the acquisition of 1H15N HMBC NMR spec-
tra with the Bruker pulse program hmbcgpndqf.
Parameter Channel f1a) Channel f2
Nucleus 1H 15N
Frequency (SFO) 600.13 MHz 60.81 MHz
Spectral Width (SW) 10 ppm 400 ppm
Off-set (OP) 7.5 ppm 200 ppm
Data points (TD) 2048 256
No. of Scans (NS) 16 -
No. of Dummy Scans (DS) 16 -
Dwell Time (DW) 83.3 µ -
Pre-scan Delay (DE) 6.55 µs -
Pulse Width (P1) 13.75 s -
J coupling (CNST13) 8.000 Hz -
Relaxation Delay (D1) 1.5 s -
Delay for coupling (D6) 62.5 µs -
FID resolution 2.93 Hz 95.03 Hz
Zero Filling (SI) 2048 1024
Spectral Resolution 2.93 Hz/pt 23.45 Hz/pt
Temperature (TE) 298 K
a) Note: Channel f1 translates to the direct dimension of the spectrum, repres-
ented by F2.
had a resolution of 2.93 Hz per data point in the F2 (1H) dimension and
23.45 Hz/pt in the F1 (15N) dimension. Sine-bell window-functions were
applied in both spectral dimensions prior to Fourier transformation.
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2.3 Results
2.3.1 Synthesis of Thiosemicarbazones
Three series of thiosemicarbazones were prepared by imine condensation
between aldehydes and thiosemicarbazides in refluxing methanol. White
crystalline powders where obtained in yields of 50 - 95 %. The com-
bination of benzaldehyde (1), N,N-dimethylamino-benzaldehyde (2), and
3-iodobenzaldehyde (3) with each thiosemicarbazide (TSC, a), 4-methyl-3-
thiosemicarbazide (TSCNMe, b) 4-dimethyl-3-thiosemicarbazide (TSCNMe2,
c), and 4-iodophenylthiosemicarbazide (TSCIPh, d) yielded 12 different
TSCs. Table 2.3 provides an overview over the substitution pattern in the
ligands 1a-d, 2a-d and 3a-d.
Table 2.3: Overview of substitution pattern in TSC ligands.
No. Name R1 R2 R3 R4
1a PTSC H H H H
1b PTSCNMe H H H CH3
1c PTSCNMe2 H H CH3 CH3
1d PTSCIPh H H H (p-C6H4-I)
2a DTSC N4(CH3)2 H H H
2b DTSCNMe N4(CH3)2 H H CH3
2c DTSCNMe2 N
4(CH3)2 H CH3 CH3
2d DTSCIPh N4(CH3)2 H H (p-C6H4-I)
3a ITSC H I H H
3b ITSCNMe H I H CH3
3c ITSCNMe2 H I CH3 CH3
3d ITSCIPh H I H (p-C6H4-I)
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PTSC (1a) PTSCNMe (1b) PTSCNMe2 (1c) PTSCIph (1d)
DTSC (2a) DTSCNMe (2b) DTSCNMe2 (2c) DTSCIph (2d)
ITSC (3a) ITSCNMe (3b) ITSCNMe2 (3c) ITSCIph (3d)
Figure 2.8: Combination of aldehydes 1-3 with four different thiosemicarbazides
a-d resulted in a library of 12 TSCs: 1a-d, 2a-d, and 3a-d discussed in this
chapter.
Each row in Figure 2.8 presents one series of TSCs according to sub-
stituents R1 and R2 on the phenyl ring. From 1 to 3 these substitu-
ents are: phenyl (P) in PTSC ligands 1a-d (R1 = R2 = H), 4-N,N-
dimethylaminophenyl (D) in DTSC ligands 2a-d, and 3-iodophenyl (I)
in ITSC ligands 3a-d. The columns in Figure 2.8 arrange the TSCs by
substituents R3 and R4, located on the thioamide side of the structure. For
example, the first column (a) represents the NH2 group in the three TSCs
1-3a, in which R3 = R4 = H. Conversely, these columns a - d allow for data
comparison that highlights the influence of phenyl substituents R1 and R2,
while comparison within a row studies the influence of amide substituents
R3 and R4.
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2.3.2 Synthesis of Arene Ruthenium TSC Complexes
Arene ruthenium complexes of the TSC ligands were synthesised accord-
ing to literature procedures.14, 15, 18 The reaction of the dinuclear Ru(II)
precursors [(p-cymene)RuX2]2 with X = Cl ([4]) or X = I ([4]) with two
equivalents of a TSC ligand HL yielded 23 different ruthenium complexes of
the general formula [(p-cymene)Ru(HL)X]+X− (Table 2.4). The complexes
formed within 30 min to 18 hours and were obtained as powders of orange
to red colour.
Figure 2.9: Reaction scheme showing the synthesis of arene RuII TSC com-
plexes.
In addition to NMR and ESI-MS analyses, the composition of those
powders was assessed by CHN elemental analysis, and the results were in
agreement with the proposed formulae. For complex [10] and [29] the
counter ion X− was exchanged to PF−6 by mixing a solution of the halido
complex in dichloromethane (DCM) with a saturated solution of NH4PF6
in methanol. Crystals of complex [10] grew upon evaporation of DCM
from the mixture. The single crystal structure was determined by X-ray
crystallography and will be presented in Section 2.3.4.
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Table 2.4: Overview of arene ruthenium TSC complexes prepared from [(p-
cymene)RuCl2]2 or [(p-cymene)RuI2]2.
Complex Ligand R1 R2 R3 R4 X Z
[6] ∗ PTSC H H H H Cl Cl
[7] PTSC H H H H I I
[8] ∗ PTSCNMe H H H Me Cl Cl
[9] ∗ PTSCNMe H H H Me I I
[10] PTSCNMe2 H H Me Me Cl PF6
[11] PTSCNMe2 H H Me Me I I
[12] PTSCNMe2 H H Me Me I PF6
[13] PTSCIPh H H H IPh Cl
[14] PTSCIPh H H H IPh I
[15] DTSC N4(CH3)2 H H H Cl Cl
[16] ∗ DTSC N4(CH3)2 H H H I I
[17] ∗ DTSCNMe N4(CH3)2 H H Me Cl PF6
[18] ∗ DTSCNMe N4(CH3)2 H H Me I I
[19] DTSCNMe2 N
4(CH3)2 H Me Me Cl PF6
[20] DTSCNMe2 N
4(CH3)2 H Me Me I I
[21] DTSCIPh N4(CH3)2 H H IPh Cl Cl
[22] DTSCIPh N4(CH3)2 H H IPh I I
[23] ITSC H I H H Cl
[24] ITSC H I H H I
[25] ∗ ITSCNMe H I H Me Cl
[26] ∗ ITSCNMe H I H Me I
[27] ITSCNMe2 H I Me Me Cl PF6
[28] ITSCNMe2 H I Me Me I I
[29] ITSCNMe2 H I Me Me I PF6
Complexes labelled with ∗ were only prepared for NMR and ESI-MS
experiments detailed in this Section, but the products were not isolated.
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2.3.3 Mass Spectrometry
Ruthenium TSC complexes were analysed by Electrospray Mass Spectro-
metry (ESI-MS) as part of the initial characterisation. The results are
summarised in Table 2.5. The spectra of all complexes showed the typical
isotopic pattern for mononuclear ruthenium species.
Each row in Table 2.5 lists data for the two complexes of one TSC ligand
HL and compares the theoretical and experimental mass-to-charge ratios
(m/ztheor. and m/zexp.) for the chlorido complex, [(p-cymene)Ru(HL)Cl]
+
to the values for their corresponding iodido congeners [(p-cymene)Ru(HL)I]+.
Table 2.5: ESI-MS data for ruthenium complexes of selected TSC ligands HL.
m/z (theor.) ≡ [(p-cymene)Ru(HL)X]+, with X = Cl, I
[(p-cymene)Ru(HL)Cl]+ [(p-cymene)Ru(HL)I]+
HL [C] m/z m/z
Δm/z
[C] m/z m/z
Δm/z
(theor.) (exp.) (theor.) (exp.)
1a [6] 449.98 414.0 35.98 [7] 541.43 414.0 127.43
1b [8] 464.01 428.0 36.01 [9] 555.46 428.0 127.46
1c [10] 478.04 442.0 36.04 [11] 569.44 442.0 127.44
1d [13] 651.97 615.9 36.07 [14] 743.43 616.0 127.43
2a [15] 493.06 457.0 36.06 [16] 612.48 485.0 127.48
2c [19] 521.11 485.0 36.11 [20] 612.48 485.0 127.48
2d [21] 695.04 659.0 36.04 [22] 786.49 659.0 127.49
3a [23] 575.88 540.0 35.88 [24] 667.33 540.0 127.33
3b [25] 589.89 554.0 35.89 [26] 681.34 553.8 127.54
3c [27] 603.93 568.0 35.93 [28] 695.38 568.0 127.38
The two columns in Table 2.5 that are labelled Δm/z present the mass-
difference between the m/ztheor. for the cationic complexes [(p-cymene)Ru(HL)X]
+
and the experimentally determined result. There is a consistent loss of 36
mass units (mu) for all chlorido complexes, and of 127.5 mu for the iodido
analogues. Furthermore, in every row, the detected m/z is identical for the
two complexes of the same TSC ligand HL. These values clearly highlight
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the loss of either HCl or HI from the structure, resulting in a complex that
has the formula [(p-cymene)Ru(L)]+.
High-resolution accurate mass data were acquired for the four arene
ruthenium TSC complexes [11], [13], [21], and [28], which were selected
as representatives of the three TSC ligand series 1-3. Complexes [13] and
[21] have a chlorido monodentate ligand, while [11] and [28] have an iodido
monodentate ligand.
Figure 2.10: Comparison between measured and calculated isotopic pattern
of the mass spectrum of complex [(p-cymene)Ru(1d)Cl]+ shows that the ex-
perimental data fits with the molecular formula for the deprotonated species
[(p-cymene)Ru(1d-H)]+.
Figure 2.10 shows that the isotopic pattern detected in the HR-MS spec-
trum of the chlorido complex [13] is in excellent agreement with a mono-
nuclear ruthenium complex of the formula C24H25N3SIRu, which does not
include any chloride atoms.
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Table 2.6: High-resolution ESI-MS data for complexes [C] ([(p-
cymene)Ru(HL)X]X) of selected TSC ligands HL.
[(p-cymene)Ru(HL)X]+ - [HX] → [(p-cymene)Ru(L)]+
[C] HL FW m/z Δm/z m/z m/z
(theor.) (exp.) (calc.)
[11] 1c 696.39 569.44 127.35 442.0890 442.0890
[13] 1d 687.42 651.97 35.983 615.9870 615.9858
[21] 2d 730.49 695.04 36.011 659.0291 659.0279
[28] 3c 822.28 695.38 127.39 567.9858 567.9856
m/z theor. ≡ [(p-cymene)Ru(HL)X]+, m/z calc. ≡ [(p-cymene)Ru(L)]+ .
Data summarised in Table 2.6 are the detected m/z for each complex,
compared to its formula weight (FW) and to the calculated m/z for a
monocationic ruthenium complex of the formula [(C10H14)Ru(L)]
+. The
molecular formulae that were used for the calculation represent the most
likely solution for the detected arene ruthenium TSC species, as the exper-
imental values match this calculated m/z to the second last digit.
For example, the molecular formula of complex [13] is C24H26N3SIRuCl2,
with a formula weight of 772.37 Da. The m/z of the same complex determ-
ined by HR-MS is 615.9866 Da, and the formula which best represents this
result is C24H25N3SIRu (calc. m/z 615.9857). This formula has changed by
two Cl atoms and one H atom, and its calc. m/z matches the low-resolution
ESI-MS results presented in Table 2.5. Because this formula does not con-
tain the halido ligand or counter ion, it is consistent with a molecule that
can form as a fragment of the chlorido complexes as well as from the iodido
analogues.
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2.3.4 X-ray Crystal Structures
For three compounds presented in this thesis, crystal structures were ob-
tained. The first one is for colourless needle-shaped crystals of N,N-dimethylamino-
benzaldehyde-4-methyl-3-thiosemicarbazone, ligand 2b. The other two struc-
tures are of two different ruthenium TSC complexes: one for orange block
crystals of [(p-cymene)Ru(PTSCNMe2)Cl]PF6, complex [10], and the other
is for red crystals obtained from the reaction of [(p-cymene)Ru(DTSCNMe2)Cl]Cl
([21]) with NH4PF6.
N,N-Dimethylaminobenzaldehyde-4-methyl-3-thiosemicarbazone (2b)
The ligand DTSCNMe (2b) crystallises with space group P2(1)/1, with
an asymmetric unit that contains one of four molecules in the unit cell.
Table 2.7 depicts the structure and lists a collection of significant interatomic
distances and torsion angles for the structure. These data show that the
TSC molecule is almost completely planar in the solid state. None of
the torsion angles that describe the TSC unit (C1 through C6), is larger
than 5◦. In fact, the largest dihedral angle between non-hydrogen atoms is
11.2(2)◦ between the aromatic ring and C14/15 of the two N-methyl groups.
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Table 2.7: Bond distances, torsion angles, and intra- and inter molecular
(hydrogen)-bond geometry (A˚, ◦) in DTSCNMe (2b).
Bond Distance (A˚)
C1—N2 1.463(1)
N2—C3 1.347(1)
S3—C3 1.716(1)
C3—N4 1.366(1)
N4—N5 1.400(1)
N5—C6 1.304(1)
C6—H6 0.950
C6—C7 1.471(1)
C10—N13 1.389(1)
N13—C14 1.466(2)
N13—C15 1.468(1)
A1 — A2 — A3 — A4 Torsion (◦)
C1 — N2 — C3 — S3 -4.7(2)
C1 — N2 — C3 — N4 174.6(1)
N2 — C3 — N4 — N5 -0.9(2)
S3 — C3 — N4 — N5 178.36(8)
C3 — N4 — N5 — C6 -177.2(1)
D-H...A D–H (A˚) H...A (A˚) D...A (A˚) < D-H...A (◦)
N2-H2...S3 $1 0.856(17) 2.932(17) 3.5076(11) 126.3(13)
N4-H4...S3 $2 0.874(18) 2.553(18) 3.4093(10) 166.4(14)
N2-H2...N5 0.856(17) 2.279(17) 2.6566(13) 106.9(13)
$1) Symmetry operators: x, -y+1/2, z+1/2 $2) -x, -y, -z
The graphic in Figure 2.11 captures the planarity of the structure. It can
be contributed to two factors: the conjugated pi-system which runs through
the length of the molecule on the one hand, and intramolecular hydrogen
bond interactions on the other. The dashed lines in Figure 2.11 highlight
the short contacts that are attributed to H-bonds, for example the contact
between N2-H2 and N5 (N2-H2...N5 = 0.856(17)).
There are also intermolecular H-bonds, between a sulfur atom S(3) and
the corresponding N4-H4 of a second TSC molecule (Figure 2.11). Be-
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Figure 2.11: Illustration of the X-ray crystal structure of N,N-
dimethylaminobenzaldehyde-4-methyl-3-thiosemicarbazone (DTSCNMe, 2b)
with atom numbering. Thermal ellipsoids are shown at 50% probability. Dashed
lines represent H-bond interactions which lead to the formation of dimeric pairs
in the solid state.
cause of this pairing, S(3) is located trans with respect to the imino group
(N(5)=CH), which is referred to as imine-E-configuration of the TSC.
[(p-cymene)Ru(PTSCNMe2)Cl]PF6 [10]
Figure 2.12 depicts the structure that was determined for the orange crys-
tals of ruthenium(II) TSC complex [10]. The unit cell contains four cationic
ruthenium complexes that have the formula [(p-cymene)Ru(PTSCNMe2)Cl]PF6.
Figure 2.12: ORTEP representation of the X-ray crystal structure of complex
[10] with atom labelling. Thermal ellipsoids are shown at 50% probability. PF6
counter ion and H-atoms omitted for clarity.
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The structure is that of a half-sandwich ‘piano-stool’ complex in which
the Ru(II) central atom bears an aromatic p-cymene ligand as ‘seat’, and
the TSC donor atoms N(5), S(6) and the Cl(1) are in the position of the
‘legs’. The asymmetric unit consists of one such molecule plus a PF6 counter
ion.
Table 2.8: Selected bond distances (A˚) and angles (◦), and H-bond geometry
for complex ([10]).
Bond Distances (A˚)
Ru(1)—N(5) 2.1364(14) N(2)—C(3) 1.329(2)
Ru(1)—S(3) 2.3589(4) C(3)—N(4) 1.343(2)
Ru(1)—Cl(1) 2.4319(4) N(4)—N(5) 1.3995(19)
C(3)—S(3) 1.7065(17) N(5)—C(6) 1.292(2)
D-H...A D—H (A˚) H...A (A˚) D...A (A˚)
N4-H4...F11 0.855(16) 2.385(19) 3.0752(19)
N4-H4...Cl1 $1 0.855(16) 2.82(2) 3.4142(16)
C6-H6...Cl1 $1 0.95 2.88 3.6014(17)
Bond Angles (◦) < D—H...A (◦)
S(3)—Ru(1)—Cl(1) 85.943(16) N(4)-H...F(11) 138.2(19)
N(5)—Ru(1)—Cl(1) 89.72(4) N(4)-H...Cl(1) $1 128.3(18)
N(5)—Ru(1)—S(3) 81.13(4) C(6)-H...Cl(1) $1 133.2
$1) Symmetry operators: 1-X,-Y,1-Z
Table 2.8 provides selected interatomic distances and angles as well as
short contacts (H-bonds). Those short contacts were located between the
TSC NH group (N(4)H) and a chloride (Cl(1)) of a neighbouring complex
(N(4)-H...Cl(1) = 0.855(16) A˚) and also between the imino CH proton C(6)-
H and the same neighbouring Cl(1) (C6-H...Cl(1) = 0.95 A˚).
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[(p-cymene)Ru(DTSCNMe2)]2[PF6]2 [30]
Red crystals of [30] formed in a mixture of complex [21] with 10 mol eq.
NH4PF6 in DCM/methanol by slow evaporation of DCM from the solution.
Complex [30] crystallises in space group P2/n. The asymmetric unit
contains a dinuclear di-cationic ruthenium complex, displayed in Figure 2.13,
of the formula [(p-cymene)Ru(DTSCNMe2)]2[PF6]2.
Figure 2.13: X-ray crystal structure and atom labels of dinuclear Ru TSC
complex [(p-cymene)Ru(DTSCNMe2)]2[PF6]2 [30]. Each molecule of [30] has
two PF6
− couterions.
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Table 2.9: Selected interatomic distances (A˚) in the crystal structure of complex
([30]). † the Ru–Ru distance does not qualify as a chemical bond but is included
for future reference.
Bond Distance (A˚)
Ru(1)—Ru(2) † 3.04
Ru(1)—N10 2.0835(16)
Ru(1)—S12 2.3511(5)
Ru(1)—S12(2) 2.4249(5)
S12—C(3) 1.7891(19)
C3—N(2) 1.365(2)
C3—N(4) 1.291(2)
N(4)—N(10) 1.400(2)
The structure consists of two identical Ru(II) piano-stool subunits, each
with a p-cymene and a chelating TSC ligand (DTSCIPh, 2d).
The two TSC molecules are arranged such that each sulfur atom bridges
the two ruthenium atoms, which results in the formation of a distorted
Ru2S2 rectangle with distances of dRu(1)–S(12) = 2.3511(5) A˚ and dRu(2)–
S(12) = 2.4249(5) A˚. The bond angles in this rectangle are 82.5 ◦ at Ru
(< S—Ru—S) and 94.4 ◦ at sulfur (< Ru—S—Ru), respectively. The imino
nitrogen N(5) of TSC ligand 2d completes the piano-stool sub-structure
of each ruthenium centre (dRu-N = 2.0835(16) A˚). Two molecules of this
dimeric structure are located in the unit cell.
In the dinuclear structure presented in Figure 2.13, the planar TSC
ligand DTSCIPh (2d) exhibits overall (Z)-configuration of the imine double-
bond. This way, the two substituted aromatic rings at either end of the TSC
ligand overlap with their respective opposite (Figure 2.13): the p-iodophenyl
ring faces the dimethylamino end of its counterpart and vice versa. This
arrangement causes two-fold rotational symmetry in the dinuclear complex.
Characteristic for the structures of both [10] and [30] is the C-S bond of
the coordinated thiosemiarbazone ligand, which is a measure of its binding
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Table 2.10: Comparison of bond lengths(A˚) in the TSC 2b, the mono-
nuclear complex [(p-cymene)Ru(1c)Cl]PF6 [10] and the dinuclear complex [(p-
cymene)Ru(2d)]2[PF6]2 [30].
Bond 2b [10] [30]
C(3)-N(2) 1.3475(14) 1.329(2) 1.365(2)
S(12)-C(3) 1.7164(11) 1.7065(17) 1.7891(19)
C(3)-N(4) 1.3660(14) 1.343(2) 1.291(2)
N(4)-N(5) 1.4002(13) 1.3995(19) 1.400(2)
mode as either neutral thione or negatively charged thiolate. In the former,
the C-S bond has double bond character and is therefore shorter, while the
C-S distance in the latter is longer due to the sigma-bond character of the
thiolate.
Table 2.10 compares significant bond lengths of the ligand with the
monomeric and the dimeric complex. The data show that the distance
between carbon and sulfur increases in the dimer (1.7891(19) A˚) compared
to the monomer (1.7065(17)), while there is no difference between the C=S
bond length in the monomer and the free ligand (1.7164(11)). At the same
time, the corresponding amide C-N bond is short in the dimer, but does not
change much between free TSC and the mononuclear complex. This differ-
ence in the bond distances is an effect of deprotonation of the TSC ligand at
the hydrazinic NH and subsequent tautomerisation to the thiolate. When
the C-S− binds to the ruthenium centre, the negative charge replaces the
chlorido ligand.Conclusively, the TSC ligand 1c is coordinated as thione in
complex [10], while ligand 2d binds as thiolate in dimer [30].
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2.3.5 NMR Spectroscopy of Thiosemicarbazones
This section presents solution state 1H and 13C NMR data for the TSC
ligands. 1H and 13C NMR chemical shifts for the characteristic moieties
such as the imino group HC1=N and the thione carbon (C=S) are listed in
Table 2.11 on the next page. The data are organised in four groups, a, b,
c, and d, according to the amide substitution pattern which is highlighted
by the structures in the first column. In each of those four blocks, three
different ligands are grouped together; 1a - 3a in the first, 1b - 3b in the
second, 1c - 3c in the third, and 1d - 3d in the final block.
Results of the 13C NMR experiments are summarised first. The C = S
column in Table 2.11 reveals that the chemical shifts for the thione carbon
are almost identical within each block. In groups a and b, δC=S is 178 ppm,
while in group c for the dimethylated TSCNMe2 ligands, the C=S carbon
signal shifts to 180 ppm. Compared to this, the 13C NMR signal for the
thione in TSCIPh ligands 1d - 3d is found 5 ppm higher at 175 ppm.
The chemical shifts for the imino carbon resonance δC=N is also shifted
downfield, to 140− 145 ppm. Here, the results are similar between the four
blocks of the the table. However, comparing the third row in each block with
the other two rows above shows that the ligands of 3-iodobenzaldehyde, i.e.
of series 3, have lower shifts for this carbon signal (140-142 ppm) than the
ligands derived from benzaldehyde (1a-d) and dimethylaminobenzaldehyde
(2a-c) with 144-145 ppm.
Next, significant 1H NMR signals are listed for the structural analysis
of TSCs and their metal complexes. These are for the imino proton H1, the
hydrazinic proton N2H2, and the proton(s) of the thioamide group (N3H2
for 1-3a). N=CH1 is one residue which all TSCs in this thesis have in
common. Its NMR signal is a sharp singlet at a chemical shift close to
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Table 2.11: 13C and 1H chemical shifts for selected atoms: δC of the thione
(C=S) and imine (C=N) carbon and δH for the imine proton H1C=N, the hy-
drazinic proton H2N and the thioamide protons N3H3†, recorded in dmso-d6 at
298 K.
Ligand
δC [ppm] δH [ppm]
C=S C=N H1 H2 H3
′† / H3
1a 177.9 142.1 8.07 11.45 8.00 / 8.22
2a 177.1 143.4 7.93 11.19 7.77 / 8.01
3a 178.1 140.5 8.00 11.49 8.16 / 8.24
1b 177.8 141.7 8.04 11.47 8.50
2b 177.1 142.8 7.92 11.19 8.28
3b 177.8 140.1 7.96 11.53 8.60
1c 180.5 143.8 8.19 10.94 –
2c n.o. 144.9 8.04 10.65 –
3c 180.5 142.2 8.12 11.01 –
1d 174.8 144.3 8.17 11.91 10.12
2d 174.8 144.3 8.04 11.67 9.94
3d 176.2 141.7 8.07 11.95 10.20
† The signal for the thioamide protons NH3 and NH3′ of ligands 1-3a is
split into two broad singlets at 298 K.
*n.o. not observed
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8.0 ppm. With a range from 7.93 - 8.19 ppm, the results for δH1 are similar
between all TSCs listed in Table 2.11. Only series 1 ligands have slightly
higher shifts for H1 than their two direct analogues in each block.
A second group which all of the presented TSCs have in common is the
hydrazinic proton N2H. This NH signal presents itself as a sharp singlet fur-
thest downfield in the spectrum, with chemical shifts as high as 11.95 ppm
(3d). The variation in the shift for N2H are approx. 1 ppm within the
range of TSCs presented here, with group c ligands showing significantly
lower shift values than the TSCs in the other three blocks.
The TSCs of series a (Table 2.11, top) have a thioamide NH2 group.
The two protons showed two separate signals, both as broad singlets with
chemical shifts in the region of 7.77 - 8.24 ppm. While the 1H NMR signal
for the thioamide NH in group b had a shift comparable to the group a
results, the respective NH proton of group d ligands 1d - 3d, is remarkably
shifted further downfield, to 10 ppm.
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2.3.6 Natural-Abundance 1H,15N NMR Spectroscopy
All TSCs contain at least three nitrogen atoms. Each has a different chem-
ical environment, as highlighted by the structure depicted in Figure 2.14:
the imino nitrogen N1, its hydrazinic neighbour N2, and the thioamide ni-
trogen N3.
Figure 2.14: General structure of TSCs with numbering scheme for 15N chemical
shift assignment by 1H15N-HMBC NMR: In series 1-3a R2 = R3 = H; for 1-3b
R2 = Me, R3 = H; for 1-3c R2 = R3 = Me; and in 1-3d R2 = 4-iodophenyl
(PhI), R3 = H.
This NMR study determined the 15N NMR chemical shifts for those
nitrogen atoms, and the results are summarised in Table 2.12 below.
Figure 2.15: Schematic representation of long-range 1H15N-couplings in TSC
ligands.
As a representative example of the spectra that were obtained in this
study, the 1H15N-HMBC NMR spectrum of DTSCIph (1d) is presented in
Figure 2.16. It shows seven significant cross-peaks for the 1H15N correlations
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in the molecule, illustrated by the schematic in Figure 2.15.
Figure 2.16: 1H15N-HMBC NMR spectrum of PTSCIPh (1d) and 2d (R =
N4Me2).
The 15N NMR chemical shifts are listed in Table 2.12. They are distrib-
uted over a range of almost 300 ppm, from 334 ppm (low field) to 53 ppm
(high field). With the information from the corresponding 1H NMR spec-
tra (data summarised in Table 2.11 on page 80), assignment of the shift
values δ15N to the corresponding nitrogen atoms in the TSC structure was
achieved.
The starting point for 15N signal assignment was the proton signal of the
imine group, δH(H1C=N), the sharp singlet at 8 ppm. This proton (H1) is
coupled to two nitrogen atoms in the TSC molecule (Figure 2.15): through
two bonds to the imine nitrogen N1 at δN = 300 ppm, and through three
bonds to N2. N2 has a direct 1JH,N coupling, visible as a double cross-peak
that is easily identified in the spectrum. The signal which matches those
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two conditions, i.e. the coupling to H1C=N and the 1JH,N coupling, is the
double cross-peak at δN = 174 ppm. H2 exhibits two further 2J correlations,
to N1 and N3.
Completing the assignment, the thioamide protons of S=C-N3H3 group
are represented by the second double cross-peak at δH = 10 ppm and δN
= 110 ppm for ligand 1d. N3 receives two further couplings, one from H2
(as mentioned above), and the other from the aromatic ortho-protons of the
p-iodophenyl substituent (Figure 2.15). Both are found in the 2D spectrum
and confirm the correct assignment to the respective nitrogen atoms in the
TSC structure.
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Table 2.12: 15N NMR chemical shifts δN and 1H15N coupling constants 1JH,N
for TSC ligands dissolved in dmso-d6 (298 K).
Ligand
δN1 δN2 1JH,N2 δN3 1JH,N3
[ppm] [ppm] [Hz] [ppm] [Hz]
1a 319 171 97.7 110 93.5 / 89.0
2a 306 170 98.5 107 95.1 / 88.7
3a 322 172 98.9 110 93.5 / 89.5
1b 316 170 99.0 104 n.o.*
2b 304 169 97.8 101 n.o.
3b 319 171 99.0 104 n.o.
1c 331 171 n.o. 103 –
2c 318 170 92.3 100 –
3c 334 171 n.o. 104 –
1d 315 174 98.8 127 91.7
2d 302 174 97.7 125 90.8
3d 319 175 99.1 128 91.5
*n.o. not observed, – not applicable because atom or bond not present in
respective ligand.
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The imino nitrogen resonance δN1 is found at around 300 ppm. This
represents the largest chemical shift for the TSC nitrogen atoms. This signal
also shows the largest variation between different ligands. ITSCNMe2 3c
has the lowest shift of 334 ppm of all TSCs presented here.
The hydrazinic nitrogen N2 shows a double cross peak around 170 ppm
with a coupling constant of 98 Hz. N2 is less downfield-shifted than N1,
and N3 resonates even further towards higher field, between 101 ppm and
128 ppm.
Ligands 2a-d also have a fourth nitrogen atom in their structure, the
dimethylamino substituent N4Me2 (Figure 2.14). Its chemical shift is found
at 53 ppm for all four TSCs of series 2. N4 is the most high-field 15N signal.
Table 2.12 lists the values of the scalar 1JNH coupling constants. The
one-bond correlation between a proton and a nitrogen atom it is directly at-
tached to are in the range of 90 to 100 Hz,19 measured as the shift difference
(in Hz) between the two cross-peaks that constitute the signal.20
The two amide protons in ligands 1-3a exhibit two different coupling
constants for the N3H2 group, one of 87.5-89.0 Hz that is smaller, and one
of 93-95 Hz that is slightly larger. For series b ligands, which bear one
proton and one methyl group at the amide position N3, the N3H coupling
was not observed. In contrast, for the hydrazinic N2H2 the coupling constant
is between 92.3 Hz and 99.1 Hz and it is the largest observed in this study.
In summary, all 1H and 13C NMR signals of thiosemicarbazones were
assigned to the structure and the most characteristic resonances were com-
pared within the series of TSCs presented here. The knowledge of the
chemical shifts of ligand signals will be crucial for the characterisation of
their ruthenium complexes. Section 2.4.5 will discuss the influence of the
structural variations between the TSCs on their NMR chemical shifts in
86
more detail.
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2.3.7 NMR Spectroscopy of Ruthenium TSC Com-
plexes
NMR spectra of TSC ruthenium complexes were recorded in three different
solvent systems. Therefore, this section is split into three parts. The first
one presents the initial NMR characterisation of the complexes, which was
carried out in deuterated chloroform (CDCl3). Selected ruthenium com-
plexes were synthesised in CDCl3 directly, with the aim to gather chemical
shift data for comparison purposes. The second part of this section de-
scribes 1H NMR spectra recorded of DMSO solutions of selected complexes.
Finally, spectra of D2O solutions of complex [15] provide an insight into
the stability of these TSC ruthenium complexes in aqueous systems.
Structure Confirmation and Chemical Shifts in CDCl3
Figure 2.17 shows the 1H NMR spectrum of complex [15], [(p-cymene)Ru(2a)Cl]Cl,
recorded in CDCl3, including the complete signal assignment of
1H NMR
resonances to the structure. From left to right, signals a,b,c and f are as-
signed to the TSC ligand 2a. The sharp singlet a at 8.75 ppm belongs to
the imino proton N=CH, and the two doublets b and c are the resonances
of the aromatic ring protons. In the aliphatic region of the spectrum, the
intense singlet f (δH = 3.5 ppm) represents the dimethylamino group of the
TSC. The remaining signals in Figure 2.17 (d, e, g-j) are of the p-cymene
protons. Of those, the two pairs of doublets around 4.8 ppm - 5.5 ppm
(d/e either side of the DCM peak), belong to the four aromatic protons.
Those signals were assigned by 2D NMR methods, using 1H/13C correla-
tions which will be discussed in detail in Section 2.4.5. With this assignment
in place, spectra of other p-cymene ruthenium complexes with TSC ligands
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Figure 2.17: 1H NMR spectrum and signal assignment for [(p-
cymene)Ru(2a)Cl]Cl ([15]), recorded in CDCl3, at 400 MHz and 298 K.
were analysed by comparison.
Table 2.13 contains 1H NMR data for 21 ruthenium TSC complexes,
aggregated in three groups: Complexes [6]-[14] have a PTSC ligand, com-
plexes [15] - [22] are of dimethylamino TSCs 2 a-d, and complexes [23] -
[28] have a iodophenyl TSC of series 3.
Within each group, the table directly compares characteristic 1H NMR
chemical shifts between the chlorido and the iodido complex of each indi-
vidual TSC ligand. The following results stand out.
• The largest shift difference (ΔδH) between chlorido complexes and
iodido complexes is for the hydrazinic N2H. This NH signal is observed
as far downfield as 13.1 ppm for chlorido complexes ([19]) or 15.2 ppm
([13]), for the corresponding iodido complexes this shift is ca. 2 ppm
lower and is found between 11.45 ppm ([20]) and 13.97 ppm ([22]),
respectively.
• Iodophenyl IPh substituted ligands 1d and 2d cause larger shifts for
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Table 2.13: Characteristic 1H NMR chemical shifts for Ru-TSC complexes:
Comparison between chlorido and iodido analogues of [(p-cymene)Ru(TSC)X]+
(X = Cl, I) for TSCs 1a - 3c.
No [(p-cymene)Ru(TSC)X]+ N2H N1=CH1 Hd Hd
′
He
′
He
6∗ PTSC (1a) Cl 14.66 9.07 5.43 4.88 4.82 4.66
8∗
PTSCNMe (1b)
Cl 14.84 8.90 5.38 4.86 4.79 4.62
9∗ I 13.48 8.96 5.31 4.85 4.75 4.50
10
PTSCNMe2 (1c)
Cl 14.03 10.12 5.34 4.96 4.73 4.66
12 I 11.76 9.88 5.33 4.95 4.76 4.66
13
PTSCIPh (1d)
Cl 15.24 8.94 5.33 4.84 4.74 4.65
14 I 13.97 9.08 5.36 4.92 4.78 4.63
15
DTSC (2a)
Cl n.o. 8.75 5.51 5.12 5.06 5.01
16∗ I n.o. 8.78 5.53 5.14 5.03 4.94
17∗
DTSCNMe (2b)
Cl 13.39 8.76 5.46 5.06 5.04 4.94
18∗ I 12.92 8.69 5.53 5.12 5.02 4.92
19
DTSCNMe2 (2c)
Cl 13.14 9.71 5.17 5.17 5.05 4.96
20∗ I 11.45 9.61 5.60 5.18 5.18 4.96
21
DTSCIPh (2d)
Cl n.o. 9.00 5.49 5.11 5.11 4.99
22 I 13.44 8.73 5.53 5.16 5.05 4.93
23
ITSC (3a)
Cl 15.08 8.95 5.54 4.92 4.92 4.88
24 I n.o. 9.02 5.43 4.89 4.80 4.73
25∗
ITSCNMe (3b)
Cl 14.94 8.83 5.48 4.91 4.86 4.84
26∗ I 13.20 9.01 5.43 4.88 4.76 4.75
27
ITSCNMe2 (3c)
Cl 14.12 10.03 5.45 5.00 4.84 4.80
28 I 11.89 9.84 5.45 4.99 4.83 4.76
† recorded in dmso-d6.
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the NH resonance than ligands of the other series a-c. This result com-
pares well with the findings for the free TSC ligands (Section 2.3.5).
The NH proton signal showed the same trend compared between the
three seies 1 -3.
• Complexes [10], [12], [19], [20], [11] and [28] of amide-NMe2 substi-
tuted TSCs 1-3c show the largest chemical shift for the imino proton
N=CH1. Their H1 signal is shifted approx. 1 ppm further downfield
(than for complexes of the other TSC ligands in their respective group.
• For all complexes, the four doublets for the aromatic p-cymene protons
Hd - He are found in the range of 4.50 ppm - 5.60 ppm, with group 1
showing the lowest and group 3 the highest shifts.
1H NMR of [(p-cymene)Ru(2a)Cl]Cl [15] in Aqueous Solution
The 1H NMR spectra of [(p-cymene)Ru(2a)Cl]Cl ([15]) in D2O solutions
(5% DMSO) were recorded at 600 MHz and 298 K.
Figure 2.18 shows the spectral region of the aromatic p-cymene protons
d/d’ and e/e’. Only two of the three spectra show clearly resolved signals.
The spectrum which was recorded 10 min after complex [15] was dissolved
does not show the same sharp peaks as the one that was recorded of the
same solution 12 hours later (Figure 2.18, middle), in which the sample
was equilibrated at room temperature. In contrast, the spectrum of the
sample of [15] which was equilibrated in NaCl solution (154 mM in D2O)
for the same period shows signals of the same chemical shifts and comparable
intensity.
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Figure 2.18: Comparison of 1H NMR signals of the aromatic p-cymene protons
d/d’ and e/e’ of [(p-cymene)Ru(2a)Cl]Cl ([15]) in D2O solutions (5% DMSO),
recorded at 600 MHz and 298 K after 10 min and after 12 h of equilibration at
room temperature, and after 12 h in NaCl solution (154 mM in D2O).
1H NMR in dmso-d6
The 1H NMR spectra of DMSO solutions of several ruthenium TSC com-
plexes showed varied results. Figure 2.19 compares the spectra of the chlor-
ido complex of ligand 1d, [(p-cymene)Ru(PTSCIPh)Cl]Cl, that were recor-
ded prior to and after the acquisition of 2D NMR data on the same sample.
The first spectrum was recorded within 10 min of dissolving the sample,
while the second was acquired 2 h later. The two spectra both show six
intense doublets in the region expected for the p-cymene proton resonances.
The roofing and intensity suggest that the two doublets at 5.8 ppm belong
to one species, and the four doublets further up-field belong to a second
species.
Figure 2.20 shows 1H NMR spectra of three complexes, each dissolved
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Figure 2.19: Comparison of 1H NMR spectra of complex [13] recorded before
and after acquisition of a 1H15N-HMBC spectrum in dmso-d6 at 298 K shows the
presence of two sets of signals for the p-cymene protons, indicating two species A
and B are present in solution and that the ratio of A to B changes in the period
of 2 h in which 2D NMR data was acquired.
in dmso-d6. The spectral region which is enlarged in the box below the
full spectra highlights the differences in the chemical shifts of the aromatic
p-cymene protons between complexes [19] (top), [12] (middle), and [29]
(bottom). For the latter two there is a second set of four doublets (marked
with ∗). The presence of this second species indicates that the complexes
undergo a structural change or substitution reaction in the solution. It is
to be investigated what the nature of the second species is, and whether, in
equilibrium, one structure is favoured.
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Figure 2.20: Comparison of 1H NMR spectra of complexes [19], [12], and [29].
Spectra were recoded in solution (dmso-d6, 600MHz, 298K). The figure shows the
signals of the p-cymene protons d,e. Spectra of complexes [12] and [29] show a
second set of those signals (∗).
Dimerisation of [(p-cymene)Ru(DTSCIPh)Cl]Cl ([21])
The reaction of complex [21] to [30] was first observed by NMR. Figure 2.21
shows the two spectra of the solution containing [21] and NH4PF6 in meth-
anol, 2 and 12 h after mixing.
The first spectrum already shows two sets of signals, with 8 doublets in
the region between 5 and 6.5 ppm, which correspond to two chiral p-cymene
complexes. The two sets exhibit a significant shift difference between each
other, with the first one ranging from 5.2 - 5.8 ppm and the second from
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Figure 2.21: 1H NMR spectra of a solution of [21] in methanol-d4 show two
species after 2 h and only one after 12 h. The dimer [30] crystallised in the NMR
tube.
5.9-6.2 ppm.
Figure 2.22 shows the 1H NMR spectrum of the dimer, recorded within
30 min after dissolving the red crystals in dmso-d6. The p-cymene signals
are shifted as far downfield as in the spectrum of the reaction mixture after
12 h (Figure 2.21). Only one set of signals is present, and the integrals of the
signals are consistent with the expected values. The signal is observed for
the hydrazinic NH proton, which is consistent with the expected structure
of the dimeric complex.
Complex [30] is stable in solution for several hours. The observation
of only one NH proton is in accordance with the crystal structure, and
comparison to the spectrum of the free ligand in the same solvent reveals
that the signal for the hydrazinic NH is lost while the thioamide proton
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Figure 2.22: Plot showing the aromatic region of the 1H NMR spectrum of
dinuclear ruthenium complex [30] in DMSO solution with peak labels and integral
values. Integrals highlight the up-field shift of
remains part of the structure after complex formation.
Due to the rotational (C2) symmetry of the molecule, the dimeric nature
is not obvious from a standard 1H NMR spectrum. Both the imine proton
and carbon signal shift to lower field, δH = 0.2 ppm, δC = 19 ppm.The
aromatic protons of the p-cymene ring shift differently in the two structures.
The arene protons are more de-shielded in the dimer, in which the ligand is
deprotonated. They are found at 5.5 - 6.3 ppm), while for the monomeric,
chloride containing complexes they are shifted closer to 5ppm (5.5-4.5 ppm).
The difference between the chemical shifts is remarkable, compared to
the data presented in Table 2.13. It is assumed that the electronic structure
of the deprotonated TSC influences the electronics at the metal and that
this effect is transferred to the arene, leading to this de-shielding that is
observed in the 1H NMR spectrum.
These shifts are solvent independent. Shift variations in polar solvents
are as small as 0.1 ppm between the spectrum in methanol-d4 (Figure 2.21
and dmso-d6 (Figure 2.22), respectively.
96
15N NMR coordination shift in Ru-bound TSCs
After the nitrogen atoms of the TSCs were characterised by their 15N-
chemical shift, the 1H15N-HMBC NMR experiment was repeated with solu-
tions of selected arene-ruthenium TSC complexes.
Figure 2.23 presents the correlation spectrum of the dinuclear complex
[(p-cymene)Ru(DTSCNMe2)]2[PF6]2 ([30], Figure 2.23 A). There are five
signals visible in the spectrum, which are caused by the couplings denoted
in the Table included in Figure 2.23 B.
Figure 2.23: 1H15N-HMBC NMR spectrum of [(p-
cymene)Ru(DTSCNMe2)]2[PF6]2 [30]
Compared to the results for mononuclear TSC complexes, the 15N NMR
signal of N2 is shifted downfield to 297 ppm, while N1 experienced an up-
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field shift to 250 ppm.
The results of the 15N NMR chemical shift determination for three fur-
ther ruthenium complexes are listed in Table 2.14. The 1H15N HMBC NMR
spectrum of complex [19] showed two cross-peaks, both correlations of the
same proton signal (δH = 8.18 ppm); the first at δN = 247.4 ppm, and the
other at δN = 292.3 ppm. Similarly, the spectrum of complex [12] also
shows two cross signals for one proton (δH = 9.17 ppm); one at δN = 271
and one at 292 ppm. Both the 1H and the 15N chemical shifts for complex
[29] were similar to those of complex [12].
Table 2.14: 15N chemical shifts for Ru-TSC complexes, recorded in solution
(50 µM in dmso-d6), at 61.8 MHz and 298 K.
Complex Peak δH [ppm] δN1 [ppm] δN2 [ppm]
[19] H1C=N 8.18 247 292
[12] H1C=N 9.17 271 292
[29] H1C=N 9.10 272 293
[30]
NH3(IPh) 8.70 187 (N3) 296
H1C=N 8.36 250 296
No coupling was observed from the NH proton in the three mononuclear
complexes [12], [19], and [29]. Compared to the data for the free ligands
1c, 2c, and 3c,
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2.4 Discussion
Three different series of TSC ligands were prepared and their structures
were fully characterised by NMR spectroscopic methods.
2.4.1 Synthesis
Thiosemicarbazones form by imine condensation between thiosemicarbazides
and carbonyl compounds. Using this common reaction has the benefit that
a broad range of starting materials is available, most of which are inexpens-
ive. Additionally, the yields are high and the reaction is comparably ‘green’;
except for one equivalent of water, all atoms from the starting materials are
also incorporated in the product molecule. The efficiency and diversity that
are provided by imine formation are attractive reasons for its use in the
design of TSC ligands for arene ruthenium anticancer complexes.
Figure 2.24: Scheme showing the multi-component reaction of aldehydes 1-3
with hydrazine (H2N-NH2) and thiosemicarbazide (d) in a one-pot reaction to
form TSC ligands 1-3d.7
A multi-component reaction,7 illustrated in Figure 2.24, was used for
the introduction of a 4-iodophenyl substituent (-C6H4-I, IPh) at the thioam-
ide nitrogen N3. Mechanistically, hydrazine first reacts with 4-iodophenyl-
isothiocyanate to form 4-iodophenylthiosemicarbazide, and this intermedi-
ate subsequently reacts with the respective aldehydes to the (4-iodophenyl)-
thiosemicarbazones 1d-3d. With this protocol, first published by Cunha
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and da Silva,7 the isolation and purification of the thiosemicarbazide inter-
mediate can be avoided by mixing all three starting materials at the same
time. However, to limit side-reactions, hydrazine monohydrate needs to be
added to the reaction vessel last, as it is the component which reacts first.
The products that were obtained under these conditions, the three iodinated
ligands 1d-3d, are novel compounds according to a search of the Cambridge
Crystallographic Data Centre database (CCDC), and their structures have
not been reported in the literature.
Preparation of Ruthenium Complexes
Arene ruthenium complexes were prepared in CDCl3 and the proton spectra
recorded within 30 min of mixing. The reactions had reached completion
during this time in all cases, which can be seen from the splitting of the
p-cymene aromatic proton resonances. In the precursors 4 and 5, these
protons resonate as two doublets, because their structures are symmetrical
and therefore non-chiral. Upon coordination of the TSC, this symmetry
is lost and the asymmetry of the metal centre renders the four aromatic
p-cymene protons magnetically inequivalent. As a result, they appear as
four signals in the NMR spectrum, each split into a doublet by a coupling
of 6 Hz, consistent with the expected three-bond coupling to its neighbour
proton.
The speed with which the reaction proceeded to completion is partic-
ularly surprising with respect to the structural change the TSCs have to
undergo in order to coordinate the metal in the N1,S-bidentate fashion that
results in a five-membered chelate ring.
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2.4.2 Mass Spectrometry
Mass spectrometric results can help to identify the molecular formula of
stable fragments of metal complexes.21 Furthermore, the isotopic pattern
is a useful indicator for identity between mass-spectrometric data and the
mathematically predicted mass-distribution.22, 23
ESI-mass spectra show the same mass/charge signal for the chlorido as
for the iodido complex, and the isotopic pattern is in agreement with a
mononuclear Ru(II) species in which not only the respective counter ion
is lost, but in addition to this the halido monodentate ligand is lost as
well. Ruthenium exhibits a wide isotopic distribution with a characteristic
fingerprint, which is easily detectable from mass spectra, even at lower
mass-accuracy.23
As concluded in Section 2.3.3, this formula is consistent with a species
that has lost the counter ion, which is the easiest ionisation pathway, but has
also lost the monodentate ligand and a proton to match the single positive
charge.
The results are coherent between all complexes that were studied here,
and research by others in the field confirms the presented findings: Su et al.
report the structure and spectroscopic data for complex [(p-cymene)Ru(BzTSC)Cl]Cl,
with BzTSC = benzaldehydethiosemicarbazone which is named PTSC (or
ligand 1a) in this thesis.24 They found a m/z of 414.0587 (calc. 428.0739)
for the species [(p-cymene)Ru(BzTSC)Cl]-HCl+. This value matches the
m/z of 414.0 that was determined for the two complexes [6] and [6] of ligand
1a (Table 2.5 on page 69).
In Chapter 1, the possibility of the TSC to tautomerise to the thiolate
form was discussed page 18. This tautomerisation is a means by which
charge can be delocalised within the molecule, and it therefore renders the
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hydrazinic proton the most acidic one in the structure. Deprotonation of
the coordinated TSC results in a negative charge on the ligand, which is
delocalised towards the metal centre to counteract the loss of the negatively
charged monodentate ligand. The result is a mono-cationic complex of the
general formula [(p-cymene)Ru(L-H)]+.
2.4.3 X-ray Crystal Structures
Crystals of DTSCNMe (2b) for structure determination by X-ray diffraction
grew in a saturated solution of the ligand in dmso-d6, probably due to water
uptake in DMSO over several days. Dmso is known to be hygroscopic,25 and
because the solubility of TSCs in aqueous systems is much lower than in
DMSO, crystallisation is facilitated by the increasing water content in the
sample.
In the structure presented in Section 2.3.4, ligand 2b shows E-configuration.
This is expected, as this configuration is the lowest energetic form for the
TSC structure due to intramolecular H-bonding interactions between the
amide NH and the imino nitrogen. H-bonding is a common structural fea-
ture in thiosemicarbazones,4, 26 and both crystallographic and structural
parameters were in good agreement with a previous report for this struc-
ture.4, 11
However, the opposite configuration is required for N,S-chelate forma-
tion. The five-membered chelate ring can only form when the azomethine
nitrogen (HC=N1) and the sulfur atom are cis-configured, i.e. both are
facing the metal. The PTSCNMe2 ligand (1c) demonstrates this in the
structure of [(p-cymene)Ru(1c)Cl]PF6 [10]. The thiosemicarbazone ad-
opts Z-configuration as it coordinates as an N/S chelating ligand to the
ruthenium, forming a five membered chelate ring. The same conformation
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was found in three different mercury complexes of the same ligand,8 while
the free ligand, which is reported in the same study, crystallised with E-
configuration.
Mononuclear Complex [(p-cymene)Ru(1c)Cl]PF6 [10]
Complex [10] appears to be the first example of an arene-ruthenium(II)-
TSC complex that has been crystallised with a terminally N-dimethylated
thiosemicarbazone. It crystallised from a concentrated methanolic solution,
in a diffusion crystallisation experiment with diethylether.27 The effect dif-
fusing ether into the sample is a gradual saturation of the methanol solution
with diethylether, causing the polarity (dielectric constant) of the solvent
mixture to change slowly. As a result, the solubility of [10] in the mixture
decreased, so that over a period of four days at 278 K, red block-shaped crys-
tals formed. In addition to the single crystal structure which was presented
in Section 2.3.4, this experiment also indicates that the compound is stable
under these conditions, i.e. dissolved in methanol, for at least four days.
However, the solution was kept in a closed atmosphere which contained only
the vial headspace volume of air. The limit of oxygen supply to the sample
appears to be a beneficial factor for the crystallisation of those Ru TSC
complexes.
Crystallographic data for complex [10] are consistent with structures
reported in the literature for similar Ru half-sandwich complexes that con-
tain other TSC ligands.14, 16, 18, 28 In particular, the space groups are mostly
monoclinic P21/C
28–30 and all significant distances in the coordination sphere
are similar to reported values. For this reason it is assumed that the struc-
tures within this series of ruthenium complexes that is presented in this
thesis are of the expected piano-stool geometry, and that the thiosemicar-
103
bazone ligands bind as neutral chelators to a Ru2+ core. This assumption
is also consistent with CHN elemental analyses for solids of the compounds,
which confirmed the presence of two halide atoms per molecule.
Comparison to the Dinuclear Structure of [30]
The dinuclear complex [30] was obtained as a result of mixing the mononuc-
lear chlorido complex [(p-cymene)Ru(DTSCIPh)Cl]Cl ([21]) of TSC ligand
2d with NH4PF6 in methanol, to exchange the chloride counter ion for hex-
afluorophosphate. Introducing this bulky, non-coordinating anion can aid
crystallisation of metal complexes by forming better ion pairs. Unexpec-
tedly, in the case of complex [21], the exchange of Cl− for PF6− did not
yield the analogue [(p-cymene)Ru(DTSCIPh)Cl]PFPF6. Instead, the dinuc-
lear complex [(p-cymene)Ru(DTSCIPh)]2[PF6]2 ([30]) crystallised during
the slow evaporation of dichloromethane from the mixture.
The main feature of this dimeric structure is a rectangular Ru2S2 cluster
which forms between the two metal centres and the sulfur atoms of the TSC
ligands. Each TSC binds to two metal centres via its sulfur donor, while
the imino nitrogen coordinates to only one ruthenium atom. Due to this
particular binding mode, the two TSCs are arranged such that the dinuclear
complex exhibits C2 symmetry, making the TSC ligands equivalent by a 180
◦
rotation around the long axis (Figure ??).
A similar dimeric structure of a p-cymene-Ru(II) complex has recently
been reported in the literature.29 Comparable to complex [30] the structure
contained two TSC ligands that bridge the two metal centres, forming a
Ru2S2 rectangle, and the TSC is deprotonated at N
2, with and elongated
C–S bond as a result.
In addition to the deprotonation, there are other structural changes in-
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volved in the reaction of [21] with itself and NH4PF6, such as the E/Z
isomerisation of the imine bond, and the formation of a second Ru-S bond
which connects the two monomers. One aim of this thesis is to study
this dimerisation in more detail, to gain an understanding of the processes
that constitute this reaction. The results of the spectroscopic investigations
presented in the following sections were undertaken to achieve this.
2.4.4 Natural-Abundance 1H,15N NMR Spectroscopy
Nitrogen NMR is a useful tool in both organic and inorganic chemistry.19, 31–33
While the two nitrogen isotopes 14N and 15N both have NMR active nuc-
lei, 15N NMR is by far the more widely used technique, because 15N has a
nuclear spin of 1
2
.34
However, direct NMR detection of nitrogen-15 signals is difficult. The
heavier isotope has a natural abundance of only 0.37%, 14N, in contrast,
accounts for 99.63% of the naturally occurring nitrogen.35 Furthermore,
the gyromagnetic ratio for 15N (γ15N/γ1H) is -0.101. Combined with the
low natural abundance of 15N, the result is a relative signal intensity of 0.1%
for nitrogen nuclei compared to an equal number of protons in the sample.
Before the use of indirect detection methods in two-dimensional quantum
coherence NMR experiments,19, 36, 37 one of two solutions led to a reasonable
15N NMR spectrum. Either long measurement times (i.e. a large number
of consecutive sweeps, followed by data averaging) or isotopic enrichment
of the sample with 15N. In other words, the acquisition of such a spectrum
was expensive.
With the introduction of Fourier Transform (FT) methods in NMR spec-
troscopy, nitrogen-15 NMR experiments became much more practical, and
the availability of stronger magnetic fields has since enhanced the sensit-
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ivity and reduced the need for expensive 15N labelling even further. The
method has, for example, been applied to the study of protein motions in
solution, by observing variations in the amide-nitrogen 15N NMR chemical
shift.38 Today, the 1H15N-HMBC experiment is used routinely for structure
elucidation of small and even large organic (bio)molecules.
Although 1H15N-HMBC is still the most insensitive39 and time-consuming
among the common two-dimensional NMR experiments used in small-molecule
characterisation,32, 33 it allows the use of naturally abundant 15N for the de-
tection of their 15N NMR chemical shift.
1H15N-HMBC-NMR and chemical shifts of TSCs
The 1H15N HMBC experiment is a 2D heteronuclear spin correlation tech-
nique by which through-bond couplings between the two nuclei 1H and 15N
can be detected. While the pulse program in this particular experiment was
optimised for correlations through two and three bonds, the direct 1JH,N
couplings were also observable, because no decoupling was applied during
signal acquisition. Hence, the one-bond NH correlations are visible as double
cross-peaks in the 2D spectra.
All 15N chemical shifts that were determined in Section 2.3.6 are con-
sistent with literature values for nitrogen atoms in similar structures.19 The
imino nitrogen can be compared with the shift of the pyridine nitrogen. The
15N chemical shift of py-N is 317 ppm, which was used for relative shift ref-
erencing.40 Figure 2.25 illustrates the influence of different substituents on
δN1 , the 15N chemical shift of the imino nitrogen. For each TSC ligand (see
ligand number on x-axis), the graph shows the value for δN1 (Table 2.12 in
the y-dimension.
The effect of phenyl substituents R1 is highlighted by the red and blue
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Figure 2.25: Influence of functional groups on the 15N NMR chemical shift of
the imino nitrogen, δ1N (data taken from Table 2.12). The phenyl substituent
within the aldehyde residue R1 and thioamide substituents R2/R3 affect the
resonance signal. While R1 = 3-iodophenyl shifts the signal furthest downfiled,
δ1N for dimethylamino TSCs 2a-d is up-field shifted by 20 ppm compared to 3a-d.
lines. The red line connects the values for series 3, and the blue line repres-
ents the shifts for series 2 ligands. This representation highlights that the
shift values for series 2 ligands are approx. 12 ppm smaller in all four groups
a - d, which demonstrates the electron-donating ability and conjugation of
the pi-electron system in these ligands.
The meta-iodo substituent in series 3 ligands, however, does not affect
the electron distribution in the TSC by as much: The purple line is shifted
ca 5 ppm downfield compared to unsubstituted PTSCs (series 1.
In contrast to the imino nitrogen N1, the 15N signal of N3 is unaffected
by methylation. The p-iodophenyl substituent in series d, however, has the
biggest influence on the chemical shift of N3. It de-shields the nitrogen
and shifts the signal downfield by approx. 20 ppm compared to the other
ligands.
The amide protons inter convert slowly on the NMR time scale due to
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hindered rotation around the thioamide C-N bond, which has partial double-
bond character.41 The descriptors cis and trans refer to the orientation
of the nitrogen-bonded proton relative to the thione sulfur (S3). Trans
describes the proton lying anti, i.e. opposite (E; H3) to the sulfur, while
and the cis proton (Z; H3’) is the one syn, or adjacent, to the sulfur. For
this reason, the chemical environment of the two most likely conformations,
cis and trans to the sulfur atom, are different and their 1H NMR chemical
shifts are inequivalent as a result.41
One-bond NH couplings have the largest magnitude of all 15N coup-
lings.19, 20 They can represent the s-character of the hybrid bonding orbital
on the nitrogen,42 which allows distinction between amino and imino NHs.
Values for one-bond couplings are characteristic of the geometry at the spe-
cific nitrogen as follows: 75, 90, 135 Hz for pyramidal, trigonal, or linear
bonding to nitrogen.19 Values of ca. 96 Hz can represent either enamine
or imino N(H) fuctionalities, with imino being C=N(+)H). Furthermore,
amide geometry (cis-trans H / O) can result in both larger and smaller
values from there (cis = 97.6 Hz , trans = 101.6 Hz).
2.4.5 NMR Spectroscopy with Ruthenium TSC Com-
plexes
Table 2.13 on page 90 summarised characteristic 1H NMR data for the 21
TSC complexes presented in this thesis. The results are in good agreement
with NMR data for other piano-stool ruthenium complexes of the same
or a similar type.30 In particular, the 1H NMR signals of the p-cymene
aromatic protons show the expected coupling pattern due to the metal-
centred chirality of the molecule.
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The reason for this phenomenon is given by the chelating ligand, which
introduces asymmetry to the structure. Because no symmetry operation
achieves degeneracy between the aromatic ring protons, they become mag-
netically inequivalent. As a result, they appear as four signals in the NMR
spectrum, each split into a doublet by a coupling of 6 Hz, consistent with
the expected three-bond coupling to its neighbouring proton.
Figure 2.26: Section of 1H,13C-HSQC (blue) / HMBC (red) NMR spectra of
[20] in CDCl3, showing correlations between the aromatic and aliphatic p-cymene
protons that were used to assign the four doublets d, d’, e, and e’.
The interpretation of 2D NMR spectra led to the full assignment of
the 1H NMR signals of the aromatic p-cymene protons. In Figure 2.26,
the 1H/13C correlations are highlighted, showing the connection between
d/d’ and the methyl group h on the one hand, and between e/e’ and the
iso-propyl substituent g,j on the other.
The region for the p-cymene proton signals correlates well with literature
reports for Ru p-cymene semicarbazone and thiosemicarbazone complexes.
Zhou et al. report a p-cymene ruthenium complex of benzaldehydesemicar-
bazone bzsc, in which the half-sandwich complex crystallises in the same
structure that is reported here. The four aromatic p-cymene protons show
the same 1H NMR chemical shifts and 3JH,H coupling constants for the
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AA ´ BB ´ -spin system (four doublets at 5.53 - 4.59 ppm with 3JH,H =
5.7 Hz), and the ESI-MS results showed the same signal for [(M+)-HCl]+,
as was discussed above.
One 1H NMR signal stands out in Table 2.13, the one for the hydrazinic
NH proton. For most of the complexes, the resonance of this exchangeable
proton is shifted as far downfield as 12-14 ppm. It is notable that these shifts
for N2H are higher for the chlorido complexes than for the iodido complexes.
This extreme downfield shift can be explained by hydrogen bonding of the
NH with the chlorido ligand of another molecule in solution.
It is known that hydrogen bonding causes downfield shifts in 1H NMR
spectra of NH-containing molecules,43 and the H-bond contacts which were
found in the crystal structure of complex [10] indicate that connections
between these groups are likely. In a non-polar solvent such as chloro-
form, solvation of the chloride is less likely, therefore the interaction with a
hydrogen-bond donor becomes favourable.
The collection of 1H NMR chemical shifts in Table 2.13 gives an overview
of the electronic influence the variety of TSC substituents can have on the
complex.
NMR spectra of the dinuclear TSC complex [30]
The aromatic protons of the p-cymene ring shift differently in the two struc-
tures. The arene protons are more de-shielded in the dimer, in which the
ligand is deprotonated. They are found around 6 ppm (5.5 - 6.3 ppm), while
for the monomeric, chloride containing complexes they are shifted closer to
5ppm (5.5-4.5 ppm). The difference between the chemical shifts is remark-
able, compared to the data presented earlier in this chapter. It is assumed
that the electronic structure of the deprotonated TSC influences the elec-
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tronics at the metal and that this effect is transferred to the arene, leading
to this de-shielding that is observed in the 1H NMR spectrum.
Confirmation of Ru-N coordination by 1H15N-HMBC-NMR
15N NMR is widely used in biological NMR, for structure elucidation of pro-
teins or smaller peptides, and 1H15N coupling constants and residual dipolar
couplings (RDC) provide a wealth of structural information, if recorded and
interpreted carefully.44 However, this technique is not used much for the
analysis of metal complexes in solution, because it is mainly a phenomenon
in large molecules that tumble slowly on the NMR timescale.
Table 2.15: 15N NMR chemical shifts for Ru-TSC complexes, recorded in solu-
tion (50 µM in dmso-d6), at 61.8 MHz and 298 K.
[C] δ1H δN1 δN1 ΔδN1 δN2 δN2 ΔδN2
(L) [C] [ppm] (L) [C] [ppm]
12 [Ru(1c)I] 9.17 331 271 - 60 171 292 + 121
19 [Ru(2c)Cl] 8.18 318 247 - 71 170 292 + 122
29 [Ru(3c)]I 9.10 334 272 - 62 171 293 + 122
30 [Ru2(2d-H)2 8.36 302 250 - 52 174 296 + 122
Here, the 15N NMR chemical shifts of thiosemicarbazones have been
determined by 1H15N-HMBC-NMR in solutions, using natural abundance
of 15N. The same technique and experiment was applied to study selected
ruthenium TSC complexes by 1H15N-HMBC-NMR in DMSO solution.
Table 2.15 presents the shift results for two 15N NMR signals of each
complex: of the nitrogen atom that binds to the metal (imino N) and its
hydrazinic neighbour. Both signals show distinct and intense coordination
shifts. The shift difference for the hydrazinic nitrogen signal, Δ δ N2 is
particularly large – the signal is shifted 122 ppm downfield, which suggests
a significant change in its electronic environment.
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One report in the literature mentions the measurement of nitrogen-15
chemical shifts for a Ga3+ bis-TSC complex, and reports the imino N signals
to be shifted to 277/288 ppm, respectively.45 However, the data are not
mentioned in the text of the article, and no details are given for a comparison
to the free ligand, or which reference scale has been used. Therefore it is
impossible to say without further data or an experiment, which nitrogen
moiety in the gallium TSC complex the signals originate from.
Delp an coworkers published 15N NMR chemical shift values for a series
of amido and amino ligands, which were studied in combination with sev-
eral metal ions or coordination compounds.46 With the aim to build a
data base for 15N NMR chemical shifts of nitrogen-bound ligands in metal
complexes.46
Their report presents one example in which the 15N NMR chemical shift
of an anilino nitrogen (Ph-NH2) shifts by -62 ppm upfield upon its reaction
with a [(Tp)Ru2+(PMe3)] complex (with Tp = trispyrazolylborate). How-
ever, the same 15N NMR signal shifts in the opposite direction, 59 ppm
downfield, when this amino group looses one proton and, as a result, binds
to the metal as anilido ligand.
Therefore, the large shift that was observed for N2 in the 15N NMR
spectra of their TSC complexes could indicate that the TSC is deprotonated
at N2 in the respective solutions.
Combined with the results from ESI-MS experiments presented above,
and the knowledge that the hydrazinic nitrogen N2 is indeed deprotonated
in the solid state structure of the dinuclear complex [30], the conclusion
from the comparison of 15N-NMR chemical shifts between complexes of the
ligands 1c, 2c, and 3c with the dimer [30], is that p-cymene ruthenium
complexes with thiosemicarbazone chelating ligands are deprotonated in
112
polar solvents and subsequently tautomerise to their monocationic form
[(p-cymene)Ru(TSC-H)]+ by means of loosing the monodentate ligand.
2.5 Summary
This chapter presented the synthesis and NMR spectroscopic characterisa-
tion of arene ruthenium thiosemicarbazone complexes. Twelve TSCs were
prepared and their 15N NMR chemical shifts fully assigned to the corres-
ponding nitrogen atoms in the structure and proved to be consistent with
literature data. In total, 25 ruthenium complexes were prepared and their
structures were characterised by spectroscopic methods. Two solid state
structures of ruthenium complexes were obtained, one for complex [10]
which confirmed the coordination mode of the TSC ligand in the arene
ruthenium complexes as the neutral N,S(thione) form. The second struc-
ture presents a dinuclear Ru-TSC complex, at the heart of which is a Ru2S2
rectangle. This dimer formed in a solution of complex [21] with PF6, and
more work will be presented in Chapter 3 to investigate this conversion.
The reactivity of ruthenium TSC complexes was demonstrated by 1H
NMR spectra of several complexes that showed conversion into a second
species in DMSO or methanol solution. ESI-MS spectra confirmed a mono-
nuclear, monocationic ruthenium TSC species, after loss of both halides, to
be the most stable form of the structure under the experimental conditions.
The result of the ESI MS study highlights that a conversion takes places in
which both the chlorido and iodido complex form the same mono-cationic
species. The most stable species contains only the central ruthenium atom
and the TSC ligand, but no monodentate ligand.
The relation of 15N NMR chemical shifts determined for the TSCs to
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their corresponding ruthenium complexes showed an up-field coordination
shift for the imino nitrogen atom which confirmed binding of the ligand
to the metal via this position. The dramatic downfield shift of the signal
for N2 suggests deprotonation of the TSC, which is consistent with the
crystal structure of the dinuclear complex 30 and the ESI-MS data discussed
above. Therefore, this deprotonation is likely part of the mechanism of
the formation of dinuclear Ru-TSC complexes, which will be investigated
further as part of Chapter 3.
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Chapter 3
Synchrotron X-ray Absorption
Spectroscopy of Arene
Ruthenium TSC Complexes
This chapter is concerned with the solid and solution-state characterisation
of ruthenium arene TSC complexes by XAS. It presents the results of ex-
periments that were performed within 24 h of experiment time at beamline
B18 at Diamond Light Source, UK.
In particular, complexes 10, 13, 14, 21, 22 and 30 were studied by
XAS in order to qualify the status of ligand-to-metal binding. EXAFS
fitting will be presented, using the X-ray crystallographic data of 10 and
30. The results of the fitting will be applied in a linear combination analysis
to solution-state XAS data of the reaction mixture of 21 to observe the
formation of the dinuclear ruthenium complex 30.
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3.1 Introduction
X-ray absorption spectroscopy is an important tool in the structural charac-
terisation of non-crystalline materials.1 In the analysis of metal complexes,
EXAFS can be used to identify the types and distances of atoms in their
coordination sphere without the need for the same long-range order as, for
example, in single-crystal X-ray crystallography.
Information about molecular structure can be gathered from samples
that are powders, amorphous materials, mixtures, or solutions. This is a
great benefit for coordination chemistry, opening up a range of experiments
which can help to observe changes within this coordination sphere, for ex-
ample as a result of a different sample environment, substitution reactions
or degradation.
The availability of structure elucidation techniques that are element spe-
cific but do not depend on long range order in the sample is one of the
reasons why bioinorganic chemists increasingly utilise XAS in the research
of metal-based drugs.2–4
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3.2 Experimental Section
The following sections describe the details of the XAS experimental set-up
and procedure as well as the data processing steps.
3.2.1 Materials
For the experiments described in this chapter, solids of complexes 10, 13,
14, 21, and 22 were used, the synthesis and characterisation of which were
described in Section 2.2.3 (p. 47ff) in the previous chapter. In addition,
the dinuclear complex 30 and its Os(II) analogue were synthesised as de-
tailed below. [(p-cymene)OsCl2]2 was prepared using a microwave method
described in the literature.5
[30] [(p-cymene)Ru(2d)]2[PF6]2 [(p-cymene)RuCl2]2 (100 mg, 0.16 mmol)
and N,N-dimethylaminobenzaldehyde-4-(4-iodophenyl)-3-thiosemicarbazone
(ligand 2d, 137 mg, 0.32 mmol) were placed in a Schlenk-tube and mixed in
dichloromethane (10 mL). The red solution was stirred at room temperat-
ure and NH4PF6 (250 mg, 1.48 mmol) was added. A red solid precipitated
while storing the solution at 278 K overnight. It was isolated by filtration
and dried under vacuum (135 mg, 0.84 mmol, 50 %). Crystals suitable
for X-ray diffraction were obtained by slow evaporation of methanol from
a solution of the compound in methanol. 1H-NMR (400 MHz, dmso-d6)
0.86 (3H, d, J=6.7 Hz), 0.92 (3H, d, J=7.3 Hz), 2.37 (4H, m), 3.01 (6H, s
), 5.93 (1H, d, J=6.1 Hz), 6.00 (1H, d, J=7.2 Hz), 6.02 (1H, d, J=6.9 Hz),
6.22 (2H, d, J=8.8 Hz), 6.27 (1H, d, J=6.6 Hz), 7.02 (2H, d, J=8.8 Hz),
7.25 (2H, d, J=8.5 Hz), 7.44 (2H, d, J=9.2 Hz), 8.18 (1H, s), 9.37 (1H, s).
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13C-NMR (100 MHz, dmso-d6) 18.6 (CH3), 21.7 (CH3), 23.0 (CH3), 40.3
(NMe2), 83.3 (CH), 83.5 (CH), 90.4 (CH), 93.1 (CH), 110.5 (2CH), 119.8
(Cq), 122.3 (2CH) 134.8 (2CH) 137.1 (2CH), 165.0 (N=CH) CHN (calc.
for C52H60N8I2S2Ru2P2F12) 38.70 (38.86) %C, 3.69 (3.76) %H, 6.88 (6.97)
%N.
[31] [(p-cymene)Os(2d)]2[PF6]2 [(p-cymene)OsCl2]2 (50 mg, 0.063 mmol)
was dissolved in methanol (10 mL) at 293 K which gave a clear yellow solu-
tion. N,N-dimethylaminobenzaldehyde-4-(4-iodophenyl)-3-thiosemicarbazone
(2d, 53 mg, 0.13 mmol) was added and dissolved to give an orange solu-
tion. The mixture was stirred at 293 K overnight. To the orange solution
NH4PF6 (100 mg, 0.60 mmol) was added, and an orange solid precipitated
which was subsequently filtered and dried in air (56 mg, 70 %). 1H NMR
(400 MHz, methanol-d4) 1.04 (3H, d, J=7.0 Hz), 1.10 (3H, d, J=7.3 Hz),
2.48 (1H, m7, J=7.8 Hz), 2.59 (3H, s), 3.19 (6H, s), 6.01 (2H, d, J=6.6 Hz),
6.01 (2H, d, J=8.9 Hz), 6.18 (1H, d, J=5.6 Hz), 6.28 (1H, d, J=5.6 Hz),
6.39 (2H, d, J=9.0 Hz), 7.14 (2H, d, J=8.9 Hz), 7.34 (2H, d, J=9.0 Hz),
7.64 (2H, d, J=9.3 Hz), 8.21 (1H, s). 1H NMR (400 MHz, CDCl3) 0.90
(3H, d, J=7.0 Hz), 1.04 (3H, d, J=6.7 Hz), 2.30 (1, m, J=6.8 Hz), 2.62
(3H, s), 3.13 (6H, s), 5.68 (1H, d, J=5.8 Hz), 5.73 (1H, d, J=5.6 Hz), 5.82
(1H, d, J=5.7 Hz), 6.27 (2H, d, J=9.1 Hz), 6.49 (1H, d, J=6.4 Hz), 7.20
(2H, d, J=9.1 Hz), 7.27 (2H, d, J=9.2 Hz), 7.69 (2H, d, J=9.1 Hz), 8.30
(1H, s). ESI-MS (MeOH) m/z (rel. int.) = 749 (100) [(M+)-HCl]+ CHN
(calc. for C52H60N8I2S2Os2P2F12) %C 34.71 (34.98), %H 3.26 (3.39), %N
6.18 (6.28).
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3.2.2 Solid-State X-ray Absorption Spectroscopy
X-ray Absorption Spectroscopy at the Ru K-edge and Os L3-edge was car-
ried out at beamline B18 at Diamond Light Source, Didcot, UK. Samples
for XAS measurements were prepared at the synchrotron, in the chemistry
lab located at the beamline, either on the day of the experiment or one day
before. Solid-state samples were stored at ambient temperature in air.
Solid-state Sample Preparation
Samples for X-ray transmission measurements were prepared as homogen-
eous ultra-finely ground powders. Approx. 50 mg of each complex were
ground in a marble mortar and mixed with cellulose powder as binding ma-
terial to achieve a total sample weight of 100 mg. The two powders were
ground together in the mortar until the colour of the mixture appeared ho-
mogenous. Each mixture was then compressed with a 5 Ton hydraulic press
into a thin disc of 13 mm diameter. The ruthenium content in those pellets
varied between 7% - 15%. Figure 3.3 shows the sample pellets assembled
in the sample stage which was used during the transmission experiment, to
move each sample into the X-ray beam consecutively.
Transmission-XAS Set-up
The sample pellets were mounted onto a holder (Figure 3.3) which was
placed in the path of the X-ray beam. Motors on the sample stage allowed
its vertical position to be adjusted remotely. Much beamtime was saved
by remotely controlling the vertical movement of the sample stage, so that
each pellet was brought into the beam consecutively without the need to
enter the experimental hutch for a sample change.
With the sample stage in place, XAS data was acquired in transmission
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Figure 3.1: A) Sample holder filled with 9 pellets prepared form powders of
ruthenium complexes mixed with cellulose. B) Sample stage located in the beam
path at beamline B18 (X-ray beam coming from the right in this view).
mode at ambient temperature as illustrated in Figure 3.2. Three argon-
filled ionisation chambers, I0, It, and Iref are positioned in the beam path:
One before and one after the sample and the third one after a reference
sample of Ru0 powder. This set-up was aligned such that the incident beam
passes through the first chamber (I0), then through the sample pellet and
subsequently through the second chamber (It). It then passes through the
reference material followed by the third ion chamber (Iref ). Signal intensity
is collected in each of the chambers, and the X-ray transmission is calculated
as the difference between the readings in two consecutive chambers.
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Figure 3.2: This scheme illustrates the experimental set-up of the solid-state
XAS experiment in transmission mode. X-rays, produced in the synchrotron, are
filtered by a double-crystal monochromator to select the required energies. Signal
is acquired in each of the three ionisation chambers I0, It, and Iref which flank
the sample holder and the reference sample. The intensity difference between the
two detector chambers I0 and It represents the absorbance of X-ray energy by
the sample.
3.2.3 Solution-State X-ray Absorption Spectroscopy
Complex 21 (40 mg, 0.05 mmol) was dissolved in chloroform (400 µL) and
immediately diluted with 3.8 mL of a saturated solution of NH4PF6 in meth-
anol. Aliquots of this reaction mixture (0.5 mL) were taken with a micro
syringe and transferred into sample-cells (Figure 3.3 B, C) after 0.5 min,
1.5 min, 3 min, 6 min, 10 min, and 15 min. These aliquots were imme-
diately frozen by submerging the sample-cells in liquid nitrogen, and the
frozen samples were then stored at -77 K until further use.
Due to the high concentration of complex 21 in the solution, the reac-
tion proceeded fast and crystallisation of the product in the reaction vessel
started 15 min after the reactants were first mixed. A second solution was
prepared by dissolving 5 mg of complex 21 in 0.05 mL of chloroform and di-
luting with 0.4 mL methanol. This solution was stored at room temperature
in a closed glass vial for 30 h.
Solution-state XAS measurements were carried out in fluorescence mode.
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Figure 3.3: Experimental equipment for XAS data collection at Beamline B18,
Diamond Light Source, UK. A - Sample stage holding pellets of powders; B
- Liquid sample cell; C - Sample cell containing liquid sample; D
¯
- Stick for
insertion of sample into cryostat: red circle shows metal plate for attaching the
sample cell.
The frozen samples were transferred from the storage dewar into a liquid
nitrogen cryostat individually before the XAS measurement. Figure 3.3 (D)
shows the cryostat on the left and the respective sample holder on the right.
The red circle marks the position at which the sample cell is attached to
the holder before insertion into the cryostat.
X-ray fluorescence of the Ru Kα line was detected using a 9-element Ge
detector? which was placed at at 90◦ to the incident beam. The sample
cell was oriented at a 45◦ angle to the incident beam. The counts in each
detector element were examined for artefacts prior to summing over all
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elements.
3.2.4 Solid-State XAS Data Collection
Ru K-edge and Os L3-edge XAS data were collected at the core-EXAFS
bending magnet beamline (B18) at Diamond Light Source, Didcot, UK.
The synchrotron provides a 3.0 GeV electron beam, which is operated in
top-up mode with injections from the booster synchrotron every 10 minutes.
On the day of the Ru XAS experiments, an average beam current of 150 mA
was maintained. The beamline optics at B18 consist of an Al 200 µm white-
beam filter, Pt-coated collimating and focussing mirrors, and a double-
crystal monochromator which allows tuning of the incident beam energy to
the required edges.
Ru K-edge XAS
Si(311) monochromator crystals were used to tune the X-ray energy in the
region of the Ru K-edge (22117 eV). In this energy range, a resolution of
3·10−5 eV is achieved, with a beam size of 200 x 250 µm on the sample.
The X-ray energy was increased step-wise from 21917.0 eV to 23765.0 eV
(Ru K-edge) with a step size of 10 eV before the edge (21917 - 22087 eV,
0.5 eV through the edge (22087 - 22127 eV) and 0.05 A˚−1 after the edge (
22127 - 23765 eV) to account for the increasing attenuation of oscillations
in higher k-space. EXAFS signal was recorded up to k = 20 A˚−1. A ref-
erence spectrum (Ru foil) was collected with each scan to allow for energy
calibration and data alignment.
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Os L3-edge XAS
Osmium L3-edge XAS was acquired as part of a second visit to beamline
B18. The general set-up of the transmission XAS experiment was the same
as for ruthenium, except for the following parameters: the beam current
in the storage ring was 300 mA; Si(111) monochromator crystals were used
to obtain X-ray energies in the Os L3-edge region; and the incident beam
energy was varied from 10660 eV to 11670 eV in steps of 0.5 eV. The energy
resolution with this set-up was 1.4 · 10−4 eV−1.
3.2.5 XAS Data Processing
Data processing and analysis was performed using the Demeter software
package,6 version 0.9.12 under windows 7 and version 9.20 with Mac OS X
10.9.5, respectively. Within Demeter, ATHENA is used for processing raw
XAS data, XANES analysis and extraction of the EXAFS, while ARTEMIS
is used for EXAFS analysis. Fitting of the optimised, Fourier-filtered exper-
imental EXAFS data to theoretical scattering amplitudes and phases was
performed in Artemis with the IFEFFIT program (FEFF6).7
Calibration and Alignment of XAS Data
For each sample, the individual data sets (scans) were imported into Athena,
including the data that was collected in the reference channel Iref . The µ(E)
spectrum of the reference channel was used for energy calibration. The
energy at which the first derivative of the reference spectrum has the first
maximum was assigned to the tabulated literature value (22117 eV for Ru
foil, 11136 eV for Ta foil).
All useful scans for each sample were aligned to the reference channel.
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Calibrated μ(E) data of the individual scans were then averaged to reduce
the signal-to-noise ratio. The edge position E0 was determined as the max-
imum of the first derivative of the averaged μ(E) spectrum for each sample.
EXAFS Extraction and Fourier Filtering
Fourier filtering is the application of window functions to the χ(k) data to
reduce the data in R-space to a meaningful range that is used for EXAFS
fitting. Normalisation to a unit edge-step and background removal were
performed on the averaged μ(E) data sets. The ‘Autobk’ function in Athena
was used to apply spline functions in a normalisation range from −150 to
−60 eV before and from +150 eV to 1150 after E0.
After extracting the EXAFS in this way, the k-space plots were examined
to determine the noise-free range (kmin - kmax) to be used for the Fourier
transformation (FT). Next, Fourier-transformed data (R-space) were eval-
uated by backwards Fourier transforming the physically meaningful region
of the R-space plot (Rmin - Rmax). Hanning window functions were applied
in both FT processes to filter, i.e. truncate the data. Comparison between
extracted k-space and the backward FT was used in addition to optimising
the height of the first-shell peak in R-space.
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3.2.6 UV-visible Spectroscopy
UV-vis spectra were measured on a Varian Cary 300 spectrometer using
quartz micro-cuvettes of 0.1 dm path length and 0.9 mL volume. The
instrument was equipped with a PTP1 Peltier temperature control unit,
which was used to regulate the temperature of the sample holding block.
Sample Preparation
A stock solution of complex 21 (1.9 mg, 2.6 µmol) in dichloromethane
(500 µL, c(21) 5.2 mM) was split into aliquots of 10 µL (0.052 µmol) which
were dried with compressed air. Each aliquot was re-dissolved in 50 µL
dmso or methanol immediately before dilution in the cuvette.
Aqueous Solution Stability
Seven solutions of different concentrations of sodium chloride were prepared
between 154 mM and 4 mM were achieved by sequential dilution of 0.9%
saline solution (c(NaCl) = 154 mM). Aliquots of 21 as prepared above
were dissolved in 50 µL dmso and diluted by adding 20 µL of the dmso
solution to a cuvette filled with 980 µL of the respective sodium chloride
solutions. The solutions were mixed inside the cuvette and the spectra
collected immediately. Spectra were recorded at 298 K for 5 - 20 min, using
a scan rate of 600 nm/min between 630 nm and 230 nm and a cycling rate
of one spectrum per minute.
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3.3 Results
XAS data is presented here for eight arene ruthenium complexes and one
osmium analogue. Comparison of the transmission XAS data, collected on
Ru K-edge or Os L3-edge, to the X-ray crystallographic results presented
in Chapter 2
3.3.1 X-ray Absorption Near-Edge Spectroscopy
The results of pre-processing and Fourier filtering are summarised in Table 3.1.
Table 3.1 presents the average edge-position E0 for each sample. All samples
Table 3.1: Results of processing and Fourier filtering Ru K-edge XAS data. Edge
position E0, upper and lower limits of meaningful EXAFS, degrees of freedom
Nind for EXAFS fit, and resolvable absorber-scatterer distances δ R.
No
1st shell
E0 kmin kmax Rmin Rmax Nind
δR
(η6-C10H14)
+ A, B, X [eV] [A˚−1] [A˚−1] [A˚] [A˚] [A˚]
4 Cl, Cl, Cl 22123.25 2.68 16.97 1.1 2.38 11.64 0.11
5 I, I, I 22122.23 2.94 14.03 1.2 2.78 11.15 0.14
10 N, S, Cl 22123.00 2.60 13.55 1.1 2.35 8.71 0.14
13 N, S, Cl 22123.70 2.60 12.20 1.1 2.35 7.64 0.16
21 N, S, Cl 22123.09 2.68 12.90 1.2 2.30 7.73 0.16
14 N, S, I 22122.58 2.70 15.30 1.1 2.72 12.99 0.12
22 N, S, I 22122.62 2.66 15.35 1.1 2.75 13.33 0.12
30 N, S1, S2 22122.73 2.64 14.72 1.1 4.00 22.30 0.13
31 N, S1, S2 10879.45 3.00 10.00 1.3 3.80 10.45 0.13
showed absorption edges in the region of 22122 to 22127 eV. Comparison
between E0 for the TSC complexes and the starting materials (dimers 4
and 5) shows that both are shifted from 22117 eV, the value for Ru(0), in
the same order of approx. + 5 eV. The results for complexes that differ in
structure by only one atom in their first coordination shell (Z = Cl vs I)
shows that iodido complexes 14 and 22 have a slightly lower edge energy
than their corresponding chlorido analogues 13 and 21.
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The change within the TSC chelating ligand from a phenyl substituent
in TSCIPh (1d) in complex 13 to the dimethylanilino moiety in DMTSCIPh
(2d) within complex 21 does not influence the XANES region. The first
coordination sphere is identical in both compounds, and so is the oxidation
state of the Ru centre.
The molecular structures of the dinuclear ruthenium precursor com-
plexes 4 and 5 are depicted in Figure 3.4. The molecules contain two
(η6-C10H14)RuX3 units (X = Cl, I) which are connected by a bridge of two
of the X ligands. Compound 4 has three chloride ions in its first shell
(X=Cl) while 5, with X = I, bears three iodide ions.
Figure 3.4: Comparison of two crystal structures for dinuclear Ru starting
materials. The distance between the central metal Ru and the halogenide half-
shell varies between 2.4 A˚ for Ru-Cl in [(p-cymene)RuCl2]2 and 2.7 A˚ for Ru-I
bonds in [(p-cymene)RuI2]2 .
The Fourier transformed signal, shown in Figure 3.5 III, reflects the
absorber - scatterer distances R. The graphs are visibly different between
the two starting materials. The radial distribution plot for the iodido dimer
5 (red) shows a second peak at∼ 2.7 A˚ which corresponds to the ruthenium-
iodide distance (Reff = 2.72 A˚).
Figure 3.6 compares the EXAFS signal and FT for monomer 21 and
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Figure 3.5: I) Normalised XAS spectra, II) First derivative, III) extracted
EXAFS, and IV) Fourier Transform of XAS data for [(p-cymene)RuCl2]2 and
[(p-cymene)RuI2]2 .
the dimer 30. The k-space data (III) suggest that the EXAFS signal of the
dimer 30 is similar compared to monomer 21.
3.3.2 EXAFS Fitting
The least-squares EXAFS fit was produced in all three k-weights. Para-
meters that were varied during the fit were the edge-shift ΔE0, the amp-
litude reduction factor S20, and the mean-square relative displacement of the
scattering path-length, σ2, (also referred to as the ‘Debye-Waller factor’ of
XAFS), presented in Table 3.2.
Inter-atomic distances in the first coordination sphere were fitted to
crystallographic data, and are summarised in Table 3.3.
For chlorido complexes 4, 10, 13 and 21 the main peak in R-space in
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Table 3.2: Results of the first-shell fits of Ru K-edge EXAFS data. Least-
squares fit of edge-shift ∆E0, amplitude reduction factor S
2
0, expansion factor α
, and the mean-square relative displacement parameter σ2. Goodness of fit given
by χ2red R-factor.
Sample χ2 χ2red R- ΔE0 S
2
0 α σ
2
factor (eV) · 10−2 · 10−2 A˚2
Ru0 - - - - -
4 104724 32369 0.019 2.8 ± 1.7 0.8 ± 0.13 n.a.a 0.3 ± 0.1
5 41188 3831 0.033 3.4 ± 0.7 0.7 ± 0.07 0.2 ± 0.2 0.5 ± 0.08
10 71554 17715 0.014 3.7 ± 1.4 0.8 ± 0.05 n.a.a 0.07 b
13 44728 17691 0.016 3.3 ± 1.7 0.8 ± 0.06 n.a.a 0.08 b
21 81317 12406 0.019 3.2 ± 1.7 0.8 ± 0.05 1.7 ± 0.8 0.4 ± 0.6
14 31495 4492 0.027 3.9 ± 1.0 0.8 ± 0.09 1.4 ± 0.4 0.17 ± 0.08
22 47533 5756 0.027 3.9 ± 1.4 0.8 ± 0.10 n.a.a 0.15 ± 0.08
30 65909 3173 0.037 4.0 ± 0.9 1.1 ± 0.08 0.8 ± 0.1 0.3 ± 0.09
31 12622 1956 0.010 7.9 ± 1.0 0.9 ± 0.08 0.1 ± 0.3 0.5 ± 0.1
30∗ 43364 5851 0.019 3.2 ± 1.1 0.8 ± 0.08 -0.4 ± 0.4 0.01 ± 0.1
a not applicable, RS was fitted as RX + ∆R.
b fixed value.
∗fitted to X-ray crystallographic data of [10]. χ2 is the goodness-of-fit
parameter, scaled to the estimated uncertainty. χ2red is χ
2 divided by the
number of free fit-parameters. R-factor describes the deviation between the
fitted and the experimental curve.
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Figure 3.6: XAS data for complexes 21 and 30. I) Normalised XAS spectra, II)
extracted EXAFS (‘k-space’), III) Fourier Transform (‘R-space’), IV) real part
of FT.
the range of Δ R = Rmax − Rmin (Table 3.1) was used for the fit. The
iodido complexes 5, 14 and 22 showed a significant second-shell peak in
the FT which was included into the fitting range after successfully fitting
the first-shell peak.
Table 3.3 compares the calculated absorber-scatterer distances (RS) to
the crystallographically determined inter atomic distances (RX). The com-
parison between the crystallographic data that were presented in Chapter 2
(Section 2.3.4, p. 72) and the Ru K-edge XAS data obtained here aims to
answer the question whether the TSCs are sulfur bound in the solid state.
The data in Table 3.3 show that the bond distances calculated by the
EXAFS fit are within± 0.05 A˚ of each other and also match the range of the
crystallographically determined distances. In particular, the Ru-S distance
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Table 3.3: Fit result for interatomic distances (A˚), fitted as separate distances
(A˚)
No. X, Y, Z d Ru-N d Ru-S1 d Ru-Cl/I/S2 δ(S1/Cl)
RX N, S, Cl 2.13 2.36 2.43 0.08
10 N, S, Cl 2.08 2.32 2.41 0.09
13 N, S, Cl 2.12 2.35 2.42 0.07
21 N, S, Cl 2.11 2.35 2.41 0.05
14 N, S, I 2.12 2.36 2.73 0.37
22 N, S, I 2.12 2.36 2.73 0.37
30
N, S1, S2 2.11 2.33 2.42 0.09
(RX = 2.1027) (RX = 2.31) (RX = 2.39) -0.08
30* N, S1, S2 2.12 2.33 2.41 0.08
*fitted to X-ray crystallographic data of 10.
is very similar between all mononuclear complexes. The theoretical values
are close to the crystallographic standard of 2.3519 A˚, except for monomer
21. For 21, the fit result of 2.3214 A˚ is closer to the Ru-S distance in
the dimer 30 (2.3113 A˚). The Ru-I distances in complexes 14 and 22 were
fitted via an arbitrary single scattering path of 2.7 A˚ length with a result
of 2.7284 A˚ for 14 and 2.7249 A˚ for 22. The last column in Table 3.3
presents the difference between the fitted distance between the Ru-S bond
and the Ru-Cl bond.
The EXAFS data of 30 were also fitted to the X-ray crystal structure of
mononuclear complex 10 to show that the geometry is different and the fit
result worse than when the correct structure of the dimer is used to build
the model. The results show that this is the case. Although a fit with a
reasonable R-factor was obtained (see Table 3.2), and the main parameters
are refinable to sensible values, the half path-length for the single scattering
paths in the first shell differ from the monomer model to a greater extent
than from the correct structure.
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It is therefore concluded that the bulk material of 30 is of dimeric nature,
because it fits better to the X-ray crystal structure of 30 than that of
monomer 10.
Os L3-edge EXAFS of complex [31]
The Os L3-edge XAS data were treated in the same way as the Ru K-
edge data. EXAFS fitting to the crystallographic data for complex 30 was
achieved by exchanging the central absorber in the model for Os prior to
the prediction of scattering paths with iffeffit.
Figure 3.8 shows the fit result in k-space and R-space, including the fit-
ting window. The optimised parameters of the fit are included in Table 3.2.
Table 3.4: Fit-results of first-shell EXAFS fit of Os L3-edge XAS of complex 31
Path N S20 σ
2 ∆ E0 Δ R Reff R
·10−3 (eV) ·10−3 A˚ A˚ A˚
N1.1 1 0.913 5.34±1.0 7.9±1.0 2.49± 2.10270 2.10520
C57.1 2 0.913 5.34±1.0 7.9±1.0 2.60± 2.18930 2.19190
C25.1 2 0.913 5.34±1.0 7.9±1.0 2.66± 2.24370 2.24636
C48.1 2 0.913 5.34±1.0 7.9±1.0 2.72± 2.29180 2.29452
S3.1 1 0.913 5.34±1.0 7.9±1.0 2.74± 2.31130 2.31404
S3.2 2 0.913 5.34±1.0 7.9±1.0 2.84± 2.39220 2.39504
C15.2 1 0.913 5.34±1.0 7.9±1.0 3.03± 2.55490 2.55793
C14.1 1 0.913 5.34±1.0 7.9±1.0 3.49± 2.94250 2.94599
C23.1 C25.1 1 0.913 5.34±1.0 7.9±1.0 3.51± 2.96210 2.96562
N2.1 1 0.913 5.34±1.0 7.9±1.0 3.67± 3.09320 3.09687
C56.2 1 0.913 5.34±1.0 7.9±1.0 4.07± 3.42770 3.43177
Os3.1 1 0.913 5.34±1.0 7.9±1.0 4.15± 3.49560 3.49975
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Figure 3.7: First-shell EXAFS fit results shown in R-space to compare chlor-
ido complex [21] to its iodido analogue [22]. Theoretical model for the fit was
produced from X-ray crystallographic data of complex [10].
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Figure 3.8: Plots demonstrating the fitting result for Os L3-edge data recorded
for Os(II) complex 31. Fit result is shown in k2-weighted k-space, and in R-
spacce. Theoretical model for the fit was produced from X-ray crystallographic
data of complex
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3.3.3 Solution-state Ru K-edge XAFS
In this experiment, the reaction of complex 21 with 10 eq. NH4PF6 in
methanol was repeated and observed by XAFS on freeze-quenched aliquots
of the reaction mixture. Because of the high concentration of complex 21
in the solution, crystallisation in the reaction vessel started after 15 min
of reaction time. For this reason, samples were collected at only four time
points.
For data analysis, a linear combination analysis (LCA) approach was
taken. In this method, the XAS data of individual reaction time steps were
analysed with respect to a linear combination of several components that
might be present in the mixture.
In order for this approach to succeed, four different samples were meas-
ured as standards: The solid-state samples of complex 21 and complex
30, a concentrated frozen solution of 21 in methanol and a concentrated
frozen solution of complex 30 in acetonitrile (due to the low solubility of
30 in methanol).
Linear Combination Fitting
After data alignment and background subtraction, the groups of individual
scans for each standard, as well as for each reaction time-step, were averaged
in µ(E) as described above.
The LCF tool in the Demeter software package (Athena) was used to fit
the spectra of the reaction steps to the two standards. First, a combinatorial
fit was executed to choose the best two endpoint standards for the fit of the
reaction data. Table 3.5 shows the results of this fit that used the solution
of the monomer (21LS1), the solution of the dimer (30LS2) and both solid
scans.
140
Table 3.5: Cominatorial fit result for the relative contribution of standards A
- D to the Ru K-edge XANES of the reaction mixture of mononuclear complex
21 with NH4PF6.
Standard weight
A 21 -0.002±0.081
B 21LS1 0.497±0.055
C 30 0.475±0.053
D 30LS2 0.030±0.025
The result of the combinatorial fit shows that the solution of the monomer
(B) and the solid-state data for the dimer (C) give the best combination of
standards. This combination showed the lowest R-factor (3.64 · 10−5) and
reduced χ2 (7.3 · 10−6).
Second, LCF was performed using the two standards A and C only, for-
cing the sum of both to be equal to one for each time step. The fitting pro-
cedure used flattened µ(E) data in the range from 22103.77 to 22153.77 eV,
which is from 20 eV below the edge energy E0 to 30 eV above the edge. The
result is summarised in Table 3.6.
Table 3.6: Relative content of monomer (21) and dimer (21) in the reaction
mixture, determined by LCF of the two endpoint standards (21L) and 30S)
forcing their sum to be equal to 1.
time E0 weight weight R χ χ
2
min [eV] (monomer) (dimer) ·10−3 ·10−5 ·10−3
1.5 22123.33 0.77 ± 0.04 0.23 ± 0.06 0.04 0.87 0.99
3 22123.77 0.66 ± 0.09 0.34 ± 0.10 0.20 3.87 4.42
6 22123.77 0.52 ± 0.04 0.48 ± 0.06 0.04 0.73 0.83
10 22123.33 0.42 ± 0.11 0.58 ± 0.12 0.32 6.45 7.35
30 h 22123.33 0.12 ± 0.07 0.88 ± 0.08 0.12 2.43 2.77
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Figure 3.9: Graph showing the decrease of monomer proportion compared to
the increasing dimer concentration over time, Reaction of a 40 mM solution of 21
in methanol, containing 5 % chloroform (T = 298 K) and 10 mol eq. NH4PF6.
Ru K-edge XANES data for each time point was collected on a frozen (freeze
quenched) aliquot of the reaction mixture. The monomer : dimer ratios are
the result of linear combination fitting (LCF) of the time-dependent Ru K-edge
XANES, fitted as flattened µ(E) from 22103.77 to 22153.77 eV.
The graph in Figure 3.9 shows the relative concentration of monomer 21
compared to dimer 30 that were present in the mixture at the time at which
the aliquot was removed from the reaction mixture. The last data point
(30 h) was obtained by measuring Ru K-edge XANES on a second sample
of the reaction mixture which was prepared with the exact same monomer
concentration, but without the addition of PF6, to avoid crystallisation of
the sample from the concentrated reaction mixture.
3.3.4 UV-vis Spectroscopy
UV/vis spectroscopy was carried out in order to test solution stability of
complex 21. For 1 hour, a solution of complex 21 in water (containing
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5% methanol) was monitored in the region between 200 to 600 nm and
Figure 3.10 shows a superimposed plot of the accumulated spectra.
Figure 3.10: Graphic shows the dynamic changes in UV-vis absorbance spectra
of complex dissolved in methanol.
Several changes were observed during this period, which are highlighted
by arrows to indicate the increase or decrease of band intensities over time.
The ESI-MS of the solution both 10 min and 21 h after dilution showed
the same signal, corresponding to the deprotonated complex that has lost
both chloride ions. This suggests that not only the arene, but also the TSC
ligand stay connected to the ruthenium centre over 21 h.
The species which appears to form in solution from arene Ru TSC com-
plexes has been described by the formula [(p-cymene)Ru(L)]+ in Chapter 2,
which is the same as one of the two halves of a Ru-TSC dimer such as [30].
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Suppression of Hydrolysis by Sodium Chloride
The concentration of sodium chloride in the solution is directly related to
the rate of hydrolysis, as was observed by UV/vis. Figure 3.11 compares
the spectra of an aqueous solution of complex 21 in the presence of varying
chloride concentrations.
Each plot presents spectra of a separate experiment in which complex
21 was added to a sodium chloride solution. Each plot therefore represents
one concentration of Cl−. In each experiment, five spectra were recorded
over a period of 5 min, and the first one marks 1 min after after the initial
mixing.
The first two graphs in Figure 3.11, for high Cl− concentrations of
154 µM and 51 µM, show no change of the spectra over the 5 min. With
decreasing chloride content, however, the dynamics in the spectra recur. At
15 µM and below, the changes in absorbance are clearly visible after the
first few minutes.
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Figure 3.11: The graphs show that dynamic changes in UV/vis absorbance
spectra of complex 21 are suppressed at higher Cl− concentrations (154 µM -
26 µM), are slow at concentrations of 15 and 8 µM, and fast at 4 µM NaCl.
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3.4 Discussion
XAS is a powerful spectroscopic technique for structure elucidation. Ru K-
edge XAS data was collected for six arene ruthenium complexes that have
been presented in the previous Chapter. Four structures are shown in Fig-
ure 3.12. Additionally, the two dinuclear starting materials [(p-cymene)RuCl2]2
[4] and [(p-cymene)RuCl2]2 [5] were studied as reference materials for the
Ru(II) oxidation state in arene complexes as well as for the EXAFS fitting
of Ru-X bond distances in half-sandwich motifs.
Figure 3.12: Structures of four Ru TSC complexes [13]/[14] and [21]/[22]
The four mononuclear Ru TSC complexes of p-iodophenyl substituted
TSCs 1d and 2d were used to confirm their structure for both the chlorido
and iodido analogues (Figure 3.12), and the mononuclear TSC complex
[(p-cymene)Ru(PTSCNMe2)Cl]PF6 [10] was used as the crystallographic
reference. EXAFS fitting to its crystal structure data was achieved for all
TSC complexes. Finally, the two dinuclear complexes were studied, the
Ru TSC dimer [(p-cymene)Ru(2d-H)]2[PF6]2 and its osmium analogue [(p-
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cymene)Os(2d-H)]2[PF6]2 which was prepared especially to confirm that
its structure matches the one for the Ru dimer.
3.4.1 X-ray Absorption Near-Edge Structure
For metal K-edge XANES, the most important spectroscopic processes are
the electronic transitions of the excited core-electron (1s) into higher atomic
or molecular orbitals. Both metal-centred d-orbitals, either empty or par-
tially filled, and metal-ligand molecular orbitals are accessible by the excited
core electron. XANES data is in most cases analysed by comparison of the
edge energy E0 with reference spectra, as these provide information about
the oxidation state of the absorber.
The edge energies that were determined for the eight structures were
all within ± 2 eV of each other, and the TSC complexes have similar edge
energies as the two p-cymene dimers [4] and [5]. This confirms their Ru(II)
oxidation state and indicates a similar geometry.8, 9
3.4.2 Extended X-ray Absorption Fine Structure
Before EXAFS data can be analysed in a useful way, it is important to
understand the phenomenon which causes the oscillations in the X-ray ab-
sorption spectra beyond the rising edge. The next sections will therefore
briefly outline the theoretical background to the technique.
The EXAFS phenomenon can be explained by electron scattering theory.
With the continuous increase in incident beam energy above the absorption
edge, the photoelectric effect causes photoelectrons to be emitted from the
absorbing atom into the continuum.i Their kinetic energy increases linearly
i‘If a beam of light or of X-rays falls on a piece of matter, the latter will emit rapidly
moving electrons.’10
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with the frequency of the incident X-rays, and their movement away from
the central atom (the absorber) can be described as a plane wave of electrons.
With increasing incident energy, the energy of the emitted photoelectron
wave increases as well.10 X-ray absorbance, however, varies non-linearly
due to interference that occurs when the photoelectrons are scattered by
surrounding atoms within the coordination sphere of the central absorber.
Constructive interference of the outgoing wave with the back-scattered wave
leads to higher transmitted energy, resulting in a local minimum in X-ray
absorbance, while destructive interference results in the opposite effect - the
total absorbance increases and the measured transmitted X-ray intensity is
lower. In summary, the back-scattering of the photoelectron wave leads to
a modulation of the total absorption intensity which is characteristic for the
nature and position of the neighbouring atoms (scatterers).11, 12
EXAFS Theory
EXAFS can be described as the difference between the observed absorption
coefficient µ(E) and the free-atom absorption coefficient µ0(E), normalised
by the free-atom contribution.13 This modulation of the absorbance that is
caused by scattering effects is mathematically expressed by the χ function
(Eq. 3.1).
χ (E) =
(µ(E)− µ(E0))
µ(E0)
(3.1)
The transformation of χ (E) into the χ (k) (‘k-space’), aids the visual-
isation of the absorbance modulation.13 χ (k) is the wave-vector dependent
form of Eq. 3.1, it captures the oscillatory portion of the absorption coef-
ficient which is used for the fit. Figure 3.6 II gives an example of a χ (k)
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plot.
The theoretical approximation of the oscillations is summarised in the
EXAFS Equation (Equation 3.2), first suggested by Stern in 1974.14 It de-
scribes χ (k) as the sum over all single scattering paths of the photoelectron
wave.
χi(k) =
∑
j
NjBj(k)
r2j
e
−2rj
λ(k) e−2k
2σ2j sin(2krj + δj(k)) (3.2)
Assuming plane-wave character, k represents the wave vector of the
scattered photoelectron, i.e. its direction. The vector lengths, then, repres-
ents one leg of a scattering path or, the absorber-scatterer distance.
EXAFS fitting is the process of theoretically modelling the oscillations
that are extracted as k-space data, by use of the EXAFS equation. Several
parameters are required to obtain a reasonable fit of theoretical amplitudes
and phases to experimantal χ (k) data. Most important is the starting point
model for the structure. The next section therefore details the structural
model for ruthenium arene TSC complexes for EXAFS analysis, followed by
the discussion of the fitting procedure in the context of the results presented
above.
3.4.3 Structural Models for EXAFS of Ruthenium Arene
Complexes
In EXAFS analysis, a ‘shell’ of scatterers describes the number Ni of atoms
of one particular element and at one particular distance Ri from the ab-
sorber. In highly ordered structures, such as rock salt which contains of
two types of scatterers A and B in alternating shells, or similarly simple
lattice types in which the atoms of type A are surrounded by atoms of type
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Figure 3.13: Illustration of the atoms in the first coordination sphere of the
ruthenium centre in complex 10 [(p-cymene)Ru(DMTSCNMe2)Cl]PF6. The
three carbon atoms C19, C25, and C29 are the main relevant scatterers in the
EXAFS fitting model used in this chapter.
B, followed by a second shell of type A, each such shell is reflected by one
peak in the Fourier-transformed EXAFS (R-space).
Because of this correlation, the magnitude of the R-space plot can be
seen as a zero-order approximation for a radial distribution function.15 Of-
ten, a material that comprises of shells that fit this description are of a
regular, salt-like structure.
The first coordination sphere of an octahedral metal complex is defined
as the six atoms which are closest in space to the metal, and which are
located in positions that allow the best interactions between populated lig-
and s- or p- orbitals and empty or partially empty metal d-orbitals while
minimising repulsive interactions between each other.
Arene ruthenium complexes are pseudo-octahedral by the above defini-
tion. The arene ligand effectively occupies three of the six positions in an
octahedral ligand field, and the remaining three nearest-neighbour positions
define the scope for the coordination of other ligands.
Figure 3.13 illustrates the first coordination sphere of the piano stool
Ru TSC complex 10 as determined by single-crystal X-ray crystallography.
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Table 3.7: Bond distances (A˚) in the mononuclear complex [(p-
cymene)Ru(1c)Cl]PF6 [10] and dinuclear complex [(p-cymene)Ru(2d)]2[PF6]2
[10].
Bond [10] [30]
Ru-N(5) 2.1364(14) 2.0835(16)
Ru-S(12) 2.3589(4) 2.3511(5)
Ru-Cl(1) 2.4319(4) -/-
Ru-S(12) -/- 2.4249(5)
Ru-C(19) 2.260(2) 2.239(2)
Ru-C(25) 2.177(2) 2.207(2)
Ru-C(29) 2.222(2) 2.217(2)
Ru-C6 centroid 1.700 1.709
Ru(1)...Ru(1) -/- 3.5042(3)
Here, the three ‘legs’ are the N and the S donor atoms of the TSC, and the
chlorido ligand. This structure was used to build the theoretical model for
the calculation of XAS scattering amplitudes, and Table 3.7 provides the
distances from the central Ru atom to the atoms in the first coordination
sphere of two complexes that were presented in the previous chapter.
Fitting of the EXAFS data for the two dinuclear starting materials
was achieved using X-ray crystallographic data which is available from the
CCDC. For 4, CCDC 618603 was used, and 5 was fitted against its Os(II)
analogue, [(η6 p-cymene)OsI2]2 (CCDC 776272).
16
3.4.4 EXAFS Fitting
Fitting of experimental EXAFS data to theoretical χ(k) amplitudes and
phases which are approximated by varying parameters of the EXAFS equa-
tion is limited by the number of independent data points (Nind) that are
available within a data set. This number can be calculated from the upper
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and lower limits of the data (Eq. 3.3).
Nind =
(2∆k∆R)
pi
(3.3)
The number of independent data points describes the degrees of freedom
within a fit as a correlation of the noise-free EXAFS range ∆ k in which
the data are analysed, and the region of the Fourier transformed spectrum
∆ R in which the data have a physically relevant meaning.17
The fitting regions were decided upon during the process of Fourier fil-
tering of the normalised XAS data as described in Section 3.2.5. They were
presented alongside the results of XAS data processing and are summar-
ised in Table 3.1. The maximum k-range was from 3 to 12 - 16 A˚−1 for
the Ru samples, which resulted in a number of independent points Nind of
7 ≤ Nind ≤ 16. With Nind = 7, a minimum number of four parameters can
be varied simultaneously during an EXAFS fit. The four parameters that
built the starting point in the EXAFS analysis of the Ru TSC complexes
are summarised in Table 3.2.
The absorber-scatterer distances R were refined as half path-length of
each single-scattering path in the fitting range Δ R. These were optimised
in one of two ways: Either by using independent parameters delr(S) (with
S denoting the scatterer) as variables for the differences between the real
distance R and the half path-length Reff as
R = Reff + delr(S) (3.4)
or by using an expansion/contraction factor α which is multiplied with
Reff :
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R = a · Reff (3.5)
Using the expansion/contraction factor α with each of the crystallo-
graphic inter-atomic distances as α · Reff has the advantage that it is
only one parameter in the fit and so allows to keep more degrees of freedom
(Eq. 3.3), while accounting for the individual differences in scattering path
length due to the atomic radius of the scatterers.
The resolution of two peaks in the radial dimension (R-space) is given,
for two identical scatterers, by
δR =
pi
(2∆k)
(3.6)
which is dependent on the quality of the data as represented by the maximal
k; the achieved resolutions (δR) are given in Table 3.2.5.
The critical evaluation of the fit results and the structural parameters ob-
tained in the theoretical fitting procedure shows that the difference in bond
length between Ru-Cl and Ru-S cannot be resolved for the data obtained on
the ruthenium chlorido complexes.17 Therefore, the data in Table 3.3 only
gives an estimate of the structure, and needs to be used in combination
with data provided by other spectroscopic or analytical techniques when
referring to the atom type at distances that are not technically resolvable.
Here, both NMR and MS have already strongly suggested that the presen-
ted ruthenium complexes have similar structures, as for example the 1H
NMR chemical shifts for the p-cymene aromatic protons show (Table 2.13).
The Ru-Ru distance in the crystal structure of dinuclear complex 30 was
determined to be 3.49 A˚. The corresponding scattering path was included
in the EXAFS fit, but the contribution of this path to the EXAFS is so
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small that it does not justify the width of the fitting range. One principle
in EXAFS fitting is that the fit range in R-space should only be as wide
as it contains useful information. In the plot in Figure 3.6 it can be seen
that beyond the first-shell peak, no significant peaks occur in the FT. In
comparison to the R-space plot in Figure 3.7, which compares the chlorido
and iodido monomers of the N,N-dimethylamino-TSC ligand 2d.
3.4.5 The Dimerisation of an Arene Ruthenium TSC
Complex
Chapter 2 presented the X-ray crystal structure of a dinuclear arene ruthenium(II)
TSC complex [(p-cymene)Ru(IPh)]2[PF6]2 which appeared to have formed
in a reaction between molecules of the mononuclear complex [(p-cymene)Ru
(DTSC(IPh)Cl]Cl (21) and ammoniumhexafluorophosphate, both dissolved
in the polar solvent methanol. The reaction scheme in Figure 3.14 illustrates
the structures of the monomer and the dimer.
Figure 3.14: Reaction scheme of the formation of dinuclear arene Ru TSC
complex 30.
This section aims to elucidate the process of the dimerisation in more de-
tail. The results presented here summarise spectroscopic information about
the molecular structures of the two complexes 21 and 30, and, in partic-
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ular, about the process of the conversion of 21 as gathered by different
spectroscopic techniques:
1H-NMR, UV-vis and ESI-MS showed that hydrolysis of the Ru-Cl bond,
deprotonation of a TSC NH, and E/Z-isomerisation of the imino bond are
part of the reaction mechanism. Solution-state XAS adds the perspective
of the metal itself to the investigation, and should reveal the time frame
in which the changes to the first coordination sphere of the two ruthenium
centres occur.
The suppression of UV-vis spectral dynamics in aqueous solutions of
complex 21 allows the conclusion that the observed process is the hydrolysis
of the Ru-Cl bond and that this process is part of the reaction mechanism
for the dimerisation of 21 to 30.
Furthermore, it supports the hypothesis that two different processes were
observed with two different techniques, one being hydrolysis by UV-vis and
the other being the E/Z isomerisation of the deprotonated TSC which occurs
as part of the crystallisation of the dimer 30.
Meier et al. have reported on the dimeristaion of Ru complexes with
2-pyridinecarbothioamide ligands.18 In their study, a Ru2S2 rectangular
structure is assumed as an intermediate before the reaction with a nucleo-
phile breaks the dimeric arrangement.
The crystal structure of the dimer showed pi-stacked aromatic rings. Aro-
matic pi-stacking as well as the dimethylamino substituent appear to play a
role in the reaction mechanism.
Qualitatively, a dependence of the reaction rate on the presence of a
non-coordinating, scaffolding anion such as hexafluorophosphate (PF6) was
noticed, but was not followed-up. During the XAFS experiment, the reac-
tion was repeated without PF6, and no crystallisation occurred during 30
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hours at highest concentration, which allowed the XAS measurement and
yielded the last data point in the LCF graph. From this, the conclusion is
that the reaction is driven towards completion by the crystallisation of the
product and resultant removal from the equilibrium.
However, to solve the mechanism, more studies are required to obtain
information about the rates of the individual processes it constitutes of. For
the aim of this work, it was important to investigate the solution structures
of arene ruthenium TSC complexes by EXAFS to establish a fitting protocol
and gain confidence in the results both experimentally and theoretically.
Next, the same technique should be applied to aqueous systems and to
biological environments such as cell-culture media and cell samples.
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3.5 Summary
The experiments presented in this chapter aimed to elucidate the first co-
ordination sphere of ruthenium arene TSC complexes and confirm whether
these are identical to the X-ray crystal structure data obtained for complex
[10].
Ru-K-edge XAS data was collected on solid samples (powders) of eight
ruthenium complexes, and the EXAFS region of the spectra was successfully
fitted to these crystallographic data, which represents the first example of
a detailed EXAFS analysis for ruthenium arene TSC complexes.
In the solution state experiment, freeze quenched aliquots of a dimerisa-
tion reaction mixture were measured in fluorescence XAS and the spectra
were fitted in a linear combination analysis to XAS spectra of the reaction
endpoint standards.
This is the first time that such a reaction of a ruthenium TSC com-
plex has been studied by XAFS. The result of linear combination fitting
showed that the subtle changes to the first coordination sphere between the
monomer and the dimer are sufficient to affect their Ru K-edge XANES.
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Chapter 4
Biological Investigations and
Iodine Tracing
This chapter combines studies of the anticancer properties of iodine-labelled
TSC ruthenium half-sandwich complexes with the quantification of both
their metal centre and chelating ligand inside cancer cells by ICP-MS.
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4.1 Introduction
Drug speciation is one of the main challenges in medicinal inorganic chem-
istry. As such, one important question that arises during the investigations
of piano-stool anticancer complexes is whether their general structure, [(η6-
arene)M(XY)(Z)]n+, remains intact after the molecule has entered the cell.
It was discussed in Chapter 1 that some piano-stool complexes can undergo
substitution reactions of the monodentate ligand Z for a water molecule,
while the assumption for the chelating ligand XY is that it stays attached
to the metal, due to the chelate effect.1 The experiments presented in this
chapter aim to test this hypothesis for the TSC chelating ligands in the
presented complexes.
12 29
Figure 4.1: The two TSC ruthenium complexes 12 and 29 differ only by one
iodine substituent at the TSC. This Chapter investigates the effect of this sub-
stituent on the compound’s anticancer properties.
In particular, the anticancer activity and mode of action of complex 29
(Figure 4.1) of the iodine-labelled thiosemicarbazone ligand 3-iodobenzaldehyde-
4-dimethyl-3-thiosemicarbazone (3c) will be compared with its non-labelled
congener 12 of ligand 1c. The influence of the iodine substituent within
the TSC 3c, highlighted in Figure 4.1, on the cytotoxicity, cellular accumu-
lation, and the mode of action of its Ru complexes is discussed.
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4.2 Experimental Section
This section describes the experiments which were carried out to study the
iodinated TSC ruthenium complexes as anticancer agents. Details of the
cell-culture experiments are included here as well as the procedures of metal
quantification, colorimetric, and flow-cytometric assays which were used to
analyse treated cells.
4.2.1 Materials
The synthesis and analytical data of the complexes presented in this chapter
have been described in Sections 2.2.3 and 2.3 in Chapter 2. Table 4.1 lists
the materials which were obtained from commercial and other sources.
Table 4.1: Materials which were used to carry out the work presented in this
chapter.
Material (Quality) Source
ICP-MS Element Standards:
Ruthenium (1.003 ± 0.5 µg/mL in 10%
HCl)
Inorganic Ventures, Inc.
Iodide (1.001 ± 3 µg/mL in 1% TEA) Inorganic Ventures, Inc.
Biological media:
Phosphate-Buffered Saline (PBS) Biological Sciences, University of
Warwick
Foetal Bovine Serum Invitrogen
Roswell Park Memorial Institute cell-
culture medium (RPMI-1640)
PAA-GE healthcareb)
Dulbecco’s Modified Eagle Medium
(DMEM)
PAA-GE healthcare
L-Glutamine PAA-GE healthcare
Penicillin/Streptomycin mixture PAA-GE healthcare
Trypsin & Trypsin/EDTA PAA-GE healthcare
b) (formerly PAA Laboratories)
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4.2.2 Inductively Coupled Plasma Mass Spectrometry
Inductively coupled plasma mass spectrometry (ICP-MS) was performed
on an Agilent technologies 7500cx ICP-MS instrument in the Mass Spec-
trometry Facility of Warwick University. The solvent for all ICP-MS exper-
iments was doubly deionised water (dd-H2O) with 3.5 % HNO3. ICP-MS
was also used for quantification of ruthenium and iodine in human ovarian
cancer cells which were treated with the complexes presented in this chapter.
Standard solutions for the external calibration of the instrument were
freshly prepared in dd-H2O for each experiment. Commercially available
standard solutions of ruthenium and iodide (see Table 4.1) were diluted
sequentially, using water for iodide and 3.5 % HNO3 for ruthenium, up
to a concentration of 1 ppm. The two solutions were then mixed in the
following dilution to achieve a mixed standard that contained 200 ppb of
both element ions. From this solution, the calibration standards of the
following concentrations were prepared by sequential dilution with 3.5 %
HNO3: 0, 5, 10, 15, 20, 25, 30 ppb.
The isotopes 101Ru and 127I were detected and quantified simultaneously
in helium collision mode, along with 166Er as internal standard to validate
the reading. The method details are summarised in Table 4.2. It was
important to inject a blank of 3.5 % HNO3 in dd-H2O after each sample
injection to allow for noise reduction in the iodine readings, which were
used without correction or background subtraction. Triplicates of three in-
dependent readings were averaged for each sample and are reported with
their standard deviations (SD), as mean±SD.
Detection of defined Ru:I ratios and their identity after nitric-acid di-
gestion were tested, and the method was validated by a standard-addition
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Table 4.2: Details of method for simultaneous detection of 101Ru and 127I by
ICP-MS
Parameter
Flow rates Plasma 15 L·min−1
Auxiliary
Nebulizer
Cooling water 1.5 L·min−1
Sample Peristaltic pump 0.3 rps
Introduction Sample uptake rate
Nebulizer
Acquisition para-
meters
Initial stabilisation
time
30 s
Acqu. mode Spectrum (multitune)
Sweep time 0.1 s per point
0.3 s per mass
Isotopes 101Ru, 127I, 166Era)
Replicates per mass 3
No of sweeps 3
Stabilisation times
between sweeps
15 s
Total acqu. time 80 s
Total wash/rinse time 90 s
Total run time 200 s
Detection limits 127I 2.50±0.05 ppb
101Ru 0.05 ppb
a)166Er was used as the internal standard to validate each reading.
experiment: A known quantity of iodide standard solution was added to a
sample of unknown iodine concentration. Readings of iodine in this sample
were taken prior to and after addition of the spike volume and the data
showed the expected increase in detected iodine, without background inter-
ference. The results presented in this chapter for the simultaneous detection
of the two elements ruthenium and iodine were obtained with an iodine de-
tection limit of 2.00±0.05 ppb.
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4.2.3 High Performance Liquid Chromatography
Complexes 10, 12, 27, and 28 were dissolved in DMSO and immediately
diluted 1:20 into dd-H2O, 0.9% NaCl in dd-H2O, or 0.9% KI in dd-H2O to
achieve a final concentration of 0.1 mM and 5% dmso (v/v). The resulting
solutions were filtered through a 0.2 µm syringe filter prior to injection
of 50 µL into the HPLC system. Samples were injected manually within
10 min after the initial preparation, and again after 24 h of equilibration at
298 K.
Reverse-phase HPLC was carried out using an Agilent 1100 instrument
with a photo-DAD detector (λ= 320 nm, reference channel 360 nm) and a
ZORBAX Eclipse Plus C18 column (250 x 4.6 mm, 5 µm pore size). The
mobile phase system was H2O containing 0.1% trifluoroacetic acid (TFA)
[A] and acetonitrile (ACN) containing 0.1% TFA [B]. With a flow rate of
1 mL · min−1, the following gradient was applied: 30% [B] to 80% [B] in
30 min, decrease to 30% [B] in 1 min, hold for 7 min.
4.2.4 Cell-Culture Experiments
Cell-culture experiments, except for the digestion of cell pellets for metal
quantification, was carried out in the facilities of the School of Life Sci-
ences, University of Warwick. The following experiments were performed in
collaboration with Dr. I. Romero-Canelo´n from the same research group.
Details of the respective experimental procedures are summarised following
this overview.
• Determination of antiproliferative activity of ruthenium TSC com-
plexes by growth inhibition of human ovarian cancer cells A2780 in
vitro, measured with the Sulforhodamine B (SRB) colorimetric assay.
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• Accumulation of ruthenium and iodine in A2780 cells after incubation
with solutions of ruthenium TSC complexes, quantified by ICP-MS of
cell-digests.
• Determination of sub-cellular Ru/I distribution by fractioning of treated
cells and Ru/I quantification by ICP-MS.
• Analysis of cell-cycle populations after drug exposure for 24, 48, and
72 h, with quantification of cells by flow cytometry.
• Detection of apoptotic populations in treated A2780 cells at the same
three time points, measured by flow cytometry.
Cell Culture
A2780 human ovarian carcinoma cells were cultured as adherent monolay-
ers2, 3 in RPMI-1640 cell-culture medium supplemented with fetal calf serum
(10 %), L-glutamine (1 %), and penicillin/streptomycin (1 %). The cells
were incubated at 310 K in a humidified atmosphere containing 5 % CO2
until they reached 80-90 % confluency. The medium was removed and the
cells were washed with phosphate-buffered saline (PBS) before addition of
trypsin-EDTA (25%). A single-cell suspension was obtained by mixing with
fresh RPMI-1640 medium and the concentration of cells in a 10 µL aliquot
was determined with a hemocytometer.
Preparation of Drug Solutions for Cell-based Assays
For all in vitro assays, solutions of complexes were prepared as follows: 10,
12, 27, and 28 were dissolved in dmso at room temperature and diluted
so that the concentration of the stock solutions was 50 µM in a 50/50 mix
(v/v) of RPMI-1640 and saline, containing 2% of dmso. From the stock,
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all test concentrations were achieved by sequential dilution into RPMI-1640
medium (fully supplemented with 10% fetal calf serum, 1% L-glutamine,
and 1% penicillin/streptomycin). Absolute concentrations of ruthenium in
the stock solutions were determined by ICP-MS, and those results were used
for the calculation of IC50 values.
In vitro growth-inhibition assay
The growth-inhibition assay was carried out using 24-well micro titre plates
seeded with 105 cells per well. The cells were pre-incubated at 310 K in drug-
free cell-culture medium for 24 hours before addition of the drug solutions.
The medium was removed with suction and replaced with solutions of the
complexes (prepared as described above) in triplicates of six concentrations
between 50 µM and 0.1 µM. After incubation with these solutions for 24 h,
the supernatant solutions were removed and the cells were washed with
PBS. No recovery time in drug-free media was allowed. For time-dependent
studies, the experiment was repeated in the same way, using 24, 48, and
72 h exposure times without recovery time. For the quantification of viable
cells, the SRB assay was used as detailed below.
Sulforhodamine B Colorimetric Assay
Cell viability was determined as percent of cell-survival compared to un-
treated control cells using the SRB colorimetric assay.4–6
Briefly, trichloroacetic acid (TCA, 50 % in H2O, 150 µL/well) was added
to each well, and the plate was left to incubate for 1 h at 277 K to fix
the cells. After removal of the TCA the plate was rinsed with tap water
and dried in air. SRB dye (dissolved at 0.4 % in 1 % acetic acid) was
added (150 µL/well) and the plate was kept at 298 K for 30 min, followed
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by removal of excess dye and washing of the plate with 1% acetic acid.
Addition of 10 mM Tris-base solution (200 µL, pH 10.5) was followed by
incubation at room temperature for 1 h to dissolve the dye. Absorbance
readings were taken at 570 nm, using a BioRad iMark microplate reader.
Percent cell-survival was plotted against the log10(c) of the complex
solutions (with c in mM) and the half-maximal inhibitory concentration
(IC50) of each complex was determined as the inflection point of the fitted
sigmoidal curves. Origin software (v.8.5) was used for curve fitting of the
experimental data. The results are reported as the mean ± SD of duplicates
of triplicates of two independent experiments.
Cellular Accumulation Studies
Accumulation of the two elements ruthenium and iodine in A2780 cells was
determined after exposure to complexes 10, 12, 27, and 28 for 24 h. The
experiment was carried out in triplicates for each complex. A2780 cells were
cultured as described above, and three petri dishes of 145 mm width were
seeded with 5x106 cells each.
These were pre-incubated in drug-free RPMI-1640 medium for 24 h.
The medium was removed from the cells and replaced with 10 mL of drug
solution at IC50 concentration (2 µM). Cells were exposed to the drugs for
24 h before the supernatant solutions were removed, the cells were washed
with PBS and detached from the plates using trypsin solution (25%). The
detached cells were suspended in 5 mL fresh RPMI medium, counted and
pelleted by centrifugation at 1000 rpm for 5 min.
The cell pellets were digested in 73% nitric acid (0.6 mL) at 353 K
overnight, diluted 1:10 with dd-H2O and the ruthenium and iodine content
were quantified by ICP-MS and compared to un-treated control cells.
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Determination of Sub-cellular Ru/I Distribution
In order to quantify the amount of ruthenium and iodine in four different
sub-cellular fractions, the cell-accumulation experiment was repeated in the
same way as described above, but with twice as many cells. This increase
was necessary to assure a sufficiently high reading of ruthenium and iodine in
the ICP-MS measurement after the pellet is divided into the four fractions.
Three large petri dishes (145 mm width) were seeded with 107cells which
were exposed to 45 mL of a 2 µM solution of complex 29 for 24 h without
recovery time. After collecting and counting the cells, the following steps
were carried out consecutively, using the buffers provided in the BioVision
FractionPREP kit according to the supplier’s instructions to obtain the
following fractions.
1. The cytosolic fraction was extracted first, by re-suspending the cell
pellet in the provided cytosol extraction buffer (CEB) and keeping
the suspension on ice for 20 min. After centrifuging for the following
10 min at 2000 rpm and 277 K, the supernatants were collected.
2. For extraction of the membrane fraction, the cells were re-suspended
in a mix of membrane extraction buffer A (MEA) and membrane ex-
traction buffer B (MEB) by vortexing for 1 min, centrifuging for 5 min
at 3400 rpm and 277 K, and collection of the supernatants.
3. Next, the nuclear fraction was obtained. The cell pellet was sus-
pended in nuclear extraction buffer (NEB) and the suspension was in-
cubated on ice for 40 min. Subsequently, after centrifuging for 10 min
at 12000 rpm and 277 K the supernatants were collected.
4. The remaining pellet represents the cytoskeletal fraction.
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Samples of each fraction were obtained in triplicates and digested overnight
in 73% nitric acid (300 µL). The amount of ruthenium and iodine in each
sample was quantified by ICP-MS after dilution into 2700 µL dd-H2O as
described earlier. To compare iodine levels to ruthenium levels in each
fraction, data were normalised to nmol ·10−6 (nmol per million) cells.
Cell-Cycle Analysis
For analysis of cell-cycle populations, A2780 cells were seeded in 6-well
plates at 106 cells per well. After 24 h of pre-incubation, the media was
replaced with solutions of complexes 12 and 29 of 2 µM, except in the wells
of the control, which remained unchanged. The cells were exposed to the
drug for 24 h in the first experiment, and for 24, 48, and 72 h in the time-
dependence experiment. After the exposure time, the supernatants were
collected and centrifuged. Viable cells were detached from the plate using
trypsin solution, removed with added RPMI 1640 medium and combined
with the cells that were harvested from the supernatant. After washing the
combined cells with PBS, the pellets were incubated in 1 mL ethanol at
253 K prior to analysis by flow cytometry.
To prepare for flow cytometry, the ethanol was removed and the cells
were washed with PBS before staining them with a mixture of propidium
iodide (PI) solution and RNAse in PBS for 30 min. The following removal
of the stain and re-suspending in fresh PBS was necessary to minimise back-
ground readings of dye in solution. Fluorescence emission of the intercalated
dye (excitation of DNA-bound PI at 536 nm) was read at 617 nm using a
Becton Dickinson FACScan flow cytometer.
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Detection of Apoptotic Populations
For the apoptosis detection assay, A2780 cells were seeded in 6-well plates
at 1 ·106 cells per well. After 24 h of pre-incubation, a solution of complexes
12 and 29 of 2 µM was added. The cells were exposed to the drug for 24, 48,
and 72 h. The population of apoptotic cells after the respective incubation
time was determined by flow cytometry on cells that were stained using
the Annexin V-FITC Apoptosis-detection kit (BioVision) according to the
supplier’s instructions. Intensity of fluorescence emissions was read using a
Becton Dickinson FACScan flow-cytometer.
Flow Cytometry
Flow cytometry was carried out using a Becton Dickinson FACScan Flow
Cytometer (courtesy of Prof. David Scanlen, School of Life Sciences, Uni-
versity of Warwick).
Single-cell suspensions were obtained by mixing the previously harves-
ted cells in the appropriate buffer, including any stains or reactants as de-
tailed in the respective experimental procedures. These suspensions were
transferred into flow-cytometry sample-tubes immediately before the meas-
urement.
Flow-cytometry data were analysed using the Flowjo software package
(version 10.0.6). After plotting the total forward-scatter against total side-
scatter (FSC vs. SSC), the entire cell population was gated to exclude debris
from useful data, thus reducing noise to achieve a population of cells to be
analysed. The data were normalised to the gated population and standard
deviations were calculated.
Cell-cycle data were further normalised against the results for the neg-
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ative control in each experiment (see Section 4.3.5) and the standard de-
viations of the resulting data were calculated using the error propagation
formula given in equation 4.1.
σy
y
=
√(σa
a
)2
+
(σb
b
)2
(4.1)
For apoptosis detection, data recorded in the two channels FL2-H (PI
fluorescence, red) and FL1-H (FITC fluorescence, green) were plotted against
each other, and in each quadrant of the plot the number of cells was coun-
ted, representing the relative population in each of the four different viability
stages.
4.2.5 Significance Tests
To determine statistical significance of the experimental results, p-values
were calculated using a two-sample, two-tailed Student’s T-test7, 8 as im-
plemented in MS excel.
Table 4.3: Significance of test results as represented by the p-value (adapted
from Coolican.9
Significance level p-value
significant 0.01 < p < 0.05
highly significant 0.001 < p < 0.01
very highly significant p < 0.001
Statistically relevant differences between the experimental results ob-
tained in this chapter and negative controls are reported as either “signi-
ficant” or “highly significant”, based on the probability levels described in
Table 4.3 as adapted from Coolican.9
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4.3 Results
Two groups of arene ruthenium complexes were synthesised and fully char-
acterised as described in Section 2.2.3 in Chapter 2. Their general struc-
ture is presented in Table 4.4, which gives an overview of the systematic
structural variations that were chosen for the comparative studies described
below.
Table 4.4: Systematic iodine labelling in arene ruthenium TSC complexes.
Complex R X Y
10 H Cl PF6
11 H I I
12 H I PF6
27 I Cl Cl
28 I I I
29 I I PF6
Four complexes in Table 4.4 have iodide as their monodentate ligand (11,
12, 28, 29). Complexes 12 and 11 both bear the non-labelled benzaldehyde-
4-dimethyl-3-thiosemicarbazone ligand 1c and only vary in their counter
ion, in the same way as complexes 28 and 29 of the iodinated TSC ligand
3-iodobenzaldehyde-4-dimethyl-3-thiosemicarbazone (3c).
As a result of this systematic labelling with iodine in three different
positions of the structure, i.e. the chelating TSC ligand, the monodentate
ligand, and the counter ion, the ratio of I : Ru increases as follows. The I :
Ru ratio is 1:1 in complex 12, it increases to 2:1 in complexes 11 and 29,
and complex 28, with iodine in three positions, shows an I : Ru ratio of 3:1.
In the following, the anticancer activity of these four compounds against
human ovarian cancer cells (A2780) will be described, followed by studies
of their cellular accumulation in those cells. The distribution of ruthenium
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and iodine in A2780 cells was investigated for complex 29. The two chlorido
complexes 10 and 27 were used in HPLC experiments in order to compare
the aqueous solution stability between the chlorido and iodido analogues in
the presence and absence of sodium chloride.
4.3.1 Antiproliferative Activity
The antiproliferative activity of complexes 11, 12, 28, 29 as well as 19 and
15 was determined in human ovarian carcinoma cells (A2780), using the
sulforhodamine B (SRB) colorimetric assay4–6 with Cisplatin (CDDP) as
positive control.
The assay relies on the binding of SRB to alkaline residues of proteins in
fixed cells at low pH. At high pH levels, the SRB dye is released quantitat-
ively, and a linear correlation between free dye and the amount of proteins is
observed. For quantification of viable cells compared to un-treated control
cells, the relative absorbance of SRB at 570 nm is used. The half-maximal
inhibitory concentrations (IC50) were determined as the inflection point of
the cell-viability vs. log(c) plot and are compared in Figure 4.2.
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Figure 4.2: Antiproliferative activity (IC50) of complexes 11, 12, 28, and 29
against human ovarian carcinoma cells (A2780) after 24 h of exposure without
cell-recovery in drug-free medium. Cisplatin (CDDP) was used as a positive
control.
All four complexes exhibit similar activity, with IC50 values in the range
of 1.6 - 2.1 µM (Table 4.6). Evaluating these results using Student’s T-Test7
to a significance level of p = 0.05 suggests that there is no statistically sig-
nificant difference (p > 0.05) between the activities of the complexes in this
series.8 The activities of the four ruthenium TSC complexes are also com-
parable to the IC50 of Cisplatin, which was determined to 4.0 µM under the
same conditions.
Table 4.5: Time dependent antiproliferative activities (IC50) of complexes 12
and 29 against A2780 cells.
Compound
Exposure IC50
Time [µM]
12
24 h 3.9 ± 0.2
48 h 2.6 ± 0.1
72 h 3.3 ± 0.5
29
24 h 3.6 ± 0.1
48 h 2.5 ± 0.1
72 h 3.4 ± 0.2
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The experiment was repeated using only complexes 12 and 29 at three
different lengths of exposure, to determine whether the duration of drug
exposure had an influence on the activities of the two compounds. The
results in Table 4.5 show that the IC50 values are similar to the results that
were obtained in the assay which only used 24 h of exposure (Table 4.6).
IC50 values were in the range of 2.45 ± 0.1 to 3.9 ± 0.2 µM. A p-value of
0.814 was determined between the results for the two complexes. It can
be concluded that the activities of 12 and 29 are identical within error.
Moreover, they also do not vary significantly between the three recorded
time points of 24, 48, and 72 h of exposure.
4.3.2 Total Cellular Ru/I Accumulation
In this experiment, the total amount of ruthenium and iodine was determ-
ined that was accumulated by A2780 cells within 24 h of exposure to the
four complexes. Four ruthenium TSC complexes were compared, and the
results are tabulated below (Table 4.6). The drug concentration to which
the cells were exposed was 2 µM of complex 11, 12, 28, or 29; representing
the average IC50 value which was determined in the previous experiment.
No recovery time was allowed prior to collecting the cells for the digestion
in nitric acid and subsequent Ru/I quantification by ICP-MS.
The bar chart in Figure 4.3 summarises the results of the quantification
of the two elements 101Ru and iodine 127I in the digested cell pellets. For
each complex, the orange (left) bar represents the ruthenium quantity, while
the purple bar represents the amount of iodine that was detected, in units
of pico mole per one million cells (pmol/106cells). This unit is a result of
normalising the initial ICP-MS data, detected in ppb (µg/L), by the atomic
mass of the respective element, the sample volume, and by the number of
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Table 4.6: Accumulation of ruthenium (101Ru) and iodine (127I) in A2780 (in
pmol per 106 cells) after 24 h of exposure to 2 µM solutions without subsequent
recovery time.
Compound
pmol Ru
p-value
pmol I
p-value
/ 106 cells / 106 cells
12 34 ± 4 0.0218 <2 -
11 35 ± 1 0.0005 <2 -
28 60 ± 14 0.0184 19 ± 4 0.0182
29 62 ± 6 0.0034 22 ± 2 0.0041
cells in each sample. This normalised value represents the average number
of ruthenium or iodine atoms accumulated by one million cells, which allows
comparison of the results not only between replicates of cell samples but also
between different elements.
For the two complexes [(p-cymene)Ru(PTSCNMe2I)]I (11) and
[(p-cymene)Ru(PTSCNMe2I)]PF6 (12) that do not have an iodine substitu-
ent as part of the TSC ligand (Table 4.4 R = H), 34 ± 4 and 35 ± 1 pmol
ruthenium were detected per one million cells, while no iodine was detected
in these cell samples. For complexes [(p-cymene)Ru(ITSCNMe2I)]I 28 and
[(p-cymene)Ru(ITSCNMe2I)]PF6 29 with R = I in the TSC, Ru accumula-
tion was twice as high (60 and 62 pmol per million cells) as for 12 and 11,
and 19 ± 4 and 20 ± 2 pmol iodine were detected. These iodine quantities
represent 1/3 of the ruthenium that was accumulated by the same cells.
In summary, the data presented in Figure 4.3 highlight that the four
complexes enter A2780 cells within 24 h of drug exposure. All quantities
were statistically significant compared to untreated control cells as shown
by p-values below 0.05 or 0.01 (Table 4.6).
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Figure 4.3: Bar chart shows statistically significant accumulation of ruthenium
(101Ru) in A2780 cells from all four complexes, and of (127I) from complexes
28 and 29. Quantities were determined by ICP-MS after 24 h of exposure to
equimolar/equipotent solutions (2 µM) without subsequent cell-recovery. The
results show significant difference compared to un-treated controls (** p < 0.01,
* p < 0.05).
4.3.3 Sub-cellular Ru/I Distribution
An experiment was performed to assess structural integrity of the complex
inside cells on the one hand, and to narrow down possible target sites on
the other. This assay quantifies the amount of ruthenium and iodine in
four different sub-cellular fractions of A2780 cells after treatment with the
iodine labelled complex 29. It aims to elucidate in which parts of the cell
the metal and the halide accumulate.
A2780 cells were exposed to complex 29 at its IC50 concentration of
2 µM for 24 h. After this, the cells were collected, and four cell-fractions
were obtained that contained the sub-cellular compartments detailed below.
Results are presented in Figure 4.4, with orange bars for ruthenium
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Table 4.7: Quantities of 101Ru and 127I (in pmol/106 cells) in four fractions of
A2780 cells after 24 h of exposure to [(p-cym)Ru(3c)I]PF6 (29, 2 µM) without
recovery time.
pmol ·10−6 cells
Ru I Ru : I p-value†
Cytoskeleton 10 ± 1 8 ± 2 1 0.10
Membrane/Particulate 33 ± 2 8 ± 1 4 0.02
Nuclear Fraction 7.5 ± 0.5 4 ± 1 2 0.10
Cytosol 1.5 ± 0.1 1.0 ± 0.2 1 0.31
Σ 52 21 2.6 -
† T-Test compares between the results obtained for the two elements per
fraction, p < 0.05 is treated as a statistically significant difference between
the levels of Ru and I.
Cytosole: Soluble proteins from the cytoplasm
Membrane: Membrane proteins, cellular organelles & their membranes
Nucleus: Soluble nuclear proteins, nuclear-membrane proteins
Cytoskeleton: Insoluble cellular proteins, genomic DNA
quantities and purple bars for iodine, and Table 4.7 provides an overview
of the ruthenium and iodine contents in each fraction.
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Figure 4.4: Compartmentalisation of 101Ru and 127I in A2780 cells, determined
after 24 h of exposure to [(p-cym)Ru(3c)I]PF6 (29, 2 µM) without recov-
ery time. Cytoskeleton: insoluble cellular proteins, genomic DNA; Cytosole:
Soluble proteins from the cytoplasm; Membrane: membrane proteins, cellular
organelles and organelle membranes; Nucleus: soluble nuclear proteins, nuclear-
membrane proteins. * All detected quantities were statistically significant com-
pared to the control (p < 0.05). The result for Ru in the membrane fraction was
significantly different from the iodine level in the same fraction (p < 0.05).
All quantities reported in Figure 4.4 were statistically significant com-
pared to un-treated control cells (p < 0.05). The membrane fraction con-
tained the largest part (63%) of the total accumulated metal in this exper-
iment, with 33 pmol ruthenium per one million cells. Of the other three
fractions, cytoskeletal and nuclear fraction both accumulated one third of
the total Ru each, with 10 pmol/106 cells and 7.5 pmol/106 cells, respect-
ively. In the cytosolic fraction, 1.5 pmol/106 cells ruthenium was detected.
Iodine distribution differed compared to the metal. In the membrane
fraction, 8 pmol iodine per one million cells were detected, and the same
quantity was found in the cytoskeletal fraction. 1.8 pmol/106 cells iodine
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were detected in the cytosol, which equals the amount that was found in
the nuclear fraction.
Comparing the two bars for each fraction against each other (Figure 4.4),
there is a 4:1 ratio of ruthenium over iodine in the membrane which stands
out from the rest of the data. A low p-value confirms the significant differ-
ence between the quantities of the two elements. In contrast to this finding,
both cytoskeletal and cytosolic fraction show a Ru:I ratio closer to 1. The
nuclear fraction showed an elevated ruthenium content over iodine, with
approx. twice as much metal as halide.
HPLC experiments were used to assess the aqueous solution speciation
of the compounds in the presence and absence of chloride ions. These aim
to explain the lack of iodine in cells treated with complexes 12 and 11.
4.3.4 HPLC of iodido and chlorido complexes
This study was designed to elucidate the speciation of the four complexes
12 (R = H, X = I), 28 (R = H, X = I), 10 (R = H, X = Cl), and 27 in
aqueous solution, using high performance liquid chromatography (HPLC).
The test was carried out by comparing four complexes, two X = Cl/I
pairs and two pairs with R = H/I (Figure 4.5), in both doubly-deionised wa-
ter and in physiological saline solution (0.9% NaCl, 154 mM). This chloride
concentration (154 mM) compares well with the concentration of chloride
in RPMI-1640 medium (140 mM). This way, the comparison between chro-
matograms in the presence and absence of Cl− should show whether there
is an exchange of the monodentate halido ligand, by appearance of more
than one signal in the chromatogramm.
Figure 4.5 shows the chromatograms that were recorded 10 min after
each of the respective samples was dissolved and diluted into dd-H2O, com-
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Figure 4.5: Reverse-phase HPLC chromatograms show a 5 min difference in
retention times between complex 12 (R = H, X = I) and 28 (R = I, X = I) as
well as between 10 (R = H, X = Cl) and 27 (R = I, X = Cl). Injections 10 min
and 24 h of after dissolving the compounds at 0.1 mM in H2O or 0.9% Saline
(both 5% dmso) at 298 K.
pared to the chromatograms of the same solutions after 24 h equilibration
at ambient temperature. The graphic shows the 5 min difference in reten-
tion times (tR) between the complexes of the iodine-labelled TSC ligand 3c
and their non-labelled analogues. Complexes 12 and 10 have a retention
time (tR) of 12 min, while complexes 28 and 27 have a retention time of
17.5 min.
The retention times do not change within 24 h of equilibration at 298 K,
and no additional peaks appear in the chromatogram. The comparison
between water and saline solution after 10 min and 24 h shows no difference
or change in the retention time. An attempt to dilute the complexes into
0.9% KI solution as a comparison resulted in precipitation of an orange-red
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solid which was removed using the syringe filter. The chromatograms of the
filtrate did not show any signals (pink graph in Figure 4.5).
Table 4.8: pH-values in HPLC sample solutions at 298 K, measured 24 h after
the complexes had been dissolved in dmso and diluted into either water or saline.
Complex pH in H2O pH in 0.9% saline
12 4.2 4.2
28 4.3 4.3
10 4.5 4.2
27 4.3 4.3
At the end of the experiment, the pH of the sample solutions was meas-
ured in order to detect any differences compared to the solvent (Table 4.8).
The pH had decreased to values between 4.2 and 4.5 (10 in saline or wa-
ter), but there was no difference between the pH of the solutions in water
or saline.
4.3.5 Cell-Cycle Analysis by Flow Cytometry
The cell replication cycle can be divided into the four phases: G1, S, G2,
and M. DNA duplication occurs in S-Phase, and the separation of the two
new cells (mitosis) occurs during M-phase.10 The flow-cytometric analysis of
these different cell-cycle phases relies on the quantification of double stran-
ded DNA (stained with the intercalator propidium iodide) that is present
in each phase of the cell-cycle. It is therefore important to understand
the different phases and their relation to DNA quantities. The two gap
phases G1 and G2 are preparatory and precede the two functional phases
S and M, respectively. The transition from a preparatory to a functional
phase is controlled rigorously by checkpoints, and only cells with undam-
aged DNA can progress to the next stage. When, due to DNA damage,
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such a checkpoint is not passed by the cell, the cell-cycle is arrested in the
previous phase. This experiment aims to detect the effect that complexes
[(p-cymene)Ru(PTSCNMe2I)]PF6 12 and [(p-cymene)Ru(ITSCNMe2I)]PF6
29 have on the cell-cycle of A2780 cells during an exposure time of 24, 48,
and 72 h at IC50 concentration (2 µM).
• G1 phase: During the first gap phase, a single copy of double-
stranded DNA is present. Propidium iodide (PI) can intercalate into
those strands to quantify them.
• S-phase: During DNA replication, between one and two copies of
DNA are present in the cell, and some of it is already single-stranded.
Although PI cannot bind to single strands, all present double strands
are quantified in this phase.
• G2-M phase: After successful DNA duplication, two complete copies
of double stranded DNA are present.
Table 4.9 summarises the populations of cells in three different cell-cycle
stages (G1, S, G2/M) at three different time points: In columns for 24 h,
48 h, and 72 h of exposure, cell populations are listed for the untreated cells
(-ve, top rows), and for cells after treatment with complexes 12 (middle)
and 29 (bottom rows) at IC50 level. Each result was compared with the
negative control (-ve) using Student’s T-Test, to determine whether the
detected effects were statistically significant (p-value < 0.05).
The distribution of untreated cells over the three stages was 51.2±1.9%
in G1 : 27.7 ± 1.5% in S : 21.1±0.6% in G2/M after 24 h. Both complex 12
and 29 significantly alter this distribution. Cells treated with 12 showed
an increase in the G1 population by more than 20% (65.7±1.4 %), while
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Table 4.9: % population of A2780 cells in cell-cycle phases G1, S, and G2/M
after incubation with complexes 12 and 29 for 24, 48, and 72 hours, without
recovery in drug-free media.
Cell-cycle % Population after
Compound phase 24 h 48 h 72 h
-ve
G1 51.2 ± 1.9 51.8 ± 0.6 74.4 ± 0.3
S 27.7 ± 1.5 23.6 ± 1.1 16.4 ± 1.6
G2 / M 21.1 ± 0.6 24.6 ± 0.6 9.2 ± 1.9
G1 65.7 ± 1.4 69.5 ± 4.5 74.2 ± 4.6
[12] S 21.4 ± 1.1 15.5 ± 2.3 15.4 ± 3.2
G2 / M 12.9 ± 1.3 15.0 ± 3.7 10.4 ± 1.4
G1 67.5 ± 2.1 66.8 ± 0.9 72.0 ± 2.4
[29] S 19.5 ± 1.1 16.0 ± 2.7 17.5 ± 1.5
G2 / M 13.0 ± 2.3 17.2 ± 2.2 10.5 ± 1.0
populations in G2/M significantly decreased by almost 50% to 12.9±1.3.
These results are similar for cells treated with complex 29, which showed
67.5±2.1% G1 population and 13.0±2.3% of cells in G2/M phase. Differ-
ences in G1 and G2/M populations compared to the control were statist-
ically significant to p < 0.01. Changes in S-phase populations were less
pronounced, but with 21.4±1.1 and 19.5±1.1% compared to 27.7±1.5 (p <
0.05) still significantly different from the control.
After 48 h of exposure, the distribution is similar to that after 24 h, but
with differences only significant to a p< 0.05 level for most populations. The
largest change compared to 24 h occurred in S-phase, where the population
of cells decreased further to 15.5% and 16.0% compared to 23.6% in the
control.
To better visualise the differences between samples and controls, and to
assess whether a change in the populations as a result of an effect by the
complexes was positive (i.e. the population in this phase after the treatment
is larger compared to the control) or negative (the population has decreased
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Figure 4.6: Relative population differences of A2780 cells in cell-cycle phases
G1, S, and G2/M compared to untreated control cells (** p < 0.01, * p < 0.05).
The time dependent cell-cycle analysis experiment used equipotent and equimolar
solutions of complexes 12 and 29 (2 µM) at 24, 48, and 72 h of exposure.
as a result of treatment), data was normalised by the control populations
at each time point.
This normalisation was achieved by dividing data for the samples that
were treated with complexes 12 and 29 by the respective value for the
control, and subtracting 1 from the result.
The graph in Figure 4.6 presents these relative population differences
and clearly highlights the significant increase in G1 populations (grey, up-
ward facing bars) after treatment with the complexes (p <0.01) for 24 h
and 48 h, respectively. Due to larger errors at the 48 h time point than at
24 h, the significance level here is only p < 0.05, but it can still be concluded
that both complexes arrest A2780 cells in G1-phase during 24 and 48 h of
exposure.
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4.3.6 Detection of Apoptotic Cell-Populations
This experiment aims to determine the extent of apoptosis in A2780 cells
that is caused by exposure to complexes 12 and 29. The assay quantifies
the loss of both membrane asymmetry and membrane integrity, which occur
as a result of programmed cell-death (PCD). Membrane asymmetry is as-
sessed by Annexin-V-FITC fluorescence. Annexin-V binds to phosphatidyl
serin (PS) that is located on the inside of the membrane bilayer.11 Mem-
brane integrity-loss is detected by intercalation of propidium iodide (PI)
into double stranded nuclear DNA and RNA. The flow-cytometer measures
fluorescence intensity of the two dyes: PI emits red fluorescence, which is
measured in channel FL-1, while Annexin-V-FITC emits green fluorescence,
read in channel FL-2. With this double-staining technique, four viability
levels can be differentiated in a cell sample:
• When the cells are viable, the outer cell-membrane is intact. This
means that neither PI nor Annexin-V can bind to their respective
targets. As a result, the fluorescence reading in both channels (FL-1
and FL-2) of the flow cytometer is low.
• In early apoptotic stages, the asymmetry of the cell membrane is
spoilt, and the inner side of the lipophilic bilayer turns to the outside.
This allows the Annexin-V stain to bind to PS which is now outward
facing. This loss of membrane asymmetry, however, does not affect the
integrity of the cell wall, and as such, PI still cannot reach its target.
Thus, only green fluorescence (FL-2) is high in early apoptotic cells.
The earlier in the apoptotic pathway, the lower is the intensity in
FL-2.
• At a late apoptotic stage, both the outer and the nuclear membrane
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are disrupted, which allows the PI stain to enter the nucleus and
intercalate into DNA. This leads to both high red and high green
fluorescence readings.
• Non-viable cells are those which did not follow apoptotic pathways.
The membrane integrity of those cells is compromised, so that PI
reaches nuclear DNA, but PS receptors are not accessible for the
Annexin-V to bind. Therefore, non-viable cells show high red, but
no green fluorescence.
Table 4.10: Percentages of apoptotic cells as determined by flow cytometry
using Annexin V-FITC / PI staining immediately after A2780 cells were exposed
to complexes 12 and 29 for 24, 48, and 72 hours without recovery time.
Time
% Viable
% Early - % Late- % Non-
[h] Apoptotic Apoptotic Viable
-ve 97.6 ± 0 0.9 ± 0.03 0.5 ± 0.05 0.99 ± 0.04
24 12 91.1 ± 0.6 3.24 ± 0.09 4.2 ± 0.4 1.5 ± 0.1
29 92.4 ± 0.4 3.10 ± 0.06 3.1 ± 0.3 1.5 ± 0.2
-ve 92.2 ± 0.3 2.22 ± 0.08 3.5 ± 0.1 2.0 ± 0.3
48 12 81.5 ± 1.6 7.8 ± 1.0 7.8 ± 0.6 2.9 ± 0.4
29 86.5 ± 0.4 5.7 ± 0.7 5.8 ± 0.3 2.0 ± 0.3
-ve 93.0 ± 0.3 1.5 ± 0.2 2.5 ± 0.2 3.1 ± 0.6
72 12 91.5 ± 0.5 2.1 ± 0.3 3.1± 0.3 3.4 ± 0.5
29 93.9 ± 3.8 1.6 ± 1.3 2.1 ± 1.4 2.4 ± 1.2
Data were gathered for A2780 cells after 24, 48, and 72 hours of exposure
to complexes 12 and 29 (see Table 4.10). The bar chart in Figure 4.7
compares the cell-counts per viability stage at each of the three time points.
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Figure 4.7: Time dependent detection of apoptotic cell-populations using com-
plexes 12 and 29. Height of the bars represents relative cell populations in four
viability stages after exposure to complexes 12 and 29 for 24, 48, and 72 h.
After 24 h, 6 - 7% of apoptotic cells were detected. These populations
were significantly higher than in the untreated control (-ve, 1.4%). Late-
stage apoptotic populations were ten times larger than in the control cells,
and early apoptotic populations were three times larger, while the number
of viable cells had decreased from 98% to 92%.
An increase in the induction of apoptosis is visible after 48 h of exposure.
Even more cells were found in both the early and late apoptotic stages,
with sums being twice as high as after 24 h (15.6% for 12 and 11.5% for
29). Viable cells were diminished compared to the control, while non-viable
populations were comparable (2-3%).
The trend of increased number of apoptotic cells after longer exposure
times did not continue at 72 h. All results were similar to the untreated
control at this time point (Table 4.10, bottom). Variations are as small as
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0.1% for early apoptotic cells to 1.0% for viable cell populations. These
differences were negligible, with p-values >> 0.05.
In summary, cells treated with complexes 12 or 29 show a statistically
significant population of early and late-stage apoptotic cells after 24 h and
48 h of exposure.
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4.4 Discussion
Six arene ruthenium TSC complexes were studied in this chapter, and four
of those were tested in a range of in vitro assays to investigate their antic-
ancer properties. All complexes are of the piano-stool geometry. The X-ray
crystal structure of 10 and all spectroscopic data for the compounds listed
in Table 4.4 was discussed in Chapter 2, and was shown to be consistent
with the presented structure. The systematic structural variations within
this series of four Ru TSC complexes are presented in Figure 4.8.
12 11
29 28
Figure 4.8: p-cymene ruthenium (II) complexes discussed in this chapter.
Complex 12 on the top left in Figure 4.8 compares to 11 (top right) by
changing the counter ion from PF6 to I
−, and the same change relates 29
(bottom left) to 28 (bottom right). The two pairs 12 / 29 (left) and 11 /
28 (right) differ only in their TSC phenyl substituent (H vs I). Their antic-
ancer activity against human ovarian cancer cells (A2780) was determined,
followed by studies of cellular ruthenium accumulation and a measurement
of the distribution of accumulated ruthenium and iodine in the same cell
line.
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Table 4.11: Overview of the results obtained for complexes 12 and 29.
Compound
12 29
tR(C18) 12.0 min 17.5 min
24 h 24 h
IC50 (µM) 2.6 ± 0.1 2.5 ± 0.1
Cell-uptake (pmol/106 cells)
101Ru 34 ± 4 62 ± 6
127I <2 22 ± 2
Cell-cycle Arrest G1 G1
Apoptosis Induction 15% 12%
Furthermore, the mode of action of two complexes was investigated, to
directly compare the iodine-labelled complex 29 to 12. Their effect on
the cell-cycle of A2780 cells was measured and related to their capacity to
induce apoptosis. Table 4.11 provides a summary of the results that where
gathered for the two compounds.
4.4.1 Antiproliferative Activity
The four TSC ruthenium iodido complexes 12, 11, 28, and 29 can be
regarded as highly active against the human ovarian carcinoma cell-line
A2780, with IC50 values in the range of 2 µM for all four compounds. Inter-
estingly, there was no significant difference between the activities determ-
ined at three different time points. In contrast to this finding, ruthenium
piperonal-TSC chlorido half-sandwich complexes reported by Beckford et al.
that exhibit low-to-moderate activities against HCT-116 (colon carcinoma)
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and Caco-2 (epithelial colorectal adenocarcinoma) cell-lines,12 were 1.3 and
2 times more active during 72 h than during 24 h of exposure.
However, this difference is of lesser impact, when the activities are
compared directly by the reported IC50 values. For the compound [(η
6-p-
cymene)Ru(Et-pTSC)Cl]Cl (with Et-pTSC = piperonal-4-ethyl-thiosemicarbazone),
IC50 values in the HTC-116 cell-line are between 77 µM after 24 h, and
50 µM after 72 h, which is one order of magnitude higher than the iod-
inated TSC complexes 28, and 29 of this thesis in A2780 cells. While it
is not strictly possible to compare IC50 values between different cell lines,
the comparison to Cisplatin as a reference is accepted practice. Compared
to the above mentioned piperonal-TSC complex, CDDP was slightly more
active in the same cell-line (41 µM after 72 h in HTC-116). Therefore, the
complexes reported by Beckford are of similar potency to CDDP, which
is consistent with the conclusion for the iodo-TSC compounds presented
in this Chapter. Overall, the literature comparison highlights that arene-
ruthenium TSC complexes show consistent cytotoxicity against cancerous
cell-lines which is sufficient to warrant further research of their use as anti-
cancer agents.
4.4.2 Accumulation and Distribution of Ruthenium
and Iodine in Cancer Cells
The high antiproliferative activity of Ru TSC complexes is congruent with
their cellular accumulation. Statistically significant ruthenium quantities
were found in A2780 cells after 24 h of exposure to the four iodido complexes
12 - 29, showing that during this time their uptake rates are higher than
their eﬄux rates. As a result, it is reasonable to assume that the cytotoxicity
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of the complexes is related to their action inside the cancer cells, and further
studies are required to elucidate the mode(s) of action for this particular
class of compounds.
The molecular structure of the four coordination compounds seems to
change either before or during internalisation into the cell. The accumu-
lation of iodine from the complexes was almost two thirds lower than of
ruthenium, which is a first indicator that not all ligands remain bound to
the metal centre during the experiment time. Interestingly, no iodine was
accumulated in cells exposed to 12 and 11, although both complexes have
either one (12) or two (11) iodide ions in their structure (Figure 4.8).
A similar result was recently obtained with osmium arene azopyridine
complexes. MCF7 (breast cancer) cells exposed to those complexes did not
accumulate iodine from radio-labelled iodido monodentate ligands.13 Both
of these independent findings suggest that the monodentate ligand X is lost
from the structure.
The fact that the detected quantity of iodine in cells treated with 29
and 28 was the same for both compounds, while the latter has one addi-
tional iodide per molecule further supports the hypothesis. Thus, all iodine
which accumulates in A2780 cells from complexes 29 and 28 originates
from the chelating thiosemicarbazone ligand ITSCNMe2 (3c), i.e. its iodide
substituent R = I.
Sub-cellular Distribution of Ruthenium and Iodine
Having confirmed in the previous experiment that it is possible to detect
both elements simultaneously in the digested cell-samples by ICP-MS, the
next questions follow naturally from this result:
1. In which sub-cellular compartments of human ovarian cancer cells
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(A2780) do the metal and the halogen accumulate?
2. Do the two elements ruthenium and iodine accumulate in the same
compartments and in the same quantities?
The results of the cell fractoning experiment (described in Section 4.3.3)
can answer those question to a good approximation.
The disadvantage of this method is that the cell-fractioning procedure
only differentiates between four different sub-groups: In the membrane frac-
tion, the plasma membrane is contained together with organelle membranes,
including the nuclear membrane. The proteins of the nuclear membrane,
however, and all other soluble nuclear proteins, are contained in the nuclear
fraction. Genomic DNA is found together with all insoluble proteins in the
cytoskeletal fraction. This must be taken into account when the quantities
in the four fractions are compared.
Interestingly, iodine accumulation was distributed differently compared
to the metal. Most of the ruthenium from complex 29 was found in the
membrane fraction (63%), which showed a high Ru:I ratio of 4:1, while
this ratio was closer to 1 in the cytosole. This suggests that the species in
the cytosole is a [(p-cymene)Ru(ITSCNMe2)]
n+ complex in which the TSC
ligand is still chelating the metal, and n is either 1 or 2, depending on the
protonation state of the TSC.
The reason for higher quantities of metal than iodine in the membrane
fractions of compartmentalised A2780 cells can be interpreted as an inter-
action between the complex and membrane proteins. Most likely, the de-
activation already occurs on the outside of the cell-wall, so that the ligand
does not enter the cell.
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Ruthenium iodido complexes of similar general structure have shown to
mainly accumulate in the membrane,14 with 88-91% being even higher than
the 63% found for complex 29 here. The same report highlights that the
corresponding chlorido complexes distribute differently inside A2780 cells,
with only 73-84% metal accumulation in cellular membranes and membrane
proteins.14 Interestingly, more of the complexes presented in this chapter is
entering the nuclear fraction than is reported for Ru-impy complexes, sug-
gesting that thiosemicarbazone complexes, especially those of higher lipo-
philicity, have a higher probability of reaching nuclear DNA as a target site.
Osmium anticancer complexes were found to exhibit greater extend of DNA
binding depending on their lipophilicity.15
ICP-MS dual detection of Ruthenium and Iodine
The cellular accumulation studies in this chapter relied on the accurate de-
termination of trace amounts of both ruthenium and iodine in cell samples.
A reliable technique to quantify both elements is by their mass, using the
high sensitivity of modern mass spectrometers, for example in inductively
coupled plasma mass spectrometry.16 While metal distribution in cancer
cells can also be assessed with fluorescence17 or X-ray imaging techniques,18
the advantage of ICP-MS is that it allows the element(s) of interest to be
quantified accurately. One aim of the work presented in this chapter was
the simultaneous detection of iodine and ruthenium by ICP-MS.
A method which can be applied to cell or tissue samples to detect both
elements at the same time and ideally in the same solution/cell-digest is
particularly useful for the quantitative study of metallodrugs in biological
tissues such as cell-culture samples.
However, simultaneous detection of iodine and metal ions by ICP-MS
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appears to not be straight forward, the reason for which is the sample envir-
onment. Because of the high sensitivity of the equipment towards particles,
all biological material such as cell samples must be completely dissolved in
concentrated nitric acid prior to sample introduction. Therefore, the stand-
ard sample environment for metal quantification by ICP-MS is in acidic
solutions.
Problems related to the quantification of iodine in acidic sample envir-
onments include the following. Iodine can be oxidised to volatile iodine,
which might cause errors to the measurement in two different ways. On
the one hand due to loss of evaporating iodine from acidic sample solutions,
and on the other hand due to gaseous iodine that can persist in the spray
chamber of the instrument and cause memory effects that lead to elevated
readings. Those two factors need to be considered as possible sources of
systematic errors to the iodine measurement by ICP-MS of acidic solutions.
While iodine quantification by ICP-MS normally uses alkaline solu-
tions,16 research shows that acidic detection of iodine is possible,19 and that
acidic digestion might be preferable over alkaline variations.20, 21 Couto et
al. state that iodide ions are not readily oxidised by nitrate ions in nitric
acid solutions.22
In the cellular accumulation experiments, 60 pmol ruthenium and 20
pmol iodine per one million cells were detected from both complexes 29
and 28, which represents a ratio of Ru : I of 3 : 1 total accumulation. In
the fractioning experiment with complex 29, the total amount of ruthenium
that was accumulated by the cells was 52 pmol/106 cells, while total iodine
was 21 pmol/106 cells. The ratio of Ru : I is 2.6 : 1, which is compar-
able to the first experiment. These results suggest that the simultaneous
determination of ruthenium and iodide by ICP-MS after nitric acid cell di-
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gestion is a reliable technique to quantify cellular accumulation of iodinated
metal complexes. This opens up perspectives for the study of speciation of
other ruthenium arenes, such as the iminopyridine complexes mentioned
previously.14
4.4.3 HPLC of Iodido and Chlorido Complexes
One reason why no iodine was accumulated in cells from either the mono-
dentate ligand or the counter ion might be that both are lost from the com-
plex before it enters the cell. However, no conversion of iodido to chlorido
complexes could be shown by HPLC methods.
The retention time on the RP-HPLC column did not vary between the
chlorido and the iodido complex in each of the two pairs. Moreover, it
remained the same even between water and saline solutions, and no signi-
ficant additional signals appeared. These findings suggest both identity and
stability of the complexes during 24 h in solution.
Two scenarios can be ruled out to explain this result: Firstly, the de-
tected species is not formed by loss of the chelating TSC ligand, because if
this was the case, the four chromatograms should show a peak at the re-
tention time of the remaining species, identical between all four complexes.
No peak with this property is detected in this study.
Secondly, the species formed from Cl/I pairs cannot be the chlorido
complex, because the retention times of Cl and I complexes is identical
even for solutions in which no chloride is present: The iodido complexes
were dissolved in dmso and diluted into doubly deionised water, which has
a chloride concentration lower than 1 µM.23
However, a number of explanations are reasonable for the observation
of identical retention times. In case the X ligand exchanges for water, both
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complexes in a pair become identical, which is also the case when a different
substitution reaction takes place in X position. Figure 4.9 suggests a third
mechanism by which the Cl/I pairs can form an identical species, which is
deprotonation of the TSC ligand, followed by loss of the monodentate ligand
X. Deprotonation of the ligand at the NH results in a negative charge which,
after electron rearrangement, is localised at the sulfur atom. The complex
then bears an overall charge of +1 and is consequently a mono-cationic
complex [(p-cymene)Ru(L-H)]+.
Figure 4.9: Deprotonation of the chelating TSC ligand, which can explain
the pH decrease in aqueous solution from pH 6 to pH 4. Subsequent electron
rearrangement towards the Ru2+ facilitates the loss of the monodentate ligand
X, by which both the chlorido complex [(p-cymene)Ru(HL)Cl]+(left) and the
iodido complex [(p-cymene)Ru(HL)I]+ (right) react to the same complex [(p-
cymene)Ru(L)]+ (middle).
The low pH after 24 h supports this mechanism, as the deprotonation
of the TSC ligands leads to acidification of the solution. Furthermore,
mass-spectrometric results were discussed in Section 2.4.2 (page 101), also
strongly support this hypothesis. ESI-MS spectra show the same species
that is formed by loss of the monodentate ligand in conjunction with de-
protonation. It is therefore concluded that this mono-cationic complex is
the most stable species in aqueous solution, even in the presence of high
concentrations of chloride.
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4.4.4 Structure-Activity Relations
Previous examples from the Sadler group have shown that a change of the
metal (Ru vs Os),24 a change of Cl for I25 can affect the antiproliferative
activity of a piano-stool complex, while only some SAR have been for-
mulated for changes in chelator-substitution. The donor atom within the
chelating ligand itself (N vs C) is another interesting switch.26
19 12 29
Figure 4.10: Comparison of substituents in the structures of complexes 19
(Chapter 2), 12, and 29.
In the studies presented here, the systematic structural variations that
were outlined above seem to not not directly affect the antiproliferative
activity of the Ru TSC iodido complexes. However, under the same ex-
perimental conditions and in the same cell line, assays with complexes 15
and 19 of the two N-dimethylated TSCs DTSC (2a) and DTSCNMe2 (2c)
showed no antiproliferative activity.
The comparison between the three complexes of ligands 1c, 2c, and 3c
(Figure 4.10) shows that the dimethylamino substituent in complex 19 leads
to loss of activity compared to 12. Between [(p-cymene)Ru(1c)Cl]PF6 (12)
with an IC50 of 2 µM and [(p-cymene)Ru(2c)I]PF6 19 which is inactive at
the highest test concentration of 50 µM. Both complexes are accumulated
in A2780 at 33 pmol· 10−6 cells. Under the assumption that the mono-
dentate ligand is not taken up by the cells, the only difference is the NMe2
substituent in the TSC ligand in complex 19.
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The electronic effects of the aromatic substituents can play an import-
ant role in the activation or deactivation of the metal centre for substitution
reactions. Dimethylamino substituents in para-position have a strong meso-
meric (+M) effect on the pi electronic system. In complex 19, the aromatic
pi-electrons are in conjugation with the TSC moiety and are easily delocal-
ised towards the ruthenium centre. This conjugation of a para-NMe2 group
to the metal had proven to enhance the cytotoxicity of arene Os azopyrid-
ine complexes,27 which was one reason for incorporating the same group in
the presented Ru TSC complexes. The difference between the two observa-
tions is yet another example for the tune-ability of piano-stool anticancer
complexes.
In contrast to the para-NMe2, the iodine substituent in ligand 3c does
not deactivate the Ru TSC complex. Compared to complex 12 with an
un-substituted phenyl-TSC moiety (1c), iodinated complex 29 of meta-
iodo-TSC 3c shows the same anticancer activity. This is consistent with
the hypothesis that delocalised electrons might deactivate the metal centre.
Iodine in meta-position has only a weak inductive effect on the pi-electrons of
the aromatic ring, which is also pulling those electrons rather than pushing
them towards the metal. In other words, electron density is delocalised
away from the ring and from the metal. This basic scheme can explain why
there is no difference between the anticancer activity of complexes 12 and
29, while complex 19 is inactive at a similar level of cellular accumulation.
When the total ruthenium uptake is compared between the four TSC
complexes, it is notable that twice as much metal is accumulated from
complexes 29 and 28 as from analogues 12 and 11. This finding suggests
that the iodine substituent of ITSCNMe2 (3c) in complexes 29 and 28 ap-
pears to facilitate the uptake. A literature report supports this hypothesis,
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as Antony et al. found that iodinated indazole ligands remain attached to
ruthenium(III) in analogues of the metallo-drug KP1019,28 and suggest that
iodination of the organic ligand increases the lipophilicity of the complex,
which could facilitate cellular uptake by passive diffusion pathways.
Lipophilicity of a molecule can be related to its retention time on a chro-
matography column.29 The stronger the interactions with the hydrophobic
stationary phase are, the longer the molecule is retained on the column.
The HPLC experiments described above (Section 4.3.4) have shown that
the retention time of complexes 28 and 27 on the reversed-phase column is
approximately 15% longer (17.5 min) than for the non-labelled complexes
12 and 10. This finding supports the hypothesis that an iodine substituent
within the TSC ligand enhances the lipophilicity of the metal complex,
and that consequently the higher cellular accumulation of the iodinated
complexes is correlated to this increase in lipophilicity. Previous research
has shown a correlation between the hydrophobicity, cytotoxicity, cellular
uptake and distribution of arene Os(II) anticancer complexes.15
4.4.5 Cell-Cycle Analysis
Proliferating, healthy cells use the cell-cycle to control tissue homeostasis
(maintenance of living cell populations). To avoid uncontrolled growth
(over-proliferation), cells initiate apoptosis, a form of programmed cell-
death which is characterised by unique features such as membrane blebbing
and cell shrinkage.30, 31 These morphological features are important signals
for the clearance of dead cells from the tissue. Cancer cells fail to regulate
the balance of dead and living cells, and these faulty processes are what
results in over-proliferation and the formation of tumours.32
Within the cell cycle, several checkpoints control the healthy progression
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Figure 4.11: Schematic of the Cell Proliferation Cycle with indicated location
of checkpoints that control cell-cycle progression. Three stages are detectable by
DNA staining of fixed cells with propidium iodide: G1 (grey), S-phase (red), and
G2/M (green). Each of the three metal complexes 29, Cisplatin, and RAPTA-C
induce cell-cycle arrest in a different phase.
of cell-division, three of which are depicted schematically in Figure 4.11.
These controls are in place to validate external growth conditions as well
as detect (possible) DNA damage, which can occur in any of the cell-cycle
phases.10, 32, 33 During G1 phase, the cells grow to twice their size while
synthesising mRNA and proteins that are necessary for DNA replication,
for which they require a healthy environment and sufficient nutrition. When
the G1/S checkpoint indicates DNA damage, the cell-cycle can be arrested
at this stage in order to halt DNA replication.
Complexes 12 and 29 both caused significant increase in A2780 cell-
populations in G1-phase after 24 h and 48 h of exposure, and one explan-
ation for this effect is interaction of the drug with DNA. Given that high
quantities of complex 29 were detected in the nuclear fraction of these cells,
it is likely that DNA is one of its target molecules. However, while DNA
damage is the cause for most cell-cycle arrests, G1 arrest can also be caused
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by other factors that lead to insufficient conditions for the cell to proceed
with proliferation.34, 35 More information is therefore required to confirm
that the G1 arrest caused by ruthenium TSC complexes is due to direct
DNA interaction.
After the first gap phase, when cells have successfully passed the G1/S
checkpoint, DNA is replicated during the next phase of the cell-cycle, S-
phase. Here, all steps that are required to reproduce DNA are carried out.
When DNA damage is detected during this phase, the reproduction of DNA
is slowed down to allow time for its repair. The more DNA molecules are
affected, the slower the repair and, consequently, the cell-cycle.35
Therefore, S-phase arrest can indicate direct DNA-drug-interactions. In
the case of Cisplatin (Figure 4.11), S-phase arrest is caused due to the
distortion of DNA double strands by covalent Pt-DNA interactions. Those
‘kinks’ in the DNA prevent its correct translation.36–38 Conclusively, S-
phase arrest is in accordance with the established mechanism of action of
the platinum drug.39
The two ruthenium complexes 12 and 29 do not arrest A2780 cells in
S-phase, and might therefore not directly target DNA. Although examples
of piano-stool Ru TSC complexes reported by Beckford appear to be weak
multi-mode DNA binders,40 their effect on the cell-cycle has not been stud-
ied so far. In contrast, G1 arrest caused by 12 and 29 shows that for these
complexes the mode of action is different from Cisplatin.
The G2/M checkpoint tests whether DNA has been replicated com-
pletely. If this is the case, the G2 checkpoint passes the cell on to the
second preparatory growth phase, otherwise, S-phase arrest is detected. If
cells sense DNA damage while in G2 phase, before entering mitosis (M-
phase), a G2/M cell-cycle arrest will occur.
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The ruthenium piano-stool complex RAPTA-C has been found to cause
G2/M cell-cycle arrest.41 Comparing the structures of TSC complex 29,
Cisplatin, and RAPTA-C (Figure 4.11), it is notable that these three mo-
lecules arrest the cell-cycle in three different stages. All three structures
include labile halido ligands that can potentially be replaced by water and,
subsequently, by DNA bases. However, only in the case of Cisplatin has this
mechanism been confirmed.42 For the purpose of this research project and
in the context of the aim to find metal complexes that exhibit anticancer
activity with novel modes of action, i.e that differ in their behaviour from
the established platinum drug, the finding that the arene ruthenium TSC
complexes arrest the cell-cycle in a different stage compared to Cisplatin is
a step in the right direction.
When investigating the effects of a molecule on the cell cycle, it is useful
to also screen for apoptosis induction under the same treatment conditions.
Because apoptosis is a response to DNA damage,35 it makes sense to re-
late the results of the cell-cycle analysis with detection of apoptotic cell
populations.
4.4.6 Apoptosis Detection
When the concept of apoptosis was first discussed by Kerr and co-workers,30
little was known about the pathways involved in those morphological changes
in cells they had investigated mostly by light microscopy. However, what
already appeared as a strictly controlled mechanism had obvious implica-
tions for the study of health and disease. Since these early findings, much
therapeutic potential has been seen in the ability to interfere with the regu-
lation of cell-death,43 and research into the processes involved in apoptosis31
has moved forward fast. Today, many proteins which are key regulators of
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programmed cell-death (PCD) have been identified, while most of their mo-
lecular mechanisms of action still remains to be elucidated.31
In apoptotic cells, the stages of PCD can be characterised by the state of
the plasma membrane and the nuclear membrane. Annexin-V staining11 was
used to obtain the results presented in Section 4.3.6. It relies on relocation
of Annexin-V receptors to the outside of the membrane during apoptosis.
The asymmetrical, but non-random distribution of lipids in eucariotic
cell-membranes is a consequence of multiple factors,44, 45 such as spontan-
eous “flipping” of polar head-groups through the hydrophobic membrane.
Disruption of phospholipid asymmetry during apoptosis is caused by lipid
scrambling enzymes, so-called “scramblases”.46 PLSCR3, for example, is
a mammalian, Ca2+-dependent phospholipid scramblase.47 An important
functional consequence of this scrambling is the controlled externalization of
phosphatidyl serine (PS), the receptor for Annexin-V binding. It is because
of this affinity that the relocation of PS allows characterisation of apoptotic
cells.11
Compared to un-treated control cells, complexes 12 and 29 induce stat-
istically significant populations of both early and late-stage apoptosis. The
two complexes did not exhibit statistically significant differences in their
respective capacity to induce apoptosis, but the incidence of both early and
late stage apoptosis doubled between 24 h and 48 h of exposure. Arene
ruthenium iminopyridine complexes, which have been studied in this re-
search group previously,14 also cause high incidences of apoptosis in 24 h
of exposure. This suggests that the two classes of ruthenium half-sandwich
complexes might share some mechanisms of anticancer activity.
There are two main ways of apoptosis induction: via death receptors on
the cell surface (extrinsic) on the one hand, and a mitochondria mediated
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(intrinsic) pathway. Tumour cells often have faulty apoptotic pathways,
which can result not only in over-proliferation and increased tumour mass,
but also in resistance to therapy.48
The intrinsic, mitochondrial pathway, characterised by loss of mito-
chondrial membrane potential (MMP), activation of caspase-9, and the
release of cytochrome c,10, 31 is the main apoptosis mechanism described
for ruthenium complexes such as RAPTA-C,41 ruthenium(II) carboranes,49
and ruthenium(II) polypyridyl complexes.50–52 These reports encourage the
thought that complexes 12 and 29 also follow the intrinsic apoptotic path-
way, but more work is required to support this conclusion.
Ruthenium(II) polypyridyl complexes can induce apoptosis through ROS-
mediated mitochondrial pathways,51, 52 which is a mechanism proposed for
iridium half-sandwich complexes.53 The relation of mitochondrial ROS pro-
duction to DNA damage and effects on the cell-cycle could explain the early
cell-cycle arrest (G1) by ruthenium TSC complexes 12 and 29. If ROS are
produced, which cause DNA damage, these are sensed by the cell earlier
than the faulty DNA itself, thus leading to G1 arrest rather than S-phase
arrest.54–56
After 72 h of exposure to complexes 12 or 29, no effect of the drugs
on the cells could be detected compared to untreated controls, neither in
the cell-cycle analysis nor for detection of apoptosis. A plausible explana-
tion for this is extrinsic induction of apoptosis via death receptors, due to
insufficient growth conditions.31, 48, 57 In the experiment described in Sec-
tion 4.2.4 (Page 171), the cells were seeded on day one, and drugs were added
as solutions in fresh cell-culture medium on day two. In wells containing
controls, however, the medium was not replaced. During the following 72 h
of continuous incubation, the untreated control cells are assumed to prolif-
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erate normally, until the conditions become unfavourable for proliferation,
either because no further nutrients and/or space are available, or because
the presence of non-viable cells has contaminated the medium. Lacking
survival signals in this way, proliferating cells induce apoptosis, after G1
arrest, as a mechanism of self-defence.58
4.5 Summary
Four arene ruthenium TSC complexes were tested for their antiproliferative
activity in human ovarian cancer cells. The complexes have IC50 values
in the low micromolar range which makes them promising candidates for
further investigations into their mechanism of action.
Through coherent, systematic labelling of four complexes with iodine
atoms, and by use of a new method for simultaneous detection of ruthenium
and iodine by ICP-MS, it was possible to quantify both the transition metal
and the chelating organic ligand of a piano-stool anticancer Ru-TSC com-
plex inside cancer cells.
It was conclusive from cell-accumulation experiments that neither the
monodentate ligand X nor the counter ion Y were accumulated in ovarian
A2780 cancer cells, but that instead the entire detected iodine stems from
the iodinated thiosemicarbazone ligand 3c. The presence or absence of the
lipophilic iodine substituent in the TSC ligand did only affect the total
accumulation of the complex but not its anticancer activity.
HPLC studies support the conclusion that the complexes lose their
monodentate halido ligand within seconds in dmso/water solutions, where
they form a stable mono-cationic species. This new species is taken up by
human ovarian cancer cells and, even though most of the metal is retained
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in the membrane, approx. 30% of the complex pass this barrier and remains
intact in the cytoplasm as well as in the nucleus, with a Ru : I ratio of close
to 1 which suggests that the ligand is still bound to the metal centre.
The detailed comparison of two complexes showed that the iodine sub-
stituent in the organic TSC ligand 3-iodobenzaldehyde-4-dimethyl-3-
thiosemicarbazone (3c) does not influence the activity of the ruthenium
complex 29 compared to its non-iodinated analogue 12. Their antiprolif-
erative activities after three different exposure times were identical within
error, and both complexes arrest the cell-cycle of ovarian carcinoma cells
in G1 phase, coinciding with the induction of apoptotic pathways and in-
creased cell-death. IC50 values do not improve significantly with extended
drug exposure, and the best result is found after an exposure time of 48
hours.
In conclusion, the findings of this chapter add to the ongoing research
of metallo-drug speciation inside cancer cells and can contribute to the
elucidation of the mechanism of action of Ru-TSC anticancer complexes.
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Chapter 5
Conclusions and Future Work
Ruthenium complexes have been investigated as alternatives to cisplatin and
its analogues, and with the Ru(III) compounds NAMI-A and NKP1339 two
promising candidates are currently undergoing clinical trials. The former is
an antimetastatic agent, and the latter is cytotoxic against solid cancers.
Arene ruthenium and osmium complexes show an interesting profile of
anticancer activity that ranges from antimetastatic activity to cytotoxicity.
The challenge in the research for metal-based drugs, therefore, is to find a
combination of ligands for a metal ion that will provide the required reactiv-
ity, i.e. bind strongly enough to provide stability of the complex, but retain
reactivity towards target site(s) inside the cancer cell or -tissue. The fact
that the two compounds NAMI-A and KP1019 (see Chapter 2, Figure 1.4,
p. 7) show different activity profiles even though their molecular structures
are highly related to one another, highlights the importance to confirm the
mode(s) of drug-action (MOA) for new therapeutic metal complexes.
In this research project, novel thiosemicarbazones have been designed
and incorporated into ruthenium arene complexes. Their design was guided,
one the one hand, by previous research that had shown NMe2 substituents
215
to enhance anticancer activity in ruthenium and osmium arene azopyridine
complexes,1 and on the other hand with the objective to trace the chelating
ligand alongside the metal in cancer-cell accumulation studies.
Iodine was chosen for this purpose because it is detectable by ICP-MS,
which is a common technique for the quantification of trace metal ions, not
exclusively in cell samples. Furthermore, with the right properties, a stable
and soluble iodinated compound might have the potential to be developed
into a radioactive iodine tracer, which use the synthetic isotope 131I.
Thiosemicarbazones have widely been studied as imaging agents,2–4 and
have also been used for radio-labelling experiments, although only in their
capacity as ligands for radioactive gallium (67Ga)4 or copper (64Cu),3 and
not for iodine. One TSC with a 3-iodophenyl substituent has been reported
in the literature, but the study does not highlight any impact of the iodine
substituent on the activity of the TSC.5, 6
5.1 Structure and Spectroscopy of Arene Ruthenium
TSC Complexes
Chapter 2 presented the design, preparation and characterisation of twelve
TSC ligands and the confirmation of their structure by X-ray crystallo-
graphy and NMR spectroscopic methods, followed by the reaction to the
corresponding ruthenium arene complexes.
The synthesis resulted in Ru complexes with a neutral TSC, coordin-
ated through the imino N1 and a thione sulfur. The crystal structure of the
chlorido complex [10] shows that the coordination mode and the bond dis-
tances around the metal centre are consistent with data for other TSC-Ru
complexes that have been reported in the literature.
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The chapter also introduces natural-abundance 15N NMR spectroscopy
(1H15N-HMBC) as a characterisation technique and presents the results in
form of a chemical-shift database with detailed description of the assignment
procedure. TSCs in complexes were characterised by their nitrogen chemical
shift, which has not been used before to characterise TSC complexes, or Ru
piano-stool complexes in general. The 15N NMR chemical shifts of the TSC
nitrogen atoms showed an up-field coordination shift for the imino nitrogen
atom N2 in ther corresponding ruthenium complexes. A dramatic downfield
shift of the signal for N2 of -122 ppm suggests deprotonation of the TSC
at the hydrazinic nitrogen, which is consistent with the crystal structure
of the dinuclear complex 30 and ESI-MS results that show the signal for a
deprotonated monocationic complex.
XAS experiments were presented in Chapter 3 which achieved solid and
solution state characterisation of the first co-ordiantion sphere of several Ru
TSC complexes. Ru K-edge XAS data was collected in a 24 h experiment
at the EXAFS beamline B18 at the Diamond Light Source Synchrotron
Facility in Didcot, UK. The XANES confirmed the oxidation state of the
TSC complexes to be the expected Ru(II) state. The edge energies E0
compare well between the Ru precursor complexes and the TSC complexes,
and are shifted by 5-6 eV to higher energies compared to Ru(0)-foil.
It was the aim of Chapter 3 to collect and analyse EXAFS data for
ruthenium TSC complexes that did not crystallise. With a total of 24
complexes but only two X-ray crystal structures, which showed two entirely
different compounds, the use of EXAFS for the solid-state characterisation
was reasonable. EXAFS fitting of the data collected for eight different
complexes was achieved by comparison to the crystallographic data, and the
fit results showed high levels of consistency with the single crystal structure
217
of the mononuclear complex 10.
Moreover, EXAFS was used successfully for the reaction monitoring of
the dimerisation of complex 21 to the dinuclear complex 30. Solution-state
X-ray absorption spectroscopy was carried out to detect and analyse changes
in the XANES region, using linear combination fitting. Time-dependent
EXAFS studies of freeze-quenched reaction mixtures represent the ability
to follow the reaction in situ and to confirm with a second technique that
the dimerisation takes place on a timescale of minutes. Remarkably, the
reaction time of only 15 min was sufficient to obtain a curve that showed
the increasing content of the dimer in solution.
5.2 Anticancer Activity and Mode of Action
of Arene Ruthenium TSC complexes
Complex 12 and complex 29 were compared in a number of cell-culture
assays using the A2780 cell-line to investigate their anticancer activity. Both
complexes have good antiproliferative activities, with stable IC50 values
of 2-4 µM that do not significantly change with extended drug exposure.
However, 48 hours gave the best results for antiproliferative activities, high
populations of cell in G1 cell-cycle arrest and the largest population of early
and late stage apoptotic cells.
From the presented results, the following points can be inferred as SAR
for arene ruthenium TSC complexes:
• Terminal dimethylation in TSC ligands of series 1c-3c is important
for the stability of the corresponding complex, but does not influence
antiproliferative activity.
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• Iodination of the TSC ligand does not alter anticancer activity.
• A lipophilic iodine substituent increases cellular accumulation of the
Ru TSC complex.
The results of Chapter 4 suggested that complexes 12 and 29 follow an
intrinsic apoptotic pathway. However, more work is required to support this
hypothesis. Mitochondrial involvement in PCD can be tested, for example
by measuring the effect of the complexes on the mitochondrial membrane
potential. Disruption of the mitochondrial membrane potential is a sign for
redox processes and ROS. This is important, as DNA damage which was dis-
cussed in correlation to the detected G1 cell-cycle arrest, can be secondary,
i.e. caused by ROS rather than by the complex directly. More information
is needed to confirm the cause of G1 arrest induced by ruthenium TSC
complexes in ovarian cancer cells A2780, and confirm or dismiss a relation
to direct DNA interaction of the complexes.
5.2.1 Iodine Labelling
Chapter 4 also presented the systematic labelling of four complexes with
iodine atoms, which was used in conjunction with a dual detection method
for ruthenium and iodide by ICP-MS. Those studies allowed to detect and
quantify both the transition metal and its chelating, organic component
of a piano-stool anticancer complex inside cells, which was a main aim of
this research project. However, this method is only one step in the process
towards understanding of metallo-drug speciation inside cancer cells, and
improvements to the detection of metal and ligand in cells are necessary.
For example, another method for ruthenium and iodine detection is
X-ray fluorescence spectroscopy. To elucidate the cellular fate of arene
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ruthenium and osmium anticancer drugs, X-ray fluorescence mapping can
be used. This is particularly interesting for biological samples because it is
a non-invasive technique.
The advantage of XAS or XRF based imaging techniques is that they can
directly observe the compound of interest, without changing its structure
or adding dyes to the sample which might obstruct information.
Examples in the literature already report the use of synchrotron X-
ray methods for the study of metal-based drugs inside cancer cells. For
example, platinum complexes have been studied by XAS on cells, and it was
shown that the intracellular reduction of platinum(IV) pro-drugs to active
platinum(II) species could be determined from XANES measurements as a
ratio of the two oxidation states.7, 8
XRF imaging of gallium and ruthenium complexes has been successfully
performed by Hummer and others.9–11 Results from Diamond Light Source’s
microXRF beamline I189, 12 and the investigation of tissue samples from in
vivo studies with the drug candidates NAMI-A and KP1019 by Aitken et
al. (Australian Light Source)11 highlight the advantages of XRF for the
research of metal-based anticancer drugs.
The aim to detect the metal and the chelating ligand of a piano-stool
anticancer complex in cells by means of XRF mapping is a logical next step
from the presented results, and the examples by other researchers in the
field who report similar approaches support this suggestion.
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Appendix
X-ray Crystallographic Parameters
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Table 5.1: Crystallographic data for the structure of TSC ligand 2b and
ruthenium chlorido complex [10]Cl
DTSCNMe (2b) [(p-cymene)Ru(PTSCNMe2)Cl]Cl [10]Cl
Empirical formula C11H16N4S C21H31Cl2N3ORuS
Formula Weight 236.34 M = 545.52
Crystal system Monoclinic Monoclinic
Space group P2(1)/c P2(1)/c
Unit cell dimensions
a, A˚ 10.3583(14) 8.80659(12)
b, A˚ 12.9262(9) 10.79573(14)
c, A˚ 10.6254(14) 24.5286(3)
β, ◦ 118.784(17) 96.0639(12)
Cell volume 1246.9(2) 2318.97(5)
Z, D(cal) 4, 1.259 Mg/m3 4, 1.563 Mg/m3
F(000) 504 1120
Crystal size, mm 0.30 x 0.20 x 0.20 0.24 x 0.22 x 0.06
Crystal colour, shape colourless, block orange, block
Temperature, θmax (K,
◦) 100 , 31.33 100, 70.67
Index range, hkl −13 ≤ h ≤ 14 −8 ≤ h ≤ 10
−17 ≤ k ≤ 18 −13 ≤ k ≤ 9
−13 ≤ l ≤ 14 −29 ≤ l ≤ 29
Absorption correction Semi-empirical from
equivalents
Max. and min. transm. 0.72 and 1.00 0.37 and 1.00
Goodness-of-fit on F2 1.052 1.128
Reflections collected /
unique (Rint)
6933 / 3646 (0.0794) 13208 / 4426 (0.0252)
Data / restraints / para-
meters
3646/ 0/ 154 4426/ 0/ 269
R1 0.0449 0.0315
wR2 0.1251 0.082
Largest peak and hole,
eA˚−3
0.557 and -0.362 1.400 and -0.845
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Table 5.2: Crystallographic data for complexes [p-cymene)Ru(1c)Cl]PF6 [10]
and [p-cymene)Ru(2d-H)]2[PF6]2 [30].
[p-
cymene)Ru(1c)Cl]PF6
[10]
[p-cymene)Ru(2d-
H)]2[PF6]2 [30]
Empirical formula C20H27ClF6N3PRuS C52.5H62F12I2N8P2Ru2S2
Formula Weight 623.00 1623.10
Crystal system Monoclinic Monoclinic
Space group P2(1)/n P2/n
Unit cell dimensions
a, A˚ 9.37387(12) 12.67920(16)
b, A˚ 12.56956(16) 16.80130(18)
c, A˚ 20.8979(3) 14.8296(2)
β, ◦ 102.2374(14) 102.7363(13)
Cell volume 2406.35(5) 3081.38(7)
Z, D(cal) 4, 1.720 Mg/m3 2, 1.749 Mg/m3
F(000) 1156 1602
Crystal size, mm 0.20 x 0.18 x 0.16 0.24 x 0.10 x 0.08
Crystal colour, shape orange, block orange, block
Temperature, θmax (K,
◦) 150, 30.64 150, 30.69
Index range, hkl −13 ≤ h ≤ 13 −17 ≤ h ≤ 17
−17 ≤ k ≤ 17 −23 ≤ k ≤ 23
−29 ≤ l ≤ 29 −21 ≤ l ≤ 21
Absorption correction
Max. and min. transm. 0.95 and 1.00 0.91 and 1.00
Goodness-of-fit on F2 1.076 1.054
R1 0.0275 0.0274
wR2 0.0585 0.0654
Largest peak and hole, eA˚−3 0.447 and -0.427 1.152 and -0.490
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